
<html lang="en"     class="pb-page"  data-request-id="1f9d655b-9ec2-41ee-a5f2-2bf43f0ec900"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-7;article:article:10.1021/acs.jmedchem.7b01682;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer" /></meta><meta name="dc.Creator" content="George S.  Tria" /></meta><meta name="dc.Creator" content="Tinya  Abrams" /></meta><meta name="dc.Creator" content="Jason  Baird" /></meta><meta name="dc.Creator" content="Heather E.  Burks" /></meta><meta name="dc.Creator" content="Brant  Firestone" /></meta><meta name="dc.Creator" content="L. Alex  Gaither" /></meta><meta name="dc.Creator" content="Lawrence G.  Hamann" /></meta><meta name="dc.Creator" content="Guo  He" /></meta><meta name="dc.Creator" content="Christina A.  Kirby" /></meta><meta name="dc.Creator" content="Sunkyu  Kim" /></meta><meta name="dc.Creator" content="Franco  Lombardo" /></meta><meta name="dc.Creator" content="Kaitlin J.  Macchi" /></meta><meta name="dc.Creator" content="Donald P.  McDonnell" /></meta><meta name="dc.Creator" content="Yuji  Mishina" /></meta><meta name="dc.Creator" content="John D.  Norris" /></meta><meta name="dc.Creator" content="Jill  Nunez" /></meta><meta name="dc.Creator" content="Clayton  Springer" /></meta><meta name="dc.Creator" content="Yingchuan  Sun" /></meta><meta name="dc.Creator" content="Noel M.  Thomsen" /></meta><meta name="dc.Creator" content="Chunrong  Wang" /></meta><meta name="dc.Creator" content="Jianling  Wang" /></meta><meta name="dc.Creator" content="Bing  Yu" /></meta><meta name="dc.Creator" content="Choi-Lai  Tiong-Yip" /></meta><meta name="dc.Creator" content="Stefan  Peukert" /></meta><meta name="dc.Description" content="In breast cancer, estrogen receptor alpha (ERα) positive cancer accounts for approximately 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation. Treatment of ER..." /></meta><meta name="Description" content="In breast cancer, estrogen receptor alpha (ERα) positive cancer accounts for approximately 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation. Treatment of ER..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 22, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01682" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01682" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01682" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01682" /></link>
        
    
    

<title>Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01682" /></meta><meta property="og:title" content="Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0028.jpeg" /></meta><meta property="og:description" content="In breast cancer, estrogen receptor alpha (ERα) positive cancer accounts for approximately 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation. Treatment of ERα positive breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs). The steroid-based anti-estrogen fulvestrant (5), the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies. Its efficacy, however, may be limited due to its poor physicochemical properties. We describe the design and synthesis of a series of potent benzothiophene-containing compounds that exhibit oral bioavailability and preclinical activity as SERDs. This article culminates in the identification of LSZ102 (10), a compound in clinical development for the treatment of ERα positive breast cancer." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01682"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01682">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01682&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01682&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01682&amp;href=/doi/10.1021/acs.jmedchem.7b01682" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 2837-2864</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01625" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01704" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">George S. Tria</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">George S. Tria</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#ea9989859e9ec49e98838baa84859c8b989e8399c4898587"><span class="__cf_email__" data-cfemail="a8dbcbc7dcdc86dcdac1c9e8c6c7dec9dadcc1db86cbc7c5">[email protected]</span></a>. Phone: 617-871-4799.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=George+S.++Tria">George S. Tria</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8597-6130" title="Orcid link">http://orcid.org/0000-0001-8597-6130</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tinya Abrams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tinya Abrams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tinya++Abrams">Tinya Abrams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Baird</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Baird</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Baird">Jason Baird</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Heather E. Burks</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Heather E. Burks</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Heather+E.++Burks">Heather E. Burks</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9115-9970" title="Orcid link">http://orcid.org/0000-0001-9115-9970</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brant Firestone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brant Firestone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brant++Firestone">Brant Firestone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">L. Alex Gaither</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">L. Alex Gaither</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=L.+Alex++Gaither">L. Alex Gaither</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lawrence G. Hamann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lawrence G. Hamann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence+G.++Hamann">Lawrence G. Hamann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guo He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guo He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guo++He">Guo He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christina A. Kirby</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christina A. Kirby</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christina+A.++Kirby">Christina A. Kirby</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sunkyu Kim</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sunkyu Kim</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sunkyu++Kim">Sunkyu Kim</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Franco Lombardo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Franco Lombardo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Franco++Lombardo">Franco Lombardo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kaitlin J. Macchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kaitlin J. Macchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kaitlin+J.++Macchi">Kaitlin J. Macchi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Donald P. McDonnell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donald P. McDonnell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27710, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donald+P.++McDonnell">Donald P. McDonnell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuji Mishina</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuji Mishina</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuji++Mishina">Yuji Mishina</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John D. Norris</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John D. Norris</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina 27710, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++Norris">John D. Norris</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jill Nunez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jill Nunez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jill++Nunez">Jill Nunez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Clayton Springer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Clayton Springer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Clayton++Springer">Clayton Springer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingchuan Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingchuan Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingchuan++Sun">Yingchuan Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Noel M. Thomsen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Noel M. Thomsen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Noel+M.++Thomsen">Noel M. Thomsen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chunrong Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chunrong Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chunrong++Wang">Chunrong Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianling Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianling Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianling++Wang">Jianling Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bing Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bing Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bing++Yu">Bing Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Choi-Lai Tiong-Yip</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Choi-Lai Tiong-Yip</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Choi-Lai++Tiong-Yip">Choi-Lai Tiong-Yip</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Stefan Peukert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Peukert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Peukert">Stefan Peukert</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01682&amp;href=/doi/10.1021%2Facs.jmedchem.7b01682" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 2837–2864</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 22, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 November 2017</li><li><span class="item_label"><b>Published</b> online</span>22 March 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 April 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01682" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01682</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2837%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGeorge%2BS.%2BTria%252C%2BTinya%2BAbrams%252C%2BJason%2BBaird%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D7%26contentID%3Dacs.jmedchem.7b01682%26title%3DDiscovery%2Bof%2BLSZ102%252C%2Ba%2BPotent%252C%2BOrally%2BBioavailable%2BSelective%2BEstrogen%2BReceptor%2BDegrader%2B%2528SERD%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BEstrogen%2BReceptor%2BPositive%2BBreast%2BCancer%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2864%26publicationDate%3DApril%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01682"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5203</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">55</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01682" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;S. Tria&quot;},{&quot;first_name&quot;:&quot;Tinya&quot;,&quot;last_name&quot;:&quot;Abrams&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Baird&quot;},{&quot;first_name&quot;:&quot;Heather&quot;,&quot;last_name&quot;:&quot;E. Burks&quot;},{&quot;first_name&quot;:&quot;Brant&quot;,&quot;last_name&quot;:&quot;Firestone&quot;},{&quot;first_name&quot;:&quot;L.&quot;,&quot;last_name&quot;:&quot;Alex Gaither&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;G. Hamann&quot;},{&quot;first_name&quot;:&quot;Guo&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Christina&quot;,&quot;last_name&quot;:&quot;A. Kirby&quot;},{&quot;first_name&quot;:&quot;Sunkyu&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Franco&quot;,&quot;last_name&quot;:&quot;Lombardo&quot;},{&quot;first_name&quot;:&quot;Kaitlin&quot;,&quot;last_name&quot;:&quot;J. Macchi&quot;},{&quot;first_name&quot;:&quot;Donald&quot;,&quot;last_name&quot;:&quot;P. McDonnell&quot;},{&quot;first_name&quot;:&quot;Yuji&quot;,&quot;last_name&quot;:&quot;Mishina&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. Norris&quot;},{&quot;first_name&quot;:&quot;Jill&quot;,&quot;last_name&quot;:&quot;Nunez&quot;},{&quot;first_name&quot;:&quot;Clayton&quot;,&quot;last_name&quot;:&quot;Springer&quot;},{&quot;first_name&quot;:&quot;Yingchuan&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Noel&quot;,&quot;last_name&quot;:&quot;M. Thomsen&quot;},{&quot;first_name&quot;:&quot;Chunrong&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Jianling&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Bing&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Choi-Lai&quot;,&quot;last_name&quot;:&quot;Tiong-Yip&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Peukert&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2837-2864&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01682&quot;},&quot;abstract&quot;:&quot;In breast cancer, estrogen receptor alpha (ERα) positive cancer accounts for approximately 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation. Treatment of ERα positive breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs). The steroid-based anti-estrogen fulvestrant (5), the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies. Its efficacy, however, may be limited due to its poor physicochemical properties. We describe the design and synthesis of a series of potent benzothiophene-containing compounds that exhibit oral bioavailability and preclinical activity as SERDs. This article culminates in the identification of LSZ102 (10), a compound in clinical development for the treatment of ERα positive breast cancer.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01682&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01682" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01682&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01682" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01682&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01682" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01682&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01682&amp;href=/doi/10.1021/acs.jmedchem.7b01682" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01682" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01682" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01682%26sid%3Dliteratum%253Aachs%26pmid%3D29562737%26genre%3Darticle%26aulast%3DTria%26date%3D2018%26atitle%3DDiscovery%2Bof%2BLSZ102%252C%2Ba%2BPotent%252C%2BOrally%2BBioavailable%2BSelective%2BEstrogen%2BReceptor%2BDegrader%2B%2528SERD%2529%2Bfor%2Bthe%2BTreatment%2Bof%2BEstrogen%2BReceptor%2BPositive%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D7%26spage%3D2837%26epage%3D2864%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292349" title="Alkyls">Alkyls</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/jmcmar.2018.61.issue-7/20180412/jmcmar.2018.61.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">In breast cancer, estrogen receptor alpha (ERα) positive cancer accounts for approximately 74% of all diagnoses, and in these settings, it is a primary driver of cell proliferation. Treatment of ERα positive breast cancer has long relied on endocrine therapies such as selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor degraders (SERDs). The steroid-based anti-estrogen fulvestrant (<b>5</b>), the only approved SERD, is effective in patients who have not previously been treated with endocrine therapy as well as in patients who have progressed after receiving other endocrine therapies. Its efficacy, however, may be limited due to its poor physicochemical properties. We describe the design and synthesis of a series of potent benzothiophene-containing compounds that exhibit oral bioavailability and preclinical activity as SERDs. This article culminates in the identification of LSZ102 (<b>10</b>), a compound in clinical development for the treatment of ERα positive breast cancer.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21765" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21765" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite recent advances in early detection and treatment, breast cancer remains the second leading cause of cancer mortality among women in the United States, accounting for an estimated 40 290 deaths in 2015 alone.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Although it is often generalized as a single disease, breast cancer is classified in a clinical setting by its molecular subtype, arising from the characterization of three key biomarkers. The presence or absence of the receptors estrogen and progesterone leads to a hormone receptor classification (HR+/HR−), and increased or decreased levels of human epidermal growth factor receptor 2 (HER2) lead to a HER2 protein classification (HER2+/HER2−). Nearly 74% of breast cancers demonstrate high expression of estrogen receptor alpha (ERα), a nuclear hormone receptor directly implicated in the progression of HR+ cancers.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This ligand-inducible transcription factor binds physiological ligands such as 17β-estradiol and induces an activating conformational change in the receptor, leading to an increase or decrease in the expression of genes that contribute to breast cancer pathogenesis.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">In patients with ERα positive breast cancer, treatment has long relied on endocrine therapies such as tamoxifen (<b>1</b>, and its active metabolite <b>2</b>)<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and anastrozole (<b>3</b>),<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> both of which prevent ligand-dependent activation of ER transcriptional activity (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Tamoxifen (<b>1</b>), which until recently was the primary standard of care for such patients, functions as a selective estrogen receptor modulator (SERM), effectively blocking the binding of estrogens to the receptor and limiting its effects in breast tissue. Women treated with this therapy often respond positively,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> but <i>de novo</i> and acquired resistance in these patients, ultimately leading to disease progression, remains a significant medical challenge. Although the specific mechanism through which ERα positive tumors develop resistance to tamoxifen is not fully understood,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> aromatase inhibitors (AIs) such as letrozole (<b>4</b>),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> in addition to their use as frontline therapies, have shown clinical efficacy in such refractory cancers.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In contrast to tamoxifen, aromatase inhibitors owe their activity to the reduction in the production of estrogens, more specifically by inhibiting the enzyme responsible for the key biosynthetic step in the formation of these mitogenic molecules.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Unfortunately, these inhibitors are also subject to therapeutic resistance and can eventually lead to disease relapse.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In such settings, selective estrogen receptor degraders (SERDs) distinguish themselves by their ability to induce receptor degradation, which may overcome mechanisms of resistance to AIs and SERMs. The only such degrader currently approved for the treatment of ER positive breast cancer is the SERD fulvestrant (<b>5</b>).<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0029.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of tamoxifen, its bioactive metabolite 4-hydroxytamoxifen, and aromatase inhibitors anastrazole and letrozole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This steroid-based anti-estrogen both binds and accelerates the degradation of the estrogen receptor by inducing a denaturing structural change within the receptor,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> a mechanism found to be clinically effective in endocrine treated patients whose disease has progressed. Fulvestrant (<b>5</b>) efficacy may be limited, however, by its poor physicochemical properties. Due to poor oral bioavailability, fulvestrant is administered intramuscularly into the gluteal area in two 5 mL injections once monthly.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Although it is efficacious,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> this dosing regimen does not appear sufficient to fully occupy the receptor.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> It was with this shortcoming in mind that we sought to address the liabilities of fulvestrant by designing an orally available compound that retained the desirable degradative properties.</div><div class="NLM_p">The nonsteroidal estrogen antagonist GW-5638 (<b>6</b>) and its more active metabolite GW-7604 (<b>7</b>), although designed to address the tissue-dependent antagonism observed with tamoxifen,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> have also been found to induce receptor degradation, a property we sought to maintain in our efforts (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> We speculated that it should be possible to combine a nonsteroidal core, such as the benzothiophene found in arzoxifene (<b>8</b>), with an appropriately selected side chain, such as the carboxylic acid moiety found in GW-7604 (<b>7</b>), and that doing so should allow for the preparation of a SERD with the desired orally available profile. It should be noted that a similar approach was undertaken in the identification of clinical candidate GDC-0810 (<b>9</b>),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> although further development was ultimately halted.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Herein, we describe the design and synthesis of a series of potent benzothiophene-containing compounds that exhibit oral bioavailability and preclinical activity as SERDs. This article culminates in the identification of LSZ102 (<b>10</b>), a clinical agent currently in Phase I/Ib trials for the treatment of ERα positive breast cancer.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0001.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of fulvestrant, GW-5638, active metabolite GW-7604, arzoxifene, GDC-0810, and <b>10</b> (LSZ102).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16245" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16245" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The chemistry efforts toward LSZ102 (<b>10</b>) involved the preparation of a number of analogues accessed through varying synthetic routes, all of which are outlined in the following schemes and <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a>. The first of this series, ether linked compound <b>16</b> and its saturated analogue <b>17</b>, were prepared starting with commercially available 6-methoxy-2-(4-ethoxyphenyl)benzo[<i>b</i>]thiophene (<b>11</b>) as outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The route to both analogues began with selective bromination of the benzothiophene starting material by treatment of <b>11</b> with <i>N</i>-bromosuccinamide in THF to afford the desired brominated intermediate as the only observed product in 97% yield after an aqueous wash.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Oxidation of this intermediate to the corresponding sulfoxide <b>12</b>, necessary for the subsequent displacement reaction, was accomplished by H<sub>2</sub>O<sub>2</sub> mediated oxidation in the presence of trifluoroacetic acid.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> This process furnished <b>12</b> in 88% yield with no observed formation of the undesired, overoxidized sulphone intermediate, and it set the stage for the S<sub>N</sub>Ar reaction with 4-bromophenol. Thus, introduction of the phenyl ether functionality was achieved by treatment of <b>12</b> with 4-bromophenol in the presence of NaH (87% yield). The sulfoxide functionality, having served its purpose, was then removed via reduction with LiAlH<sub>4</sub> to afford bromo-benzothiophene <b>13</b> in 91% yield. Heck reaction with bromide <b>13</b> allowed for installation of the carboxylic acid functionality found in both <b>16</b> and <b>17</b>. Standard coupling conditions [Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] with <i>tert</i>-butyl acrylate as the alkene partner afforded fully protected ether intermediate <b>15</b> in 63% yield. Global deprotection with BBr<sub>3</sub> at 0 °C gave the final cinnamic acid containing compound <b>16</b> (53% yield). Alternatively, intermediate <b>15</b> could also be subjected to reductive conditions (H<sub>2</sub>, 10% Pd/C, quantitative) followed by BBr<sub>3</sub> mediated deprotection to afford the corresponding propanoic acid derivative <b>17</b> (31% yield).</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Ether-Linked Benzothiophene Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>-bromosuccinimide, THF, 0 → 25 °C, 97%; (b) H<sub>2</sub>O<sub>2</sub>, TFA, CH<sub>2</sub>Cl<sub>2</sub>, 88%; (c) 4-bromophenol, NaH, DMF, 87%; (d) LiAlH<sub>4</sub>, THF, 0 °C, 91%; (e) <i>tert</i>-butyl acrylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 120 °C, 63%; (f) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 53%; (g) H<sub>2</sub> (balloon), 10% Pd/C, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (4:1), 99%; (h) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 31%; (i) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 77%; (j) for <b>18</b>: 4-vinyl-1-methyl imidazole, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 150 °C, 58%; for <b>19</b>: <i>tert</i>-butyl 4-vinyl-1<i>H</i>-imidazole-1-carboxylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 150 °C, 15%. THF = tetrahydrofuran, TFA = trifluoroacetic acid, DMF = <i>N</i>,<i>N</i>-dimethylformamide.</p></p></figure><div class="NLM_p">Imidazole analogues <b>18</b> and <b>19</b> were obtained in a similar two-step Heck coupling sequence from bromide <b>13</b>. In this case, demethylation of <b>13</b> allowed for direct access to the final compounds via Heck coupling of the corresponding bromide <b>14</b> and bypassed the need for a final BBr<sub>3</sub> deprotection step. Thus, as outlined with the earlier analogues, treatment of <b>13</b> with BBr<sub>3</sub> at 0 °C afforded des-methyl <b>14</b>, which was subsequently treated with either 4-vinyl-1-methyl or <i>tert</i>-butyl 4-vinyl-1<i>H</i>-imidazole-1-carboxylate imidazole under standard coupling conditions [Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] to afford both compounds in modest yields (58 and 15% yield, respectively). It should be noted that in the case of <b>19</b>, the <i>tert</i>-butyl carbamate protected imidazole moiety was deprotected under the elevated temperatures of the Heck reaction.</div><div class="NLM_p">The preparation of amine-linked compounds <b>24</b> and <b>25</b> differed slightly from that of the ether-linked compounds and is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Beginning with bromide intermediate <b>21</b>, an intermediate from <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, a Buchwald–Hartwig amination gave a modest yield of fully protected amine <b>22</b> (15% yield). Subjection of intermediate <b>22</b> to NaH in the presence of excess methyl iodide resulted in methylated amine <b>23</b> (36% yield) en route to final compound <b>25</b>. Two-step deprotection of this material was accomplished by treatment with BBr<sub>3</sub> to first remove the methyl ether groups, followed by LiOH mediated ester hydrolysis, which gave the methyl amine-linked compound <b>25</b> (21% overall yield). The desmethyl analogue <b>24</b> was also accessed through intermediate <b>22</b>; this time simple treatment with BBr<sub>3</sub> at 0 °C was followed by treatment with NaOH to afford the final amine compound <b>24</b> (22% overall yield).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Amine-Linked Compounds <b>24</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 4-aminocinnamate, K<sub>3</sub>PO<sub>4</sub>, RuPhos palladacycle, 1,4-dioxane, 120 °C, 15%; (b) methyl iodide, NaH, DMF, 36%; (c) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (d) LiOH, EtOH, 21% (two steps); (e) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (f) NaOH, EtOH, 22% (two steps). DMF = <i>N</i>,<i>N</i>-dimethylformamide.</p></p></figure><div class="NLM_p">Ketone-linked analogue <b>29</b> similarly began with commercially available benzothiophene <b>11</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Friedel–Crafts acylation of <b>11</b> with 4-bromobenzoyl chloride (<b>26</b>) gave bromide <b>27</b> in 96% yield and allowed for a very similar end-game sequence to be used for the preparation of <b>29</b>. As previously outlined with the ether analogues in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, Heck coupling of <b>27</b> with <i>tert</i>-butyl acrylate afforded the fully protected keto intermediate <b>28</b>. Global deprotection with BBr<sub>3</sub> at 0 °C yielded the final cinnamic acid containing compound <b>29</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Ketone-Linked Compound <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AlCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 → 25 °C, 96%; (b) <i>tert</i>-butyl acrylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 120 °C, 88%; (c) BBr<sub>3</sub> (1.0 M in CH<sub>2</sub>Cl<sub>2</sub>), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 42%. DMF = <i>N</i>,<i>N</i>-dimethylformamide.</p></p></figure><div class="NLM_p">The synthesis of the direct aryl-linked analogue <b>33</b> is outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Beginning again with brominated benzothiophene intermediate <b>21</b>, Suzuki coupling with methyl 4-boronocinnamate <b>30</b> under standard conditions gave a 65% yield of methyl ester <b>31</b>. As before, two-step deprotection of this intermediate began by treatment of <b>31</b> with BBr<sub>3</sub> at 0 °C (46% yield) and was followed by LiOH promoted ester hydrolysis, which afforded <b>33</b> in 88% yield.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Na<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, dimethoxyethane/water (4:1), 100 °C, 65%; (b) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 46%; (c) LiOH (2.0 N aqueous), THF/water (4:1), 60 °C, 88%. THF = tetrahydrofuran</p></p></figure><div class="NLM_p">Amide analogues <b>35a</b>–<b>e</b> were prepared in one of two methods: either direct HATU mediated coupling with <b>16</b> (see <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> for synthesis) or by stepwise coupling with intermediate <b>34</b> followed by methyl ether cleavage (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). In the case of compounds <b>35a</b>–<b>d</b>, treatment of <b>16</b> (or <b>34</b> in the case of <b>35b</b>) with the corresponding amine (methylamine, NH<sub>4</sub>Cl, or ethanolamine) under standard HATU coupling conditions (HATU, DIEA) led directly to the final compounds. For compound <b>35e</b>, HATU mediated coupling afforded the methyl ether protected material, which was unmasked in the presence of BBr<sub>3</sub> to give the final compound (62% overall yield).</div><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Ether-Linked Compounds <b>35a</b>–<b>e</b> and Tetrazoles <b>37</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) R<sup>1</sup> = H for <b>35a</b>, <b>35c</b>, and <b>35d</b> and R<sup>1</sup> = Me for <b>35b</b>, HATU, DIEA, DMF, 30–80%; (b) R<sup>1</sup> = Me for <b>35e</b>, HATU, DIEA, DMF, 72%; (c) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 86%; (d) Bu<sub>2</sub>SnO, TMSN<sub>3</sub>, dimethoxyethane, 180 °C, 83%; (e) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 40%; (f) methyl iodide, K<sub>2</sub>CO<sub>3</sub>, DMF, 91% (combined yield of both 1- and 2-methyl tetrazole); (g) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 32–35%. HATU = <i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate, DIEA = <i>N</i>,<i>N</i>-diisopropylethylamine, DMF = <i>N</i>,<i>N</i>-dimethylformamide, Me = methyl, Bu = butyl, TMS = trimethysilyl.</p></p></figure><div class="NLM_p">In a similar fashion, tetrazole compounds <b>37</b>–<b>39</b> were prepared from primary amide intermediate <b>35b</b>. Reaction of <b>35b</b> with dibutyltin oxide and trimethylsilylazide resulted in conversion to the corresponding tetrazole <b>36</b> (83% yield), which was then either directly deprotected or further methylated. Deprotection of <b>36</b> with BBr<sub>3</sub>, as outlined with previous benzothiophene analogues, yielded tetrazole <b>37</b> in 40% yield. Subjection of intermediate <b>36</b> to K<sub>2</sub>CO<sub>3</sub> and excess methyl iodide led to a mixture of the 1- and 2-methyl substituted tetrazole intermediates, which were separated by column chromatography and subjected to BBr<sub>3</sub> to afford both <b>38</b> and <b>39</b> (35 and 32% yield, respectively).</div><div class="NLM_p">The exploration of substituted phenyl linkers, outlined in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>, was accomplished in much the same manner as previously outlined (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) with the variability arising from the phenol displacement partner. Sulfoxide <b>12</b> was once again employed as an activated bromide intermediate for displacement. Reaction of <b>12</b> with the appropriately substituted hydroxycinnamate (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis of hydroxycinnamates) under basic conditions (NaH) gave the corresponding ether intermediate <b>40</b> (43–86% yield). Reduction of the sulfoxide functionality was achieved by treatment with TMS-Cl/PPh<sub>3</sub>, which led to the protected benzothiophene intermediate <b>41</b> (65–98% yield).<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> As before, stepwise deprotection of this intermediate (<b>41</b>) was accomplished by reaction with BBr<sub>3</sub> followed by basic hydrolysis (LiOH) to afford the final analogues <b>42a</b>–<b>f</b> in good to modest yields over the two steps.</div><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0014.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Linker-Substituted Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, 43–86%; (b) TMSCl, PPh<sub>3</sub>, THF, 75 °C, 65–98%; (c) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 16–93% (<b>42d</b> was obtained directly from this step); (d) LiOH (2 N aqueous), EtOH, 41–80% (for <b>42a</b>–<b>c</b> and <b>42e</b>–<b>f</b>); (e) 5-hydroxypyridine-2-carboxylate, NaH, DMF, 80 °C, 52%; (f) LiAlH<sub>4</sub>, THF, 0 °C, 93%; (g) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (h) methyl 2-triphenylphosphoranylidene)acetate, CH<sub>2</sub>Cl<sub>2</sub>, 32% (2 steps); (i) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (j) LiOH, THF/water (1:1), 9% (two steps). Ac = acetate, DMF = <i>N</i>,<i>N</i>-dimethylformamide, TMS = trimethylsilyl, Ph = phenyl, THF = tetrahydrofuran.</p></p></figure><div class="NLM_p">Pyridine analogue <b>45</b> was accessed through a slightly modified route, but again, it began with bromide displacement using intermediate <b>12</b>. Reaction of benzothiophene <b>12</b> with 5-hydroxypyridine-2-carboxylate in the presence of NaH (52% yield) was followed by reduction of the carboxylate moiety with LiAlH<sub>4</sub> to give alcohol <b>43</b> (93% yield). MnO<sub>2</sub> promoted oxidation to the corresponding aldehyde, and subsequent Wittig olefination afforded protected cinnamate <b>44</b> (32% overall yield). Deprotection of the methyl ethers (BBr<sub>3</sub>) followed by ester hydrolysis (LiOH) gave the final compound <b>45</b> in 9% overall yield.</div><div class="NLM_p">An approach to 2-substituted benzothiophenes where diversity is introduced at the 2-position late in the synthesis was achieved by the synthesis of key intermediate <b>49</b>, outlined in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Synthesis of dibromo intermediate <b>47</b> was accomplished as previously reported in the literature.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Ether formation by addition of 4-bromophenol to <b>47</b> in the presence of Cs<sub>2</sub>CO<sub>3</sub> afforded <b>48</b> in 98% yield. Reduction of the pendant thiophene bromide in <b>48</b> was achieved by addition of NaBH<sub>4</sub> (97% yield) and followed by DIBAL-H reduction of the dioxide functionality to afford the key benzothiophene intermediate <b>49</b> (84% yield).</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0015.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Key Intermediate <b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-bromophenol, Cs<sub>2</sub>CO<sub>3</sub>, THF, 98%; (b) NaBH<sub>4</sub>, DMSO/MeOH (3:1), 97%; (c) DIBAL-H, THF, 75 °C, 84%. THF = tetrahydrofuran, DMSO = dimethyl sulfoxide, DIBAL-H = diisobutylaluminum hydride.</p></p></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>, Heck coupling of intermediate <b>49</b> with either methyl acrylate or <i>tert</i>-butyl acrylate afforded the protected benzothiophene intermediates <b>50a</b> and <b>50b</b> (61–66% yield), which were poised for further functionalization. The final synthesis of analogues <b>53d</b>–<b>r</b> and <b>10</b> was accomplished using one of two major pathways, the first of which involved rebromination of intermediate <b>50a</b> by treatment with <i>N</i>-bromosuccinamide to afford brominated intermediate <b>51</b> in 90% yield. This material was then either subjected directly to Suzuki coupling conditions in the case of <b>53o</b> or partially deprotected with BBr<sub>3</sub> to furnish the intermediate methyl-ester phenol (45% yield). This brominated methyl-ester intermediate (structure not shown) was then paired with appropriate boronic acids or boronate esters, under standard reaction conditions [Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>], to give the corresponding ester-protected intermediates in good yields (42–87%). Intermediate <b>52a</b>, which was only encountered for compound <b>53o</b>, was then subjected to LiOH mediated hydrolysis of the pendant methyl ester followed by thiophenol cleavage of the methyl ether, affording <b>53o</b> in 3% yield over the two-step process. For compounds <b>53m</b>,<b>q</b>,<b>r</b> and <b>10</b>, obtained through Suzuki coupling of the partially protected methyl-ester phenol intermediate (structure not shown), a final LiOH mediated hydrolysis furnished the final compounds in 11–70% yield. Alternatively, intermediate <b>50b</b> was also directly subjected to C–H activation conditions (K<sub>2</sub>CO<sub>3</sub>, trimethylacetic acid, BrettPhos palladacycle first generation) with corresponding halogens to yield intermediates <b>54</b> in good overall yield (39–97%). Subsequent deprotection of both the <i>tert</i>-butyl ester as well as the methyl ether functionalities was achieved in either a direct BBr<sub>3</sub> mediated reaction or a stepwise fashion and afforded final compounds <b>53d</b>−<b>l</b>, <b>53n</b>, and <b>53p</b>.</div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0016.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Phenyl-Substituted Benzothiophene Analogues <b>53d</b>–<b>r</b> and LSZ102 (<b>10</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl acrylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 120 °C, 61%; (b) <i>tert</i>-butyl acrylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 120 °C, 66%; (c) <i>N</i>-bromosuccinimide, THF, 90%; (d) 2-(methoxymethyl)benzeneboronic acid, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, 110 °C, 79% (only <b>53o</b> was made in this manner); (e) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 45%; (f) boronic acid/ester, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, 110 °C, 42–87%; (g) LiOH, MeOH/water (3:1), 11–70%; (h) LiOH, MeOH, 55% (compound <b>53o</b> only); (i) thiophenol, K<sub>2</sub>CO<sub>3</sub>, <i>N</i>-methyl-2-pyrrolidone, 190 °C, 6% (compound <b>53o</b> only); (j) K<sub>2</sub>CO<sub>3</sub>, trimethylacetic acid, BrettPhos palladacycle (first generation), DMA, 150 °C, 39–97%; (k) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 20–66%; (l) thiophenol, K<sub>2</sub>CO<sub>3</sub>, <i>N</i>-methyl-2-pyrrolidone, 200 °C, 22–77%; (m) HCl (4 N in 1,4-dioxane), THF, 50 °C, 19–34%.</p><p class="last"><span class="fn-label"><sup>b</sup></span>Compounds <b>53a</b>–<b>c</b> were synthesized in a similar sequence to <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>; for full details see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a>. DMF = <i>N</i>,<i>N</i>-dimethylformamide, THF = tetrahydrofuran, dppf = 1,1′-bis(diphenylphosphino)ferrocene, DME = 1,2-dimethoxyethane, DMA = <i>N</i>,<i>N</i>-dimethylacetamide.</p></p></figure><div class="NLM_p last">A select number of substituted benzothiophenes were made by introducing the desired 2-phenyl moiety in the first step. Thus, BrettPhos palladacycle mediated C–H functionalization of 6-methoxybenzo[<i>b</i>] thiophene (<b>46</b>) in the presence of the corresponding phenyl bromide afforded the desired 2-substituedbenzothiophenes, which were further functionalized en route to final compounds <b>53a</b>–<b>c</b> (for details, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As mentioned earlier, the efforts leading to the discovery of LSZ102 (<b>10</b>) centered around the hypothesis that it would be possible to combine a nonsteroidal benzothiophene core with an appropriate side chain, such as the carboxylic acid functionality found in GW-7604 (<b>7</b>). In doing so, we thought it should be possible to obtain a candidate that retained the selective degrader functionality while imparting a more pharmaceutical friendly profile that would allow for oral administration. Although we did explore alternative nonsteroidal replacements for the fulvestrant core, one of which is outlined in our earlier publication,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> for the purposes of this article we will focus on our work with the benzothiophenes. As outlined in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, our earliest investigation in to the benzothiophene scaffold included the preparation of a number of linkers through which the benzothiophene was ultimately connected to our cinnamic acid side chain. As shown in the table, these compounds varied from the ether and amine tethers shown in compounds <b>16</b> and <b>24</b>–<b>25</b>, respectively, to the carbonyl connection of <b>29</b> or even the direct C–C bond tether shown in compound <b>33</b>.</div><figure id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0002.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Benzothiophene-based linker exploration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to characterize the aforementioned compounds, we utilized a number of <i>in vitro</i> assays, allowing us to quantify both the anti-estrogen activity and the ability to degrade ERα. Anti-estrogen activity was evaluated with an estrogen-responsive reporter gene in ER+ MCF-7 breast cancer cells (ERα transcription IC<sub>50</sub>) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Degradation of ERα was measured using an in-cell western protocol with two distinct setups, both of which involved treatment of MCF-7 cells with compound for 18 h followed by fixation and processing for in-cell visualization using an anti-ERα antibody that monitored the amount of receptor remaining. The first in-cell western assay assessed the remaining ERα levels when compounds were added at 10 μM (% ERα remaining). A follow-up assay was used for compounds inducing significant receptor degradation to determine the concentration of test compound at which half of the ERα receptor level remained (ERα degradation IC<sub>50</sub>). Synthesized compounds were also benchmarked against known ERα modulators/degraders with the most common metric being fulvestrant and tamoxifen/4-hydroxytamoxifen. This allowed us to characterize our early prototype compounds both from an anti-estrogen (i.e., antagonist) perspective as well as their ability to degrade the ERα receptor.</div><div class="NLM_p">Evaluating the compounds outlined in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> set the context for our further exploration into the benzothiophene scaffold. As expected, tamoxifen and 4-hydroxytamoxifen were not effective in degrading the receptor at 10 μM with 90 and 94% ERα remaining, respectively. Fulvestrant clearly stands out in terms of both its ERα antagonistic potency as well as its ability to efficiently degrade the receptor (18% ERα remaining at 10 μM); however, the notably high clogD no doubt contributes to its limited pharmacokinetic profile. These initial compounds (<b>16</b>, <b>24</b>, <b>25</b>, <b>29</b>, <b>33</b>) generally appeared to reduce the lipophilicity as compared to fulvestrant, which gave some early indication that they were reasonable medicinal chemistry starting points. Taking a further look at the <i>in vitro</i> data in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, we see that ether-linked compound <b>16</b> was both active as an ERα antagonist (ERα transcription IC<sub>50</sub> = 748 nM) and efficient in reducing receptor levels at 10 μM with 41% ERα remaining. Compounds <b>24</b> and <b>25</b> both were able to degrade the ERα receptor comparably to <b>16</b> at 10 μM (44 and 30% versus 41% ERα remaining) but demonstrated less antagonistic activity than <b>16</b>. Compounds <b>29</b> and <b>33</b> were poor ERα antagonists and degraders; therefore, the ether-linked benzothiophene <b>16</b> was ultimately selected for further optimization.</div><div class="NLM_p">Having selected benzothiophene <b>16</b> as our lead compound for further optimization, we hypothesized it might be possible to further improve its degradative properties by tuning the cinnamic acid functionality. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> outlines these results and begins with a look at the saturated propionic acid analogue <b>17</b>, which was prepared to probe the necessity of the α,β-unsaturation found in the parent compound (<b>16</b>). Propionic acid <b>17</b> was found to be nearly equipotent as an ERα antagonist (ERα transcription IC<sub>50</sub> = 457 nM) but slightly less effective as an ERα degrader (58% ERα remaining), suggesting that the rigidity of the cinnamic acid moiety found in <b>17</b> is favorable. Taking a further look into the optimization of the carboxylic acid functionality, we investigated a number of amide-containing analogues. All four of the amides shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> (<b>35a</b>,<b>c</b>–<b>e</b>) demonstrated improved antagonistic activity when compared to <b>16 (</b>ERα IC<sub>50</sub> values = 10–55 nM); however, they are nearly equivalent to the parent compound when comparing their efficacy in degrading ER at 10 μM (40–48% ERα remaining). Primary amide <b>35c</b> demonstrated that the carboxylic acid moiety is not alone in its ability to effectively degrade ERα (48% ERα remaining), and secondary amides <b>35a</b>,<b>d</b>,<b>e</b> followed up on this with equally comparable ERα remaining values. Unfortunately, the amide analogues were found to be less soluble than the parent cinnamic acid (<b>16</b>), and for this reason, they were not pursued further. Tetrazole <b>37</b> and its methylated analogues <b>38</b> and <b>39</b>, although improved as antagonists, did not appreciably improve the level of ERα degradation achieved (33–76% ERα remaining at 10 μM). Imidazole <b>19</b> and methylimidazole <b>18</b> were improved as antagonists (ERα IC<sub>50</sub> values of 53 and 125 nM, respectively) but were again equally effective as degraders when compared to <b>16</b>. Furthermore, as was observed with the amide analogues discussed earlier, the imidazole compounds were significantly less soluble than the parent. Given this data, we prioritized the cinnamic acid functionality of <b>16</b> as our ERα degradation functionality and sought to improve its antagonistic properties with further modification.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effects of Carboxylic Acid Replacements</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0017.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0018.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">n.d. = not determined.</p></div></div><div></div></div><div class="NLM_p">Replacement of the central core ring was investigated as outlined in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and began with the introduction of a pyridine ring (<b>45</b>). This substitution had a slightly positive effect on the ability to degrade ERα (26% ERα remaining) but led to a decrease in ERα antagonistic activity (ERα transcription IC<sub>50</sub> = 7750 nM). Similarly, methyl and methoxy substitutions around this ring were explored (<b>42a</b>–<b>c</b>), but again, although this was tolerated from a standpoint of effecting degradation of the ERα (27–37% ERα remaining), the modifications, at best, led to a retention of ERα antagonistic potency as compared to <b>16</b>, and in the case of methoxy compound <b>42c</b>, they lead to a nearly 7-fold drop in potency. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows similar results for compounds <b>42d</b>–<b>f</b>, in which we explored direct substitution on the double bond. In all cases, it was shown that substitution, while tolerated from a potency perspective as an antagonist (ERα transcription IC<sub>50</sub>’s = 216–886 nM), did not lead to any marked improvements in the ability to effect ERα degradation (33–42% ERα remaining). For this reason, further functionalization around the cinnamic acid moiety of the compounds was not pursued, and the unsubstituted cinnamic acid <b>16</b> remained the frontrunner.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effect of Variation of Linker Substituents</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0019.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0020.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Cinnamic Acid Substitution</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0021.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center" char=".">ERα transcription IC<sub><b>50</b></sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">% ERα remaining</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42d</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">886</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">316</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42f</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">216</td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr></tbody></table></div></div><div class="NLM_p">With <i>in vitro</i> potency beginning to focus in on key compound functionality, we evaluated a number of our early analogues for their pharmacokinetic (PK) properties (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) to assess what, if any, pharmacokinetic liabilities these compounds might have. Oral dosing of a 3 mg/kg solution of <b>16</b> in Sprague–Dawley rats gave our first look into the PK properties of this structural class and showed rather low bioavailability (6%) as well as low peak plasma concentration (<i>C</i><sub>max</sub> po = 80 nM) and high clearance (54 mL/min/kg). Our first attempt to improve this profile focused around the introduction of proximal substi tution to the potentially metabolic labile phenolic functionality on the right-hand half of <b>16</b>. This led to the preparation of methyl-substituted <b>53a</b>, which, although slightly improved in our <i>in vitro</i> potency assays (ERα transcription IC<sub>50</sub> = 327 nM, 26% ERα remaining), did not prove advantageous from a pharmacokinetic perspective (oral bioavailability = 2% and clearance = 46 mL/min/kg in C57BL/6 mice). The methoxy variant <b>53s</b>, although not explored in a pharmacokinetic setting, did lead to an interesting conclusion from the <i>in vitro</i> potency data. <b>53s</b> was equipotent as an antagonist (ERα transcription IC<sub>50</sub> = 647 nM) and more efficient as an estrogen receptor degrader at 10 μM (18% ERα remaining), demonstrating that the free phenol functionality was not required to maintain activity in either setting. This finding set up our exploration for alternative functionality at the 4-position and ultimately led to the preparation of compound <b>53b</b>, a <i>para</i>-fluoro substituted analogue with only slightly reduced potency (ERα transcription IC<sub>50</sub> = 1823 nM) that maintained the degradative properties at 10 μM (26% ERα remaining). Additionally, this compound led to an improvement in the bioavailability and clearance in both mouse and rat species (oral bioavailability = 19 and 33% and clearance = 22 and 24 mL/min/kg, respectively). Finally, the 4-CF<sub>3</sub> substituted analogue <b>53d</b> further improved the pharmacokinetic profile while maintaining activity in both of our key <i>in vitro</i> potency assays, leading to an antagonist analogue equipotent to parent compound <b>16</b>, with reduced clearance in mice and rats (clearance = 6 and 30 mL/min/kg, respectively) and increased bioavailability (oral bioavailability = 28 and 74%, respectively).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Potency and Pharmacokinetic Parameters of Benzothiophene Analogues <b>16</b> and <b>53a</b>,<b>b</b>,<b>d</b>,<b>s</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0022.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0023.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Dose: 1 mg/kg iv, 3 mg/kg po. Formulation = solution. Vehicle <b>16</b>: PBS solution containing 5% 0.1 N NaOH/10% PEG300/25% (of 20% Solutol) and 1 N HCl for pH adjustment; <b>53a</b>,<b>b</b>,<b>d</b>: PBS solution containing 2 equiv of 0.1 N NaOH/10% PEG300/25% (of 20% Cremophore) and 1 N HCl for pH adjustment.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">n.d. = not determined. F = bioavailability.</p></div></div><div></div></div><div class="NLM_p">As these early pharmacokinetic studies were being run, we were also working to improve the potency of parent compound <b>16</b> and came across an interesting effect through which we were able to markedly improve our antagonistic activity as well as the potency as an ERα degrader. Although unsubstituted phenyl analogue <b>53c</b> is a promising lead, its ERα potency (ERα transcription IC<sub>50</sub> = 2306 nM; <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) is slightly decreased from that of the phenolic parent compound <b>16</b>. As we began exploring substitution around this aromatic ring, we found that introduction of an <i>ortho</i>-methyl group, as seen with compound <b>53e</b>, led to a rather notable 26-fold improvement in antagonistic activity (ERα transcription IC<sub>50</sub> = 89 nM) and 7-fold increase in potency as a degrader (ERα degrader IC<sub>50</sub> = 4 nM). Incrementally increasing the size of the substituent to the ethyl group (<b>54f</b>) led to a further modest potency improvement (ERα transcription IC<sub>50</sub> = 36 nM), whereas substantially increasing the size to a <i>tert</i>-butyl group (<b>53g</b>) had no further positive effect on activity (ERα transcription IC<sub>50</sub> = 36 nM). However, introduction of an <i>ortho</i> isopropyl (<b>53h</b>) did demonstrate that further improvement was possible, leading to an increase in potency (ERα transcription IC<sub>50</sub> = 6 nM) and a very potent ERα degrader (ERα degrader IC<sub>50</sub> = 0.4 nM with 13% ERα remaining).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Discovering the <i>Ortho</i> Effect</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0024.gif" alt="" id="fx8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0025.gif" alt="" id="fx9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Torsion angle between the 2-aryl ring and benzothiophene core was measured from the ligand bound to the ligand-binding domain of ERα.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Torsion angle between the 2-aryl ring and benzothiophene core was calculated from molecular mechanics for the unbound conformation.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">n.d. = not determined.</p></div></div><div></div></div><div class="NLM_p">Interestingly, during the course of our study, this <i>ortho</i>-substituted pattern and its effect on potency on the ER has, to our knowledge, only been reported by Katzenellenbogen et al. during their exploration of modified 2,3-diarylindenes.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> In their work, a methyl group introduced to a 2-phenyl substituent in the <i>ortho</i> position to its attachment to the indene nucleus increased binding affinity 11-fold over the unsubstituted system. Upon further investigation with our benzothiophene analogues, we found that the <i>ortho</i>-substitution pattern leading to this potency increase was torsionally constraining the compounds and organizing the 2-aryl ring almost perpendicular to the plane of the benzothiophene core (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). A comparison of the torsion angles in the energy-minimized conformation of the ligands unbound to the receptor and the conformation found in the bound state to the ligand-binding domain of ERα suggests that preorganization of the 2-aryl ring might, in combination with increased hydrophobic interactions within the ligand-binding pocket, contribute to the observed potency increase.</div><div class="NLM_p">In a final push to optimize the benzothiophene analogues, and based both on the pharmacokinetic data outlined in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> with the <i>ortho</i> effect observed in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, we set out to combine these two advantageous structural features. As such, preparation of compound <b>53i</b> demonstrated that the two functionalities could indeed be combined to afford a compound with both suitable pharmacokinetic properties (clearance = 33 mL/min/kg and oral bioavailability = 34%) as well as increased transcriptional activity (ERα transcription IC<sub>50</sub> = 78 nM) as compared to the desmethyl parent <b>53b</b> (ERα transcription IC<sub>50</sub> = 1823 nM, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). As a replacement for the isopropyl moiety found in <b>53h</b>, <i>ortho</i>-CF<sub>3</sub> analogue <b>53j</b> was only slightly less potent (ERα transcription IC<sub>50</sub> = 23 nM) than <b>53h</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), likely owing to its similar size as compared to the isopropyl group. <i>Para</i>-substitution of this compound gave rise to <b>53k</b>, which again demonstrated good transcriptional inhibitory activity (ERα transcription IC<sub>50</sub> = 12 nM) while also showing suitable oral bioavailability (oral bioavailability = 30%) and peak plasma concentration (<i>C</i><sub>max</sub> po = 1501 nM). In an attempt to further reduce lipophilicity and introduce some polarity, compounds <b>53l</b>–<b>o</b> were prepared, each having obvious structural similarities to the parent compound <b>53h</b>. While all four analogues were efficient degraders at 10 μM (11–22% ERα remaining), they were all less active than the parent when compared in the transcriptional assay (ERα transcription IC<sub>50</sub> = 123–669 nM), leading us to the conclusion that polarity is not well tolerated in this part of the molecule. As a final approach to optimize potency, a variety of fluorinated analogues were prepared in an attempt to both optimize activity and minimize any metabolic liabilities that might arise from moving forward with an isopropyl substituent. To that end, compounds <b>53p</b>–<b>r</b> and <b>10</b> were prepared, leading to a slight increase in activity from <b>53p</b> to <b>53q</b> (ERα transcription IC<sub>50</sub> = 52 and 25 nM, respectively) and a further increase upon introduction of the difluoroethyl moiety found in <b>53r</b> (ERα transcription IC<sub>50</sub> = 11 nM). Finally, combining the difluoroethyl group with the <i>para</i>-fluoro group found in the earlier analogues resulted in <b>10</b>. Whereas <b>53r</b> had unsatisfactory pharmacokinetic properties, most notably a low oral bioavailability of 5% in C57BL/6 mice, <b>10</b> showed an acceptable PK profile with 12% oral bioavailability and at the same time was our most potent ERα antagonist and degrader.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Optimizing the <i>Ortho</i> Effect and the Corresponding Pharmacokinetic Data</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0026.gif" alt="" id="fx10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0027.gif" alt="" id="fx11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Dose: 1 mg/kg iv, 3 mg/kg po. Formulation = solution. Vehicle <b>53h</b>,<b>i</b>,<b>k</b>: PBS solution containing 2 equiv of 0.1 N NaOH/10% PEG300/25% (of 20% Cremophore) and 1 N HCl for pH adjustment; <b>53r</b>: PBS solution containing 1 N NaOH/10% PEG300/25% (of 20% Cremophore); <b>10</b>: PBS solution containing 1 equiv of 1 N NaOH/10% PEG300/25% (of 20% Cremophore) and 1 N HCl for pH adjustment; <b>9</b>: PBS solution containing 3% 1 N NaOH/15% PEG200/50% (of 20% Cremophore) and 1 N HCl for pH adjustment.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">n.d. = not determined. F = bioavailability.</p></div></div><div></div></div><div class="NLM_p">Crystallography was used to gain a structural understanding of how the difluoroethyl substitution of <b>10</b> influences ligand binding. The structure of ERαLDB (301–553) in complex with <b>10</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F">6B0F</a>) was solved to 2.86 Å. The overall fold of the ERαLBD structure compares well with that of the previously described structures<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> with an rmsd value of 0.486 Å when including main chain atoms from residues 310–525 of chain A with those same atoms of ERαLBD bound to raloxifene (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERR">1ERR</a>). Consistent with ERα structures that contain ligands with a hydroxyl moiety on the A-ring is the hydrogen bonding network among residues Arg394 and Glu353 and this hydroxyl group. Aside from these interactions, the remainders occur within the largely hydrophobic core of the ligand binding domain (LBD). The A/B-rings of <b>10</b> are positioned between Phe404 on one side of the pocket and Leu387 on the other and make additional interactions with Leu349, Met388, and Leu391, whereas the D-ring is within van der Waals distances to Met421, Ile424, and Leu525. The difluoroethyl forces a repositioning of Phe425 to further increase the volume of the ligand-binding pocket as compared to an E2 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERE">1ERE</a>) or GW5638 (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>) bound structure. This same repositioning mimics that seen in the structure of ERα in complex with raloxifene. The induced pocket is defined by additional interactions with Phe404, Phe425, Leu428, and Met421 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). A van der Waals excluded surface was generated using PyMOL<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> to demonstrate the ability of <b>10</b> to adequately fill the available space within the LBD (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0003.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Binding pocket of ERα in complex with <b>10</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F">6B0F</a>) highlighting residues that form the ligand-binding pocket. (B) van der Waals excluded surface of the ligand-binding pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Pharmacokinetics and Pharmacodynamics of <b>10</b></h3><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>In Vitro</i> Characterization of <b>10</b></h4><div class="NLM_p">ERα degradation observed in the in-cell assay format was confirmed by western blot analysis and shown to be proteosome-mediated (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Compound <b>10</b> as well as fulvestrant and the previously reported tetrahydroisoquinolone <b>40</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> induces significant degradation of ERα after 24 h when given as a 10 μM solution to MCF-7 cells. However, simultaneous incubation with MG132, a pan-proteasome inhibitor, rescues ERα degradation, suggesting that degradation of ERα is mediated through this process.</div><figure id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0004.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proteasome-dependent ERα degradation by <b>10</b>. Western blot analysis of the effect of <b>10</b>, THIQ 40, and fulvestrant (10 μM, 24 h) on ERα levels with or without MG132 pretreatment for 24 h. IB = immunoblot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Evaluation of dose-dependent ERα degradation in an in-cell western assay is shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, demonstrating, as expected, that 4-hydroxytamoxifen did not induce degradation, consistent with its reported profile.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> In this format, compound <b>10</b> was found to be more potent (ERα degradation IC<sub>50</sub> = 0.2 nM) than fulvestrant (ERα degradation IC<sub>50</sub> = 1.2 nM). As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, fulvestrant and compound <b>10</b> cannot fully degrade ERα in MCF-7 cells even at saturating biochemical concentrations. The remaining low levels of ERα might not be accessible in the cell to proteolytic degradation of the compounds and result in a low level of remaining ER.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The residual pool of ER may be bound to a multiprotein complex in the nuclear compartment and be slow to turn over or exported from the nucleus.</div><figure id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0005.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Measurement of ERα reduction by <b>10</b>, fulvestrant, and 4-hydroxytamoxifen (<b>2</b>) in MCF-7 cells grown in 10% charcoal dextran-stripped serum supplemented media. For the in-cell western, cells were incubated with compounds for 18 h followed by fixation and processing to determine the amount of ERα protein remaining.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we evaluated the anti-proliferative effect of <b>10</b> in ER positive estradiol dependent MCF-7 cells over a dose response of compound. We observed robust inhibition of cell proliferation in MCF-7 cells upon incubation with <b>10</b> with a half-inhibitory concentration of 1.7 nM (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Fulvestrant and 4-hydroxytamoxifen had IC<sub>50</sub> values of 4.4 and 9.9 nM, respectively, significantly higher than that of <b>10</b>. The more potent effect of <b>10</b> on cellular proliferation suggests that its superior potency as an ER degrader over fulvestrant translates into more potent anti-profilerative activity.</div><figure id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0006.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Proliferation of MCF-7 cells. Cells were incubated in RPMI (without phenol red) plus 10% charcoal dextran-stripped serum and treated with compounds in the presence of 0.1 nM estradiol for 6 days. Cell viability was determined by CellTiter-Glo assay. IC<sub>50</sub> values were calculated using the XLfit software and are defined as the inflection point of the fitted inhibition curves. RPMI = Roswell Park Memorial Institute.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further determine the effect of <b>10</b> on ER-mediated gene transcription, we developed an MCF-7 cell line that stably expresses a 3× ERE-luciferase reporter. Our data demonstrated that <b>10</b> effectively inhibited the estrogen-induced activation of the ERE-luciferase reporter using charcoal-stripped serum treated with E2 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). The IC<sub>50</sub>’s of <b>10</b> and fulvestrant were similar (0.3 and 0.2 nM, respectively), whereas the IC<sub>50</sub> of 4-hydroxytamoxifen was 10-fold higher at 2 nM.</div><figure id="fig8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0007.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of ER-mediated gene transcription by <b>10</b>. MCF-7-EREluc and MCF-7 cells were incubated in phenol-red free RPMI plus 10% charcoal dextran-stripped serum and treated with compounds in the presence of 0.1 nM E2 for 24 h. (A) Cell luciferase signal from MCF-7-EREluc was measured using Bright-Glo assay and normalized to DMSO control. (B) mRNA of ER target gene GREB1 from treated MCF-7 cells was quantified by TaqMan assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">One challenge with using a 3× ERE reporter gene is that the signal is greatly amplified above physiological levels normally seen in the cell. To address this issue, we also measured the activity of <b>10</b> on the canonical endogenous ER target gene GREB1. Interestingly, we found that fulvestrant this time had the most robust inhibition on mRNA levels with an IC<sub>50</sub> of 3.8 nM, whereas <b>10</b> had an IC<sub>50</sub> of 8.9 nM, which was similar to that of 4-hydroxytamoxifen (IC<sub>50</sub> of 10.2 nM) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). Although it is not clear why there is a potency difference between fulvestrant and <b>10</b> to inhibit GREB1 expression, it could be unique features of promoters of ER target genes that confer more or less activity to the two degrader compounds.</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> <i>In Vivo</i> Characterization of <b>10</b></h4><div class="NLM_p">To evaluate the anti-tumor activity of <b>10</b>, efficacy was assessed in the MCF-7 human breast cancer xenograft model in mice supplemented with estradiol pellets to support robust tumor growth. Treatment of the mice with <b>10</b> once daily at 20 mg/kg resulted in significant tumor growth inhibition as compared to the control group treated with vehicle alone, resulting in tumor stasis (mean change in tumor volume of <b>10</b> vs control = %Δ<i>T</i>/ΔC of 2.4% on day 48, <i>p</i> < 0.05). Plasma samples collected on day 19 after treatment started showed an exposure of <b>10</b> of 3230 nM·h by AUC with a maximal concentration of 1068 nM. Tamoxifen and fulvestrant, used as controls, induced statistically significant tumor stasis and a growth inhibition of %Δ<i>T</i>/ΔC of 24%, respectively (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A). Tumors were collected and processed for mRNA and protein isolation from the end of the efficacy study on day 48 postimplantation at 7 h post last treatment to assess pharmacodynamics marker changes. Consistent with its anti-tumor efficacy, <b>10</b>, as well as the tamoxifen and fulvestrant controls, strongly inhibited transcription of the ER-regulated target gene for progesterone receptor (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). The two SERD compounds fulvestrant and <b>10</b> also showed a marked reduction in ER levels in the tumors, with 67 and 63% inhibition as compared to the untreated control, respectively (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C).</div><figure id="fig9" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0008.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Anti-tumor efficacy of <b>10</b> in the ER+ human breast cancer MCF-7 xenograft model. Tumors were established in female NSG mice by injection of 10<sup>7</sup> cells into the axillary mammary fat pad area of each mouse. Mice were implanted with 0.72 mg estradiol/90-day release pellets several days prior to cell implantation. When tumors reached an average of 200 mm<sup>3</sup>, mice were randomized according to tumor volume into treatment groups (<i>n</i> = 8). Test agents were administered at the dose levels and schedules indicated. <b>10</b> or its vehicle alone was orally administred once daily, and tamoxifen was orally administered 5 times a week. Fulvestrant was administered subcutaneously (sc) once a week (5 mg/mouse). (A) Tumor volumes of treatment groups vs days post randomization. <i>p</i> < 0.05, ANOVA, Holm–Sidak posthoc test, versus vehicle control. Inhibition of progesterone receptor mRNA levels as analyzed by RT-PCR (B) and ER protein levels as analyzed by quantification of a western blot (C) as compared to the vehicle control at the end of the efficacy study at 7 h post last dose are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Pharmacokinetic Characterization of <b>10</b> in Advanced Preclinical Species</h4><div class="NLM_p">Pharmacokinetic parameters of <b>10</b> were finally evaluated in rats and dogs to assess if sufficient exposure for toxicological studies could be achieved (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Dosing of 3 mg/kg solution of <b>10</b> in male Sprague–Dawley rats resulted in 33% bioavailability and a dose-normalized exposure of 620 nM·h. A separate study in female Wistar Han rats dosing amorphous <b>10</b> in suspension in a dose escalating study demonstrated dose proportional exposure from 30 to 100 mg/kg. Increased dosing to 300 mg/kg lead to an over proportional exposure by AUC, whereas <i>C</i><sub>max</sub> was under proportional with dose. In dogs, a low clearance of 5 mL/min/kg (15% of hepatic blood flow) was measured, and oral administration yielded a biovailalability of 12% and good exposure (e.g., the 10 mg/kg dose in dogs resulted in an exposure roughly 3-fold higher than the fully efficacious exposure required in the mouse xenograft model, seen in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A, from a 20 mg/kg dose: 9625 versus 3230 nM·h). Dosing of a suspension to dogs resulted in a small drop in exposure with a dose-normalized exposure of ∼2/3 of the exposure seen with solution dosing.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters for <b>10</b> in Advanced Preclinical Species</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="/" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="/">dose (iv/po, mg/kg)</th><th class="colsep0 rowsep0" align="center">formulation</th><th class="colsep0 rowsep0" align="center" char=".">clearance (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> po dn<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub> iv dn<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nMh)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub> po dn<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a> (nM·h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> for elimination (h)</th><th class="colsep0 rowsep0" align="center" char=".">oral F<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a> rat</td><td class="colsep0 rowsep0" align="char" char="/">1/3</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">240</td><td class="colsep0 rowsep0" align="char" char=".">1849</td><td class="colsep0 rowsep0" align="char" char=".">620</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WH<a class="ref internalNav" href="#t7fn5" aria-label="e">e</a> rat</td><td class="colsep0 rowsep0" align="char" char="/">–/30</td><td class="colsep0 rowsep0" align="left">suspension<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1259</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2117</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="/">–/100</td><td class="colsep0 rowsep0" align="left">suspension<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">513</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1940</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="/">–/300</td><td class="colsep0 rowsep0" align="left">suspension<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">334</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3405</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">beagle dog</td><td class="colsep0 rowsep0" align="char" char="/">0.3/10</td><td class="colsep0 rowsep0" align="left">solution<a class="ref internalNav" href="#t7fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">268</td><td class="colsep0 rowsep0" align="char" char=".">7713</td><td class="colsep0 rowsep0" align="char" char=".">962</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="/">–/30</td><td class="colsep0 rowsep0" align="left">suspension<a class="ref internalNav" href="#t7fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">123</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">624</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">dn = dose normalized.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">F = bioavailability.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">SD = Sprague–Dawley.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">Vehicle: PBS containing 1 equiv of 1 N NaOH/10% PEG300/25% (of 20% Solutol) and 1 N HCl for pH adjustment.</p></div><div class="footnote" id="t7fn5"><sup><sup>e</sup></sup><p class="last">WH = Wistar Han.</p></div><div class="footnote" id="t7fn6"><sup><sup>f</sup></sup><p class="last">Vehicle: 0.5% methyl cellulose and 0.1% Tween 80.</p></div><div class="footnote" id="t7fn7"><sup><sup>g</sup></sup><p class="last">Vehicle: PBS containing 5% NaOH/20% PEG300/5% Solutol.</p></div></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Chemistry optimization resulted in benzothiophene-based compound <b>10</b> (LSZ102), which was found to be a potent ERα antagonist and degrader. Substitution at the <i>ortho</i> position of the 2-aryl ring proved to be crucial to achieve high potency, and substitution at the <i>para</i> position was beneficial for the pharmacokinetic properties. <b>10</b> is a very potent ERα degrader, as shown in western assays, inducing a proteosome-mediated proteolysis of the receptor. <b>10</b> exhibited robust anti-tumor efficacy and inhibition of PD markers in a MCF-7 human breast cancer model at well-tolerated dose level and together with its acceptable exposure upon oral administration is an attractive compound for study in a clinical setting. <b>10</b> is currently being evaluated in advanced or metastatic ERα+ breast cancer in a Phase I/Ib trial.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Preliminary results from this study indicate that oral single-agent LSZ102 appears well-tolerated, with a manageable safety profile.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Chemical Methods</h3><div class="NLM_p">Starting materials, reagents, and solvents were obtained from commercial sources and used as received. THF and diethyl ether were anhydrous grade. Compound <b>47</b> was prepared as described in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>. Progress of the reactions was monitored by analytical LC/MS using an Agilent 1100 series with UV detection at 214 and 254 nm and an electrospray mode (ESI) coupled with a waters ZQ single quad mass detector. Progress of the reactions was also monitored by analytical LC/MS using an Waters Classic AcQuity UPLC with UV detection at 214 and 254 nm and an electrospray mode (ESI) coupled with a waters SQ single quad mass detector. Analytical thin-layer chromatography (TLC) was carried out on S-2 0.25 mm E. Merck silica gel plates (60F-254) using UV light as visualizing agent and ethanolic <i>p</i>-anisaldehyde, aqueous ammonium cerium nitrate/ammonium molybdate, or basic aqueous potassium permanganate as developing agent. Purification of intermediates and final products was carried out on a normal phase using an ISCO CombiFlash system and prepacked SiO<sub>2</sub> cartridges eluted with optimized gradients of either ethyl acetate/heptane mixture or methanol/dichloromethane as described. Preparative high pressure liquid chromatography (HPLC) was performed on a Waters instrument. Systems were run with the described acetonitrile/water gradient with an <i>n</i>-propanol, NH<sub>4</sub>OH, or TFA modifier as described. Preparative SFC was perform a Thar-80 with UV detection based collection. Analytical chiral SFC was performed on a Waters/Thar SFC Investigator, with UV and MS detection. All compounds where biological data are presented have >95% purity as determined by HPLC. NMR spectra were recorded on a Bruker Ultrashield 400 plus instrument. Chemical shifts (δ) are reported in parts per million (ppm) relative to deuterated solvent as the internal standard (CDCl<sub>3</sub> 7.26 ppm, DMSO-<i>d</i><sub>6</sub> 2.50 ppm, CD<sub>3</sub>OD 3.31 ppm), and coupling constants (<i>J</i>) are in hertz (Hz). Peak multiplicities are expressed as follows: singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q), multiplet (m), and broad (br).</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>E</i>)-3-(4-((2-(2-(1,1-Difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>10</b>)</h4><div class="NLM_p last">To a solution of (<i>E</i>)-3-(4-((2-bromo-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (1.8 g, 4.60 mmol, see procedure <b>53m</b> for synthesis) in 1,4-dioxane (10 mL) and water (4 mL) were added 2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (2.633 g, 9.20 mmol, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis), K<sub>2</sub>CO<sub>3</sub> (3.179 g, 23.00 mmol), and XPhos Pd cycle (340 mg, 0.460 mmol). The resulting mixture was heated to 150 °C under microwave irradiation for 45 min, after which time the reaction was filtered to remove solids. The filtrate was diluted with DCM and acidified by addition of sat. aq. citric acid solution. The phases were separated, and the combined organic phases were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The resulting crude material was purified by reverse phase HPLC (basic conditions, 0.1% NH<sub>4</sub>OH in CH<sub>3</sub>CN/H<sub>2</sub>O), and the fractions were treated with 1 N HCl to pH 5 and diluted with DCM. The organic layer was collected and concentrated <i>in vacuo</i> to afford (<i>E</i>)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (1.6 g, 3.40 mmol, 74% yield) as a pale orange solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.80 (t, <i>J</i> = 18.44 Hz, 3H), 6.23 (d, <i>J</i> = 16.17 Hz, 1H), 6.71–6.81 (m, 3H), 7.03 (td, <i>J</i> = 8.21, 2.78 Hz, 1H), 7.08–7.14 (m, 2H), 7.22–7.32 (m, 2H), 7.37 (d, <i>J</i> = 8.59 Hz, 2H), 7.47 (d, <i>J</i> = 16.17 Hz, 1H). <sup>19</sup>F NMR (376 MHz, CD<sub>3</sub>OD) δ ppm = −84.91, −113.27. <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 25.36, 107.69, 113.49, 114.99, 115.87, 116.75, 117.59, 121.62, 121.95, 122.33, 123.59, 124.3, 128.59, 129.89, 135.66, 137.92, 139.56, 140.48, 143.03, 155.95, 158.74, 161.88, 167.54. HRMS ESI <i>m</i>/<i>z</i> 471.0865 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-Bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-Oxide (<b>12</b>)</h4><div class="NLM_p">Step 1: To a 500 mL round-bottom flask containing 6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene (22 g, 81 mmol) in THF (250 mL) at 0 °C was added <i>N</i>-bromosuccinamide (15 g, 84 mmol). The reaction mixture was stirred at 0 °C for 60 min and then allowed to warm to room temperature and stirred for an additional 2 h. Upon completion, the reaction mixture was concentrated to 50% volume and quenched with sat. aq. sodium thiosulfate solution. The resulting solution was extracted with diethyl ether 3×, and the combined organic layers were dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford 3-bromo-6-methoxy-2-(4-methoxyphenyl)-benzo[<i>b</i>]thiophene (27.5 g, 97% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 7.63 (d, <i>J</i> = 9.1 Hz, 1H), 7.55–7.61 (m, 2H), 7.19 (d, <i>J</i> = 2.5 Hz, 1H), 6.96–7.02 (m, 1H), 6.87–6.95 (m, 2H), 3.81 (s, 3H), 3.79 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 350.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of 3-bromo-6-methoxy-2-(4-methoxyphenyl)-benzo[<i>b</i>]thiophene (4 g, 11.45 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at room temperature was added trifluoroacetic acid (20 mL) dropwise; the reaction went from orange to dark brown in color. Upon addition, the resulting mixture was stirred at room temperature for 10 min and then hydrogen peroxide (30% wt aq., 1.58 mL, 16.47 mmol) was added dropwise. After 90 min at room temperature, the reaction mixture was quenched with sodium bisulfite (1.71 g, 16.47 mmol) followed by 3.0 mL of water. The resulting suspension was stirred vigorously for 15 min and then concentrated <i>in vacuo</i> to remove CH<sub>2</sub>Cl<sub>2</sub> and most of the trifluoroacetic acid. The residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and sat. aq. NaHCO<sub>3</sub> solution (40 mL) and separated. The organic layer was collected, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the crude product, which was purified by column chromatography (SiO<sub>2</sub>, 1–40% EtOAc/heptane) to afford 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide (4.6 g, 88% yield) as an orange solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.51–7.65 (m, 2H), 7.37–7.51 (m, 2H), 7.08 (dd, <i>J</i> = 2.27, 8.34 Hz, 1H), 6.79–6.96 (m, 2H), 3.74 (s, 3H), 3.68 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 367.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-(4-Bromophenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene (<b>13</b>)</h4><div class="NLM_p">Step 1: To a solution of 4-bromophenol (469 mg, 2.71 mmol) in DMF (3 mL) was added sodium hydride (60% suspension in oil, 108 mg, 2.71 mmol); the resulting mixture was allowed to stir for 10 min at room temperature. To the solution was added 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide (900 mg, 2.46 mmol) as a solid. The reaction was heated to 80 °C for 18 h. Upon completion, the reaction was cooled to room temperature, quenched with water, and diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was collected (phase separator) and concentrated <i>in vacuo</i> to afford the crude product. The crude material was purified by column chromatography (SiO<sub>2</sub>, 0–60% EtOAc/heptane) to afford 3-(4-bromophenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide (980 mg, 87% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 7.70–7.78 (m, 2H), 7.53 (d, <i>J</i> = 2.02 Hz, 1H), 7.41 (d, <i>J</i> = 8.59 Hz, 2H), 6.90–7.06 (m, 6H), 3.91 (s, 3H), 3.83 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 459.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: A solution of 3-(4-bromophenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide (970 mg, 2.12 mmol) in THF (5 mL) was cooled to 0 °C. To the cooled solution was added LiAlH<sub>4</sub> (129 mg, 3.39 mmol) in one portion. The reaction mixture was stirred at 0 °C for 30 min, after which the mixture was poured into 1.0 M aq. NaHSO<sub>4</sub> solution and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was collected (phase separator) and concentrated <i>in vacuo</i> to afford the crude product, which was purified by column chromatography (SiO<sub>2</sub>, 0–30% EtOAc/heptane) to afford 3-(4-bromophenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene (850 mg, 91% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 3.83 (s, 3H), 3.90 (s, 3H), 6.80–6.99 (m, 5H), 7.22–7.32 (m, 2H), 7.32–7.44 (m, 2H), 7.65 (d, <i>J</i> = 9.09 Hz, 2H). LC/MS ESI <i>m</i>/<i>z</i> 443.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-(4-Bromophenoxy)-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-6-ol (<b>14</b>)</h4><div class="NLM_p last">To a 30 mL vial containing 3-(4-bromophenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene (100 mg, 0.23 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added BBr<sub>3</sub> (1.0 M in hexanes, 0.680 mL, 0.68 mmol), and the reaction mixture was stirred for 1 h at room temperature. Upon completion, the reaction was quenched with 4 mL of MeOH and stirred for 10 min. The mixture was the concentrated <i>in vacuo</i> onto silica gel, and the crude material was purified by column chromatography (SiO<sub>2</sub>, 1–100% EtOAc/heptane) to afford 3-(4-bromophenoxy)-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-6-ol (72 mg, 77% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.47–7.57 (m, 2H), 7.35–7.45 (m, 2H), 7.20 (d, <i>J</i> = 2.02 Hz, 1H), 7.16 (d, <i>J</i> = 8.59 Hz, 1H), 6.73–6.90 (m, 5H). LC/MS ESI <i>m</i>/<i>z</i> 414.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>E</i>)-<i>tert</i>-Butyl 3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>15</b>)</h4><div class="NLM_p last">To a solution of 3-(4-bromophenoxy)-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene (79 mg, 0.18 mmol) in DMF (1.7 mL) was added triethylamine (0.125 mL, 0.90 mmol) followed by <i>tert</i>-butyl acrylate (0.184 mL, 1.25 mmol) and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (18.9 mg, 0.03 mmol). The mixture was then subjected to microwave irradiation for 1 h at 120 °C, after which the reaction was diluted with water (15 mL) and extracted with EtOAc (4 × 10 mL). The combined organic layers were washed with brine (30 mL), passed through a phase separator to remove water, and concentrated <i>in vacuo</i> to give the crude product as an orange oil which was purified by column chromatography (SiO<sub>2</sub>, 0–50% EtOAc/heptane) to give (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate as a pale yellow oil (55 mg, 63% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 1.44 (s, 9H), 3.71 (s, 3H), 3.78 (s, 3H), 6.13 (d, <i>J</i> = 15.66 Hz, 1H), 6.76–6.83 (m, 3H), 6.86 (m, <i>J</i> = 8.59 Hz, 2H), 7.14–7.19 (m, 2H), 7.31 (m, <i>J</i> = 8.59 Hz, 2H), 7.42 (d, <i>J</i> = 16.17 Hz, 1H), 7.54 (d, <i>J</i> = 8.59 Hz, 2H). LC/MS ESI <i>m</i>/<i>z</i> 433.5 [M – <i>t</i>-Bu + H]<sup>+</sup>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>16</b>)</h4><div class="NLM_p last">To a solution of (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)-benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (40 mg, 0.08 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.5 mL) at 0 °C was added BBr<sub>3</sub> (1.0 M in CH<sub>2</sub>Cl<sub>2</sub>, 0.33 mL, 0.33 mmol) dropwise; a solid immediately precipitated from the solution. The resulting mixture was stirred at 0 °C for 100 min, after which the reaction was quenched by addition of sat. aq. NaHCO<sub>3</sub> (4 mL) solution and a white precipitate was  observed. The aqueous layer was then extracted with 5% MeOH/EtOAc (4 × 12 mL), and the combined organic layers were passed through a phase separator to remove water and concentrated <i>in vacuo</i> to afford the crude product, which was dissolved in MeOH (2 mL) and purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (17.5 mg, 53% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 6.32 (d, <i>J</i> = 16.17 Hz, 1H), 6.75 (d, <i>J</i> = 8.59 Hz, 2H), 6.78–6.82 (m, 1H), 6.92 (d, <i>J</i> = 8.59 Hz, 2H), 7.15 (d, <i>J</i> = 8.59 Hz, 1H), 7.19 (d, <i>J</i> = 2.02 Hz, 1H), 7.44–7.53 (m, 4H), 7.59 (d, <i>J</i> = 16.17 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 108.96, 115.81, 116.74, 117.08, 118.19, 122.74, 124.88, 127.78, 128.31, 129.92, 130.36, 131.21, 138.23, 139.68, 145.54, 157.25, 158.75, 161.04, 171.00. HRMS ESI <i>m</i>/<i>z</i> 405.0790 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)propanoic Acid (<b>17</b>)</h4><div class="NLM_p">Step 1: To a solution of <i>tert</i>-butyl (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (27 mg, 0.055 mmol) in 4:1 MeOH:CH<sub>2</sub>Cl<sub>2</sub> (2.5 mL) was added palladium on carbon (10 wt %, 0.6 mg). The reaction vessel was evacuated and purged with hydrogen, and the mixture was stirred vigorously under a hydrogen atmosphere (balloon) at room temperature for 18 h. The solution was then purged with nitrogen, and the catalyst was removed by filtration though a pad of Celite and washed with CH<sub>2</sub>Cl<sub>2</sub>. The resulting solution was concentrated <i>in vacuo</i> to afford crude <i>tert</i>-butyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)propanoate (27 mg, 99% yield), which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 1.41 (s, 9H), 2.50 (t, <i>J</i> = 7.83 Hz, 2H), 2.86 (t, <i>J</i> = 7.83 Hz, 2H), 3.81 (s, 3H), 3.88 (s, 3H), 6.85–6.92 (m, 5H), 7.08 (d, <i>J</i> = 8.59 Hz, 2H), 7.25–7.28 (m, 2H), 7.67 (d, <i>J</i> = 8.59 Hz, 2H). LC/MS ESI <i>m</i>/<i>z</i> 491.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of <i>tert</i>-butyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)propanoate (27 mg, 0.055 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.7 mL) at 0 °C was added BBr<sub>3</sub> (1.0 M in CH<sub>2</sub>Cl<sub>2</sub>, 0.220 mL, 0.220 mmol) dropwise (the reaction turned brown in color, and a solid immediately precipitated from the solution). The resulting mixture was stirred at 0 °C for 1 h, after which the reaction was quenched with ice water (3.0 mL) and allowed to warm to room temperature with vigorous stirring. The resulting mixture was concentrated <i>in vacuo</i>, dissolved in MeOH (2 mL), and then purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford 3-(4-((6-hydroxy-2-(4-hydroxyphenyl)-benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)propanoic acid (7 mg, 31% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 2.54 (t, <i>J</i> = 7.58, 2H), 2.85 (t, <i>J</i> = 7.58 Hz, 2H), 6.72–6.79 (m, 3H), 6.82 (d, <i>J</i> = 8.59 Hz, 2H), 7.08–7.19 (m, 4H), 7.52 (d, <i>J</i> = 8.59 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 31.36, 37.08, 108.87, 115.58, 116.53, 116.65, 122.98, 125.21, 127.42, 128.67, 129.85, 130.75, 136.13, 138.16, 140.39, 157.06, 157.79, 158.56, 177.04. HRMS ESI <i>m</i>/<i>z</i> 407.0943 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>E</i>)-2-(4-Hydroxyphenyl)-3-(4-(2-(1-methyl-1<i>H</i>-imidazol-4-yl)vinyl)phenoxy)-benzo[<i>b</i>]thiophen-6-ol (<b>18</b>)</h4><div class="NLM_p last">The title compound was prepared as a white solid in 58% yield from 3-(4-bromophenoxy)-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-6-ol and 4-vinyl-1-methyl imidazole using the procedure described for the synthesis of <b>15</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 3.82 (s, 3H), 6.57–6.74 (m, 3H), 6.75–6.93 (m, 3H), 6.98–7.14 (m, 3H), 7.32–7.54 (m, 5H), 8.73 (s, 1H). LC/MS ESI <i>m</i>/<i>z</i> 441.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>E</i>)-3-(4-(2-(1<i>H</i>-Imidazol-4-yl)vinyl)phenoxy)-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-6-ol (<b>19</b>)</h4><div class="NLM_p last">The title compound was prepared as a white solid in 15% yield from 3-(4-bromophenoxy)-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-6-ol and <i>tert</i>-butyl 4-vinyl-1<i>H</i>-imidazole-1-carboxylate using the procedure described for the synthesis of <b>15</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.57 (s, 1H), 7.43 (d, <i>J</i> = 8.59 Hz, 2H), 7.30 (d, <i>J</i> = 8.59 Hz, 2H), 6.96–7.14 (m, 3H), 6.74–6.96 (m, 4H), 6.53–6.74 (m, 3H). LC/MS ESI <i>m</i>/<i>z</i> 427.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>E</i>)-Ethyl 3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)amino)phenyl)acrylate (<b>22</b>)</h4><div class="NLM_p last">To a large microwave vial (10–20 mL) were added 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene (350 mg, 1.00 mmol), ethyl 4-aminocinnamate (383 mg, 2.00 mmol), and K<sub>3</sub>PO<sub>4</sub> (425 mg, 2.00 mmol). 1,4-Dioxane (6.0 mL) was then added followed by chloro-(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II) methyl-<i>tert</i>-butyl ether adduct (RuPhos palladacycle, 73.0 mg, 0.10 mmol), and the reaction was subjected to microwave irradiation at 120 °C for 3 h. Upon completion, the reaction mixture was transferred to round-bottom flask with EtOAc and concentrated <i>in vacuo</i>. The resulting material was partitioned between water and EtOAc and separated; the aqueous layer was then further extracted with EtOAc (3×), and the combined organic layers were passed through a phase separator to remove water and concentrated <i>in vacuo</i>. The crude material was purified by column chromatography (SiO<sub>2</sub>, 0–30% EtOAc/heptane) to afford (<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)amino)phenyl)acrylate (69.0 mg, 15% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 1.21–1.26 (m, 3H), 3.76 (s, 3H), 3.85 (s, 3H), 4.15 (q, <i>J</i> = 7.07 Hz, 2H), 6.24 (d, <i>J</i> = 16.17 Hz, 1H), 6.58 (d, <i>J</i> = 8.59 Hz, 2H), 6.94–7.01 (m, 3H), 7.34 (d, <i>J</i> = 8.59 Hz, 1H), 7.41 (d, <i>J</i> = 8.59 Hz, 2H), 7.48 (d, <i>J</i> = 15.66 Hz, 1H), 7.53 (d, <i>J</i> = 2.02 Hz, 1H), 7.58 (d, <i>J</i> = 9.09 Hz, 2H), 8.25 (s, 1H). LC/MS ESI <i>m</i>/<i>z</i> 460.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>E</i>)-Ethyl 3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)(methyl)amino)phenyl)acrylate (<b>23</b>)</h4><div class="NLM_p last">To a solution of (<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)amino)phenyl)acrylate (69.0 mg, 0.15 mmol) in DMF (6.0 mL) at room temperature was added NaH (60% suspension in oil, 139 mg, 3.48 mmol). After 15 min, methyl iodide (0.272 mL, 4.35 mmol) was added, and the resulting solution was allowed to stir at room temperature for 45 min, after which time the reaction was quenched with brine and diluted with water. The resulting solution was then extracted with EtOAc (3×), and the combined organic layers were washed with brine (2×), passed through a phase separator, and concentrated <i>in vacuo</i> to afford the crude product which was purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford ((<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)(methyl)amino)phenyl)acrylate (25.5 mg, 36% yield) as a white solid. LC/MS ESI <i>m</i>/<i>z</i> 474.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)amino)phenyl)acrylic Acid (<b>24</b>)</h4><div class="NLM_p">Step 1: To a solution of (<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)amino)phenyl)acrylate (200 mg, 0.44 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3.0 mL) at 0 °C was added BBr<sub>3</sub> (1.0 M in CH<sub>2</sub>Cl<sub>2</sub>, 1.74 mL, 1.74 mmol) dropwise. After 2 h at 0 °C, the reaction was quenched with water and extracted with 10% 2-propanol/CH<sub>2</sub>Cl<sub>2</sub>; the combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford crude ethyl (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)amino)phenyl)acrylate, which was used without further purification. LC/MS ESI <i>m</i>/<i>z</i> 432.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of crude ethyl (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)amino)phenyl)acrylate (70.5 mg, 0.163 mmol) in EtOH (1.0 mL) at room temperature was added LiOH (2 N aq., 1.0 mL, 12.24 mmol); the reaction was allowed to stir at room temperature for 18 h, after which time the reaction was quenched with 4 N HCl until pH ∼ 3 and then extracted with EtOAc (2×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give the crude product, which was purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)amino)phenyl)acrylic acid (38.1 mg, 22% yield over two steps). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 6.19 (d, <i>J</i> = 15.66 Hz, 1H), 6.63 (d, <i>J</i> = 8.59 Hz, 2H), 6.75 (d, <i>J</i> = 15.66 Hz, 2H), 6.82 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.19 (d, <i>J</i> = 2.02 Hz, 1H), 7.28–7.38 (m, 3H), 7.42–7.50 (m, 2H), 7.54 (d, <i>J</i> = 15.66 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 108.63, 113.87, 114.83, 115.37, 116.62, 123.79, 125.27, 126.31, 128.36, 130.56, 131.12, 132.38, 133.83, 139.35, 147.22, 151.32, 156.77, 158.65, 171.79. HRMS ESI <i>m</i>/<i>z</i> 404.0945 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)(methyl)amino)phenyl)acrylic Acid (<b>25</b>)</h4><div class="NLM_p">Step 1: To a solution of (<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)(methyl)amino)phenyl)acrylate (25.5 mg, 0.05 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at 0 °C was added BBr<sub>3</sub> (1.0 M in CH<sub>2</sub>Cl<sub>2</sub>, 0.215 mL, 0.21 mmol) dropwise. After 4 h at 0 °C, the reaction was quenched with sat. aq. NaHCO<sub>3</sub> and extracted with 5% MeOH/EtOAc; the combined organic layers were passed through a phase separator and concentrated <i>in vacuo</i> to afford crude (<i>E</i>)-ethyl 3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)(methyl)amino)phenyl)acrylate, which was used without further purification. LC/MS ESI <i>m</i>/<i>z</i> 446.5 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of crude (<i>E</i>)-ethyl 3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)(methyl)amino)phenyl)acrylate (25 mg, 0.06 mmol) in EtOH (1.5 mL) at room temperature was added LiOH (2 N aq., 0.168 mL, 0.34 mmol); the reaction was allowed to stir at room temperature for 18 h, after which time the reaction was quenched with 1 N HCl (4 mL) and concentrated <i>in vacuo</i> to remove EtOH. The resulting suspension was extracted with 5% MeOH/EtOAc (3×), dried, and concentrated <i>in vacuo</i> to give the crude product, which was purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)(methyl)amino)phenyl)acrylic acid (4.98 mg, 0.01 mmol, 21% yield over two steps) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 3.12 (s, 3H), 6.11 (d, <i>J</i> = 15.66 Hz, 1H), 6.56 (d, <i>J</i> = 8.59 Hz, 2H), 6.65 (d, <i>J</i> = 9.09 Hz, 2H), 6.69 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 6.98 (d, <i>J</i> = 8.59 Hz, 1H), 7.11 (d, <i>J</i> = 2.02 Hz, 1H), 7.24 (d, <i>J</i> = 9.09 Hz, 2H), 7.30 (d, <i>J</i> = 9.09 Hz, 2H), 7.48 (d, <i>J</i> = 16.17 Hz, 1H). HRMS ESI <i>m</i>/<i>z</i> 418.1065 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (4-Bromophenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)methanone (<b>27</b>)</h4><div class="NLM_p last">To a solution of 6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene (350 mg, 1.295 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (11 mL) at 0 °C was added 4-bromobenzoyl chloride (284 mg, 1.295 mmol) followed by AlCl<sub>3</sub> (190 mg, 1.424 mmol). The resulting mixture was allowed to warm to room temperature, and after 3.5 h, it was quenched by addition of potassium sodium tartrate and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give the crude material, which was purified by column chromatography (SiO<sub>2</sub>, 0–30% EtOAc/heptane) to afford (4-bromophenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)methanone as a yellow solid (562 mg, 96% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 3.77 (s, 3H), 3.91 (s, 3H), 6.76 (d, <i>J</i> = 9.09 Hz, 2H), 6.98–7.04 (m, 1H), 7.30 (d, <i>J</i> = 8.59 Hz, 2H), 7.34 (d, <i>J</i> = 2.02 Hz, 1H), 7.41 (d, <i>J</i> = 8.59 Hz, 2H), 7.59–7.64 (m, 3H). LC/MS ESI <i>m</i>/<i>z</i> 455.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>tert</i>-Butyl (<i>E</i>)-3-(4-(6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene-3-carbonyl)phenyl)acrylate (<b>28</b>)</h4><div class="NLM_p last">The title compound was prepared as a yellow solid in 88% yield from (4-bromophenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)methanone and <i>tert</i>-butyl acrylate using the procedure described for the synthesis of <b>15</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 1.54 (s, 9H), 3.74 (s, 3H), 3.91 (s, 3H), 6.36 (d, <i>J</i> = 16.17 Hz, 1H), 6.74 (d, <i>J</i> = 9.09 Hz, 2H), 6.98–7.03 (m, 1H), 7.31 (d, <i>J</i> = 8.59 Hz, 2H), 7.34 (d, <i>J</i> = 2.53 Hz, 1H), 7.38 (d, <i>J</i> = 8.59 Hz, 2H), 7.50 (d, <i>J</i> = 16.17 Hz, 1H), 7.64 (d, <i>J</i> = 9.09 Hz, 1H), 7.75 (d, <i>J</i> = 8.08 Hz, 2H). LC/MS ESI <i>m</i>/<i>z</i> 501.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>E</i>)-3-(4-(6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophene-3-carbonyl)phenyl)acrylic Acid (<b>29</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-butyl (<i>E</i>)-3-(4-(6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene-3-carbonyl)phenyl)acrylate (41 mg, 0.092 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2.5 mL) at 0 °C was added BBr<sub>3</sub> (1.0 M in CH<sub>2</sub>Cl<sub>2</sub>, 0.37 mL, 0.37 mmol) dropwise; the resulting mixture was stirred at 0 °C for 75 min, after which the reaction was quenched by addition of sat. aq. NaHCO<sub>3</sub> (4 mL) solution, reacidifed to pH 3 with conc. HCl. The aqueous layer was then extracted with 5% MeOH/EtOAc (4 × 12 mL). The combined organic layers were passed through a phase separator to remove water and concentrated <i>in vacuo</i> to afford the crude product, which was dissolved in MeOH (2 mL) and purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophene-3-carbonyl)phenyl)acrylic acid (16.1 mg, 42% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 6.54 (d, <i>J</i> = 15.66 Hz, 1H), 6.66 (d, <i>J</i> = 8.59 Hz, 2H), 6.88 (dd, <i>J</i> = 8.84, 2.27 Hz, 1H), 7.16 (d, <i>J</i> = 8.59 Hz, 2H), 7.32–7.40 (m, 2H), 7.50 (d, <i>J</i> = 16.17 Hz, 1H), 7.59–7.64 (m, 2H), 7.65–7.70 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 107.20, 115.41, 115.73, 122.61, 123.54, 123.61, 128.31, 129.04, 129.86, 130.12, 132.07, 137.77, 138.94, 139.37, 141.99, 142.81, 155.59, 158.07, 167.41, 193.18. HRMS ESI <i>m</i>/<i>z</i> 417.0786 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Methyl (<i>E</i>)-3-(4-(6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)phenyl)acrylate (<b>31</b>)</h4><div class="NLM_p last">To a solution of 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene (200 mg, 0.573 mmol) in 4:1 dimethoxyethane:water (5.0 mL) was added (<i>E</i>)-(4-(3-methoxy-3-oxoprop-1-en-1-yl)phenyl)boronic acid (130 mg, 0.630 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (33.1 mg, 0.029 mmol), and Na<sub>2</sub>CO<sub>3</sub> (121 mg, 1.145 mmol). The mixture was then subjected to microwave irradiation for 1 h at 100 °C, after which the reaction was diluted with water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were concentrated <i>in vacuo</i> to give the crude product, which was purified by column chromatography (SiO<sub>2</sub>, 0–20% EtOAc/heptane) to give methyl (<i>E</i>)-3-(4-(6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)phenyl)acrylate (160 mg, 65% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 3.80 (s, 3H), 3.84 (s, 3H), 3.91 (s, 3H), 6.48 (d, <i>J</i> = 16.17 Hz, 1H), 6.80 (d, <i>J</i> = 9.09 Hz, 2H), 6.97 (dd, <i>J</i> = 9.09, 2.53 Hz, 1H), 7.23 (d, <i>J</i> = 8.59 Hz, 2H), 7.33–7.40 (m, 3H), 7.45 (d, <i>J</i> = 8.59 Hz, 1H), 7.56 (d, <i>J</i> = 8.08 Hz, 2H), 7.74 (d, <i>J</i> = 16.17 Hz, 1H). LC/MS ESI <i>m</i>/<i>z</i> 431.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Methyl (<i>E</i>)-3-(4-(6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)phenyl)acrylate (<b>32</b>)</h4><div class="NLM_p last">To a solution of methyl (<i>E</i>)-3-(4-(6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)phenyl)acrylate (150 mg, 0.348 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at 0 °C was added BBr<sub>3</sub> (1.0 M in heptane, 1.394 mL, 1.394 mmol), and the reaction mixture was stirred for 2 h. Upon completion, the reaction was quenched by addition of sat. aq. NaHCO<sub>3</sub> solution, extracted with CH<sub>2</sub>Cl<sub>2</sub> (2×), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give the crude product. The crude material was purified by column chromatography (SiO<sub>2</sub>, 10–100% EtOAc/heptane) to give methyl (<i>E</i>)-3-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)phenyl)acrylate (65 mg, 46% yield) as a light yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 3.75 (s, 3H), 6.63 (d, <i>J</i> = 16.17 Hz, 1H), 6.68 (d, <i>J</i> = 8.59 Hz, 2H), 6.87 (dd, <i>J</i> = 8.84, 2.27 Hz, 1H), 7.07 (d, <i>J</i> = 8.59 Hz, 2H), 7.27 (d, <i>J</i> = 8.59 Hz, 1H), 7.29 (d, <i>J</i> = 2.02 Hz, 1H), 7.32 (d, <i>J</i> = 8.08 Hz, 2H), 7.70 (d, <i>J</i> = 16.17 Hz, 1H), 7.75 (d, <i>J</i> = 8.08 Hz, 2H), 9.48 (d, <i>J</i> = 13.64 Hz, 2H). HRMS ESI <i>m</i>/<i>z</i> 403.0985 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>E</i>)-3-(4-(6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)phenyl)acrylic Acid (<b>33</b>)</h4><div class="NLM_p last">To a solution of methyl (<i>E</i>)-3-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)phenyl)acrylate (60 mg, 0.149 mmol) in 4:1 THF:MeOH (5.0 mL) at room temperature was added LiOH (2 N aq., 1.0 mL, 13.42 mmol); the reaction was warmed to 60 °C and stirred. After 2 h, the mixture was cooled to room temperature and concentrated <i>in vacuo</i> to remove organics. The remaining aqueous layer was acidified with concentrated HCl, and the resulting precipitate was filtered, washed with cold water, and dried under vacuum overnight to afford (<i>E</i>)-3-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)phenyl)acrylic acid (51 mg, 88% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 6.56 (d, <i>J</i> = 16.17 Hz, 1H), 6.68 (d, <i>J</i> = 8.59 Hz, 2H), 6.86 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.05 (d, <i>J</i> = 8.59 Hz, 2H), 7.26–7.35 (m, 4H), 7.62 (d, <i>J</i> = 16.17 Hz, 1H), 7.73 (d, <i>J</i> = 8.08 Hz, 2H), 9.66 (br d, <i>J</i> = 11.12 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 107.22, 114.93, 115.57, 119.51, 123.27, 124.31, 128.69, 130.42, 130.45, 130.61, 132.99, 133.23, 136.05, 137.36, 139.20, 143.45, 155.31, 157.29, 167.74. HRMS ESI <i>m</i>/<i>z</i> 389.0845 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>E</i>)-3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>34</b>)</h4><div class="NLM_p">Step 1: To a solution of (<i>E</i>)-methyl 3-(4-hydroxyphenyl)acrylate (190 mg, 1.07 mmol) in DMF (5 mL) was added sodium hydride (60% suspension in oil, 42.7 mg, 1.07 mmol). The resulting mixture was allowed to stir for 10 min at room temperature, after which 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide (300 mg, 0.82 mmol) was added, as a solid. The reaction was heated to 80 °C for 18 h, and upon completion, it was cooled to room temperature, quenched with water, and diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was collected, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the crude product, which was purified by column chromatography (SiO<sub>2</sub>, 0–80% EtOAc/heptane) to afford (<i>E</i>)-methyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (370 mg, 97% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 7.75 (d, <i>J</i> = 9.09 Hz, 2H), 7.65 (d, <i>J</i> = 15.66 Hz, 1H), 7.54 (d, <i>J</i> = 2.02 Hz, 1H), 7.43–7.52 (m, <i>J</i> = 9.09 Hz, 2H), 7.07–7.16 (m, <i>J</i> = 8.59 Hz, 2H), 6.98–7.07 (m, 1H), 6.93 (d, <i>J</i> = 9.09 Hz, 3H), 6.35 (d, <i>J</i> = 16.17 Hz, 1H), 3.91 (s, 3H), 3.82 (d, <i>J</i> = 1.52 Hz, 6H). LC/MS ESI <i>m</i>/<i>z</i> 463.4 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2: To a 30 mL vial containing (<i>E</i>)-methyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (200 mg, 0.43 mmol) were added THF (5 mL), triphenylphosphine (420 mg, 1.60 mmol), and TMS-Cl (0.553 mL, 4.32 mmol). The reaction was heated to 75 °C for 18 h, after which time the mixture was cooled to room temperature, quenched with sat. aq. NaHCO<sub>3</sub>, and diluted with DCM. The organic phase was collected, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the crude product, which was purified by column chromatography (SiO<sub>2</sub>, 0–60% EtOAc/heptane) to afford (<i>E</i>)-methyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (110 mg, 57% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 7.58–7.73 (m, 3H), 7.38–7.50 (m, <i>J</i> = 8.59 Hz, 2H), 7.28 (t, <i>J</i> = 2.27 Hz, 2H), 6.96–7.05 (m, <i>J</i> = 8.59 Hz, 2H), 6.85–6.96 (m, 3H), 6.32 (d, <i>J</i> = 15.66 Hz, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 3.82 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 447.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 3: To a 30 mL vial containing (<i>E</i>)-methyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (110 mg, 0.25 mmol) were added THF (2.00 mL), MeOH (1.00 mL), H<sub>2</sub>O (1.00 mL), and LiOH (29.5 mg, 1.23 mmol). The resulting mixture was stirred at room temperature for 60 min, after which the reaction was concentrated <i>in vacuo</i>, diluted with water, and acidified to pH 2 with 6 M HCl, causing a precipitate to form. The mixture was diluted with 20 mL of CH<sub>2</sub>Cl<sub>2</sub> and 2 mL of MeOH, and the organic layer was collected, dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (98 mg, 92% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.51–7.69 (m, 5H), 7.43 (d, <i>J</i> = 2.02 Hz, 1H), 7.25 (d, <i>J</i> = 9.09 Hz, 1H), 6.88–7.02 (m, 5H), 6.37 (d, <i>J</i> = 15.66 Hz, 1H), 3.89 (s, 3H), 3.80 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 433.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-<i>N</i>-methylacrylamide (<b>35a</b>)</h4><div class="NLM_p last">To a solution of (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (97 mg, 0.240 mmol) in 10:1 THF:DMF (4.4 mL) were added HATU (137 mg, 0.360 mmol) and DIEA (0.209 mL, 1.199 mmol), and the mixture was stirred for 10 min, after which time methylamine hydrochloride was added (48.6 mg, 0.720 mmol) and the mixture was stirred at room temperature for 6 h. The reaction was quenched with water and diluted with EtOAc, the layers were separated, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the crude product. The material was dissolved in MeOH (2 mL) and purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-<i>N</i>-methylacrylamide (80.6 mg, 80% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 2.66–2.71 (m, 3H), 6.43 (d, <i>J</i> = 15.66 Hz, 1H), 6.69–6.86 (m, 3H), 6.90–7.00 (m, 2H), 7.10 (d, <i>J</i> = 8.59 Hz, 1H), 7.26 (d, <i>J</i> = 2.02 Hz, 1H), 7.33 (d, <i>J</i> = 15.66 Hz, 1H), 7.42–7.55 (m, 4H), 7.75–7.87 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 25.71, 108.13, 115.05, 115.71, 115.93, 120.68, 121.40, 122.43, 125.59, 126.01, 128.34, 129.41, 129.48, 135.98, 137.60, 137.85, 155.90, 157.45, 158.14, 165.55. HRMS ESI <i>m</i>/<i>z</i> 418.1102 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (<i>E</i>)-3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylamide (<b>35b</b>)</h4><div class="NLM_p last">In a 30 mL vial, (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (98 mg, 0.23 mmol) was dissolved in DMF (2 mL). The vial was charged with HATU (129 mg, 0.34 mmol) and DIEA (0.119 mL, 0.68 mmol), and the mixture was stirred for 10 min. A color change from pale orange to a dark orange was observed. To the solution was added NH<sub>4</sub>Cl (24.24 mg, 0.45 mmol), and the reaction mixture was stirred for 30 min at room temperature. The reaction was quenched with sat. aq. NH<sub>4</sub>Cl and diluted with DCM. The organic phase was collected (phase separator) and concentrated to afford the crude product. The crude material was purified by column chromatography (SiO<sub>2</sub>, 1–10% MeOH/DCM) to afford (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylamide (77 mg, 79% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 8.00 (s, 4H), 7.59–7.70 (m, 2H), 7.45–7.55 (m, 2H), 7.42 (d, <i>J</i> = 2.02 Hz, 1H), 7.24 (d, <i>J</i> = 8.59 Hz, 1H), 6.84–7.02 (m, 4H), 6.52 (d, <i>J</i> = 15.66 Hz, 1H), 3.88 (s, 2H), 3.79 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 432.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylamide (<b>35c</b>)</h4><div class="NLM_p last">The title compound was prepared in 34% yield from (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid and NH<sub>4</sub>Cl using the procedure described for the synthesis of <b>35a</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 6.48 (d, <i>J</i> = 15.66 Hz, 1H), 6.73–6.76 (m, 1H), 6.76–6.78 (m, 1H), 6.80 (dd, <i>J</i> = 8.84, 2.27 Hz, 1H), 6.89–6.98 (m, 2H), 7.16 (d, <i>J</i> = 8.59 Hz, 1H), 7.19 (d, <i>J</i> = 2.02 Hz, 1H), 7.42–7.55 (m, 5H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 108.97, 115.81, 116.74, 117.06, 119.91, 122.75, 124.90, 127.74, 128.32, 129.92, 130.59, 130.89, 138.23, 139.73, 142.20, 157.27, 158.75, 160.74, 171.31. HRMS ESI <i>m</i>/<i>z</i> 404.0944 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-<i>N</i>-(2-hydroxyethyl)acrylamide (<b>35d</b>)</h4><div class="NLM_p last">The title compound was prepared in 30% yield from (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid and ethanolamine using the procedure described for the synthesis of <b>35a</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 3.41 (t, <i>J</i> = 5.56 Hz, 2H), 3.65 (t, <i>J</i> = 5.81 Hz, 2H), 6.47 (d, <i>J</i> = 15.66 Hz, 1H), 6.71–6.77 (m, 2H), 6.79 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 6.88–6.96 (m, 2H), 7.15 (d, <i>J</i> = 9.09 Hz, 1H), 7.18 (d, <i>J</i> = 2.02 Hz, 1H), 7.42–7.54 (m, 5H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 43.29, 61.78, 109.12, 116.07, 116.90, 117.05, 120.35, 122.68, 124.70, 127.55, 128.07, 129.88, 130.68, 130.77, 138.24, 139.70, 141.23, 157.87, 159.18, 160.67, 169.27. HRMS ESI <i>m</i>/<i>z</i> 448.1205 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-<i>N</i>-(3,3,3-trifluoropropyl)acrylamide (<b>35e</b>)</h4><div class="NLM_p">Step 1: To a 30 mL vial containing (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (41 mg, 0.10 mmol) was added DMF (3 mL), followed by 3,3,3-trifluoropropan-1-amine (13.94 mg, 0.12 mmol), HATU (54.1 mg, 0.14 mmol), and DIEA (0.050 mL, 0.28 mmol). The mixture was stirred at room temperature for 30 min, after which the reaction was quenched with sat. aq. NH<sub>4</sub>Cl and diluted with DCM. The organic phase was collected (phase separator) and concentrated <i>in vacuo</i> onto silica gel. The crude material was purified by column chromatography (SiO<sub>2</sub>, 0–30% EtOAc/heptane) to afford (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-<i>N</i>-(3,3,3-trifluoropropyl)acrylamide (38 mg, 72% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.64 (d, <i>J</i> = 9.09 Hz, 2H), 7.45–7.56 (m, 3H), 7.42 (d, <i>J</i> = 2.02 Hz, 1H), 7.25 (d, <i>J</i> = 8.59 Hz, 1H), 6.90–7.02 (m, 5H), 6.47 (d, <i>J</i> = 15.66 Hz, 1H), 3.88 (s, 3H), 3.74–3.85 (m, 3H), 3.54 (t, <i>J</i> = 7.07 Hz, 2H), 2.34–2.56 (m, 2H). LC/MS ESI <i>m</i>/<i>z</i> 528.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a 30 mL vial containing (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-<i>N</i>-(3,3,3-trifluoropropyl)acrylamide (38 mg, 0.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) was added BBr<sub>3</sub> (1 M in heptane, 0.072 mL, 0.07 mmol), and the reaction was stirred at room temperature for 1 h. The reaction was quenched with 4 mL of MeOH and stirred for 10 min at room temperature, after which time the resulting mixture was concentrated to 50% volume and the crude product was purified by reverse phase HPLC (acidic conditions, 0.1% TFA in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-<i>N</i>-(3,3,3-trifluoropropyl)acrylamide (31 mg, 86% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.40–7.63 (m, 5H), 7.21 (d, <i>J</i> = 2.02 Hz, 1H), 7.15 (d, <i>J</i> = 8.59 Hz, 1H), 6.88–6.98 (m, 2H), 6.68–6.87 (m, 3H), 6.45 (d, <i>J</i> = 15.66 Hz, 1H), 3.54 (t, <i>J</i> = 7.07 Hz, 2H), 2.46 (tq, <i>J</i> = 6.82, 10.95 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 34.18, 34.46, 108.96, 115.80, 116.74, 117.08, 119.92, 122.75, 124.90, 126.74, 127.75, 128.33, 129.48, 129.92, 130.59, 130.84, 138.23, 139.73, 141.60, 157.25, 158.75, 160.73, 169.07. LC/MS ESI <i>m</i>/<i>z</i> 500.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (<i>E</i>)-5-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-1<i>H</i>-tetrazole (<b>36</b>)</h4><div class="NLM_p last">To a microwave vial, (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylamide (75 mg, 0.174 mmol) and Bu<sub>2</sub>SnO (4.33 mg, 0.02 mmol) were suspended in dimethoxyethane (3 mL). The vial was charged with TMSN<sub>3</sub> (0.023 mL, 0.17 mmol), and the reaction was heated for 60 min at 180 °C under microwave irradiation. The reaction mixture was filtered to remove solids and concentrated onto silica gel. The crude material was purified by column chromatography (SiO<sub>2</sub>, 1–20% MeOH/DCM) to afford (<i>E</i>)-5-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-1<i>H</i>-tetrazole (66 mg, 83% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.45–7.61 (m, 5H), 7.32 (d, <i>J</i> = 2.02 Hz, 1H), 7.15 (d, <i>J</i> = 9.09 Hz, 1H), 6.98 (d, <i>J</i> = 16.67 Hz, 1H), 6.86–6.93 (m, 2H), 6.78–6.86 (m, 3H), 3.78 (s, 3H), 3.69 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 457.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>E</i>)-3-(4-(2-(1<i>H</i>-Tetrazol-5-yl)vinyl)phenoxy)-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-6-ol (<b>37</b>)</h4><div class="NLM_p last">The title compound was prepared as a pale yellow solid in 40% yield from (<i>E</i>)-5-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-1<i>H</i>-tetrazole using the procedure described for the synthesis of <b>14</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.45–7.56 (m, 3H), 7.38–7.45 (m, 2H), 7.10 (d, <i>J</i> = 2.02 Hz, 1H), 7.06 (d, <i>J</i> = 8.59 Hz, 1H), 6.98 (d, <i>J</i> = 16.17 Hz, 1H), 6.84–6.92 (m, <i>J</i> = 9.09 Hz, 2H), 6.70 (dd, <i>J</i> = 2.02, 8.59 Hz, 1H), 6.61–6.67 (m, 2H). LC/MS ESI <i>m</i>/<i>z</i> 429.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (<i>E</i>)-2-(4-Hydroxyphenyl)-3-(4-(2-(1-methyl-1<i>H</i>-tetrazol-5-yl)vinyl)-phenoxy)benzo[<i>b</i>]thiophen-6-ol (<b>38</b>) and (<i>E</i>)-2-(4-Hydroxyphenyl)-3-(4-(2-(2-methyl-2<i>H</i>-tetrazol-5-yl)vinyl)-phenoxy)benzo[<i>b</i>]thiophen-6-ol (<b>39</b>)</h4><div class="NLM_p">Step 1: To a 30 mL vial containing (<i>E</i>)-5-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-2<i>H</i>-tetrazole (15 mg, 0.03 mmol) in DMF (2 mL) were added with iodomethane (2.260 μL, 0.04 mmol) and K<sub>2</sub>CO<sub>3</sub> (13.62 mg, 0.10 mmol), and the reaction was stirred at room temperature for 18 h. The reaction was quenched with sat. aq. NH<sub>4</sub>Cl (15 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (25 mL). The organic phase was collected (phase separator) and concentrated <i>in vacuo</i> to afford the crude product. The crude product was purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-5-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-1-methyl-1<i>H</i>-tetrazole (8 mg, 0.08 mmol, 52% yield) and (<i>E</i>)-5-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-2-methyl-2<i>H</i>-tetrazole (6 mg, 0.01 mmol, 39% yield) both as a white solids.</div><div id="sec5_1_28_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (<i>E</i>)-5-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-1-methyl-1<i>H</i>-tetrazole</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.48–7.60 (m, 3H), 7.39–7.48 (m, 2H), 7.30 (d, <i>J</i> = 2.02 Hz, 1H), 7.14 (d, <i>J</i> = 9.09 Hz, 1H), 6.95 (d, <i>J</i> = 16.67 Hz, 1H), 6.77–6.90 (m, 5H), 4.24 (s, 3H), 3.76 (s, 3H), 3.68 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 471.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_28_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (<i>E</i>)-5-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-2-methyl-2<i>H</i>-tetrazole</h5><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.75 (d, <i>J</i> = 16.17 Hz, 1H), 7.59–7.70 (m, 4H), 7.43 (d, <i>J</i> = 2.02 Hz, 1H), 7.27 (d, <i>J</i> = 8.59 Hz, 1H), 7.09 (d, <i>J</i> = 16.17 Hz, 1H), 6.97–7.05 (m, 2H), 6.90–6.97 (m, 3H), 4.14 (s, 3H), 3.89 (s, 3H), 3.80 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 471.4 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2 for preparation of <b>38</b>: The title compound was prepared as a white solid in 35% yield from (<i>E</i>)-5-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-1-methyl-1<i>H</i>-tetrazole using the procedure described for the synthesis of <b>14</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.52 (d, <i>J</i> = 16.67 Hz, 1H), 7.38–7.48 (m, 4H), 7.09 (d, <i>J</i> = 2.02 Hz, 1H), 7.06 (d, <i>J</i> = 8.59 Hz, 1H), 6.96 (d, <i>J</i> = 16.67 Hz, 1H), 6.81–6.90 (m, 2H), 6.61–6.73 (m, 3H), 4.24 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 443.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2 for preparation of <b>39</b>: The title compound was prepared as a white solid in 32% yield from (<i>E</i>)-5-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)styryl)-2-methyl-2<i>H</i>-tetrazole using the procedure described for the synthesis of <b>14</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.64 (d, <i>J</i> = 16.17 Hz, 1H), 7.51–7.59 (m, <i>J</i> = 8.59 Hz, 2H), 7.37–7.47 (m, <i>J</i> = 8.59 Hz, 2H), 7.10 (d, <i>J</i> = 2.02 Hz, 1H), 7.07 (d, <i>J</i> = 8.59 Hz, 1H), 6.97 (d, <i>J</i> = 16.17 Hz, 1H), 6.88 (d, <i>J</i> = 8.59 Hz, 2H), 6.61–6.76 (m, 3H), 4.03 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 443.3 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>E</i>)-Ethyl 3-(4-((6-Methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)-2-methylphenyl)acrylate (<b>40a</b>)</h4><div class="NLM_p last">The title compound was prepared in 54% yield from 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide and ethyl (<i>E</i>)-3-(4-hydroxy-2-methylphenyl)acrylate (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis) using the procedure described for the synthesis of <b>34</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 491.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>E</i>)-Ethyl 3-(4-((6-Methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)-3-methylphenyl)acrylate (<b>40b</b>)</h4><div class="NLM_p last">The title compound was prepared in 43% yield from 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide and ethyl (<i>E</i>)-3-(4-hydroxy-3-methylphenyl)acrylate (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis) using the procedure described for the synthesis of <b>34</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 491.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>E</i>)-Ethyl 3-(2-Methoxy-4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>40c</b>)</h4><div class="NLM_p last">The title compound was prepared in 54% yield from 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide and ethyl (<i>E</i>)-3-(4-hydroxy-2-methoxyphenyl)acrylate (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis) using the procedure described for the synthesis of <b>34</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 507.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>E</i>)-Ethyl 3-(4-((6-Methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-2-methyl acrylate (<b>40d</b>)</h4><div class="NLM_p last">The title compound was prepared in 86% yield from 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide and (<i>E</i>)-ethyl 3-(4-hydroxyphenyl)-2-methyl acrylate (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis) using the procedure described for the synthesis of <b>34</b>, step 1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 1.35 (t, <i>J</i> = 7.07 Hz, 3H), 2.09 (d, <i>J</i> = 1.52 Hz, 3H), 3.81 (s, 3H), 3.90 (s, 3H), 4.28 (q, <i>J</i> = 7.07 Hz, 2H), 6.91 (d, <i>J</i> = 8.59 Hz, 2H), 6.94 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 7.05–7.12 (m, 3H), 7.33 (d, <i>J</i> = 8.59 Hz, 2H), 7.52 (d, <i>J</i> = 2.53 Hz, 1H), 7.60 (s, 1H), 7.73 (d, <i>J</i> = 9.09 Hz, 2H). LC/MS ESI <i>m</i>/<i>z</i> 491.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Methyl (<i>E</i>)-3-(4-((6-Methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)but-2-enoate (<b>40e</b>)</h4><div class="NLM_p last">The title compound was prepared in 67% yield from 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide and methyl (<i>E</i>)-3-(4-hydroxyphenyl)but-2-enoate (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis) using the procedure described for the synthesis of <b>34</b>, step 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.48–7.61 (m, 3H), 7.34–7.45 (m, 2H), 6.94–7.16 (m, 4H), 6.77–6.89 (m, 2H), 6.00 (d, <i>J</i> = 1.52 Hz, 1H), 3.81 (s, 3H), 3.69 (s, 3H), 3.62 (s, 3H), 2.42 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 478.4 [M + H<sub>2</sub>O]<sup>+</sup>.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Ethyl (<i>E</i>)-2-(4-((6-Methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)benzylidene)butanoate (<b>40f</b>)</h4><div class="NLM_p last">The title compound was prepared in 76% yield from 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophene 1-oxide and ethyl (<i>E</i>)-2-(4-hydroxybenzylidene)butanoate (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis) using the procedure described for the synthesis of <b>34</b>, step 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.02 (t, <i>J</i> = 7.58 Hz, 3H), 1.22 (t, <i>J</i> = 7.07 Hz, 3H), 2.39 (q, <i>J</i> = 7.58 Hz, 2H), 3.68 (s, 3H), 3.81 (s, 3H), 4.14 (q, <i>J</i> = 7.07 Hz, 2H), 6.78–6.85 (m, 2H), 6.99–7.11 (m, 4H), 7.25 (d, <i>J</i> = 8.59 Hz, 2H), 7.45 (s, 1 H), 7.48–7.57 (m, 3H). LC/MS ESI <i>m</i>/<i>z</i> 505.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Ethyl (<i>E</i>)-3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-methylphenyl)acrylate (<b>41a</b>)</h4><div class="NLM_p last">The title compound was prepared in 78% yield from (<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)-2-methylphenyl)acrylate using the procedure described for the synthesis of <b>34</b>, step 2.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Ethyl (<i>E</i>)-3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-3-methylphenyl)acrylate (<b>41b</b>)</h4><div class="NLM_p last">The title compound was prepared in 67% yield from (<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)-3-methylphenyl)acrylate using the procedure described for the synthesis of <b>34</b>, step 2. LC/MS ESI <i>m</i>/<i>z</i> 475.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Ethyl (<i>E</i>)-3-(2-Methoxy-4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>41c</b>)</h4><div class="NLM_p last">The title compound was prepared in 76% yield from (<i>E</i>)-ethyl 3-(2-methoxy-4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>34</b>, step 2. LC/MS ESI <i>m</i>/<i>z</i> 491.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>E</i>)-Ethyl 3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-2-methyl acrylate (<b>41d</b>)</h4><div class="NLM_p last">The title compound was prepared in 77% yield from (<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-2-methyl acrylate using the procedure described for the synthesis of <b>34</b>, step 2. LC/MS ESI <i>m</i>/<i>z</i> 475.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Methyl (<i>E</i>)-3-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)but-2-enoate (<b>41e</b>)</h4><div class="NLM_p last">The title compound was prepared in 65% yield from methyl (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)but-2-enoate using the procedure described for the synthesis of <b>34</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.52–7.65 (m, 2H), 7.27–7.38 (m, 2H), 7.13–7.23 (m, 2H), 6.84–6.93 (m, 2H), 6.75–6.84 (m, 3H), 6.01 (d, <i>J</i> = 1.52 Hz, 1H), 3.80 (s, 3H), 3.72 (s, 3H), 3.66 (s, 3H), 2.46 (d, <i>J</i> = 1.01 Hz, 3H). LC/MS ESI <i>m</i>/<i>z</i> 461.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Ethyl (<i>E</i>)-2-(4-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)benzylidene)butanoate (<b>41f</b>)</h4><div class="NLM_p last">The title compound was prepared as a white solid in 98% yield from ethyl (<i>E</i>)-2-(4-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)benzylidene)butanoate using the procedure described for the synthesis of <b>34</b>, step 2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 1.15 (t, <i>J</i> = 7.58 Hz, 3H), 1.34 (t, <i>J</i> = 7.07 Hz, 3H), 2.54 (q, <i>J</i> = 7.24 Hz, 2H), 3.81 (s, 3H), 3.88 (s, 3H), 4.26 (q, <i>J</i> = 7.07 Hz, 2H), 6.90 (d, <i>J</i> = 8.59 Hz, 3H), 6.98 (d, <i>J</i> = 9.09 Hz, 2H), 7.25–7.29 (m, 2H), 7.31 (d, <i>J</i> = 8.59 Hz, 2H), 7.57 (s, 1H), 7.66 (d, <i>J</i> = 9.09, 2H). LC/MS ESI <i>m</i>/<i>z</i> 489.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-methylphenyl)acrylic Acid (<b>42a</b>)</h4><div class="NLM_p">Step 1: To a solution of ethyl (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-methylphenyl)acrylate in CH<sub>2</sub>Cl<sub>2</sub> (3.0 mL) at 0 °C was added BBr<sub>3</sub> (1 M in hexanes, 0.697 mL, 0.697 mmol), and the resulting mixture was stirred for 1 h at 0 °C. Upon completion, the reaction was quenched with water and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with sat. aq. NaHCO<sub>3</sub>, dried over anhyhdrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the crude product, which was purified by column chromatography (SiO<sub>2</sub>, 0–30% EtOAc/heptane) to afford ethyl (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-methylphenyl)acrylate (78 mg, 93% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 1.34 (t, <i>J</i> = 7.07 Hz, 3H), 2.36 (s, 3H), 4.27 (q, <i>J</i> = 7.07 Hz, 2H), 4.77 (br s, 2H), 6.25 (d, <i>J</i> = 16.17 Hz, 1H), 6.74–6.87 (m, 5H), 7.22–7.26 (m, 2H), 7.45 (d, <i>J</i> = 8.59 Hz, 1H), 7.56–7.63 (m, 2H), 7.89 (d, <i>J</i> = 15.66 Hz, 1H). HRMS ESI <i>m</i>/<i>z</i> 447.1245 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of ethyl (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-methylphenyl)acrylate (51 mg, 0.114 mmol) in EtOH (1.0 mL) at room temperature was added LiOH (2 N aq., 0.4 mL, 0.800 mmol); the reaction was allowed to stir at room temperature for 18 h, after which time the reaction was quenched with 4 N HCl until pH ∼ 3 and then extracted with EtOAc (2×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give the crude product, which was purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 1–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-methylphenyl)acrylic acid (30 mg, 63% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 2.34 (s, 3H), 6.26 (d, <i>J</i> = 16.17 Hz, 1H), 6.61–6.90 (m, 5H), 7.08–7.32 (m, 2H), 7.41–7.65 (m, 3H), 7.90 (d, <i>J</i> = 16.17 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 20.06, 108.95, 114.79, 115.78, 116.73, 118.50, 118.77, 122.77, 124.94, 127.70, 128.40, 128.95, 129.51, 129.89, 138.19, 139.69, 141.43, 143.11, 157.23, 158.72, 160.76, 170.88. HRMS ESI <i>m</i>/<i>z</i> 417.0779 [M – H]<sup>−</sup>.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-3-methylphenyl)acrylic Acid (<b>42b</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 77% yield from ethyl (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-3-methylphenyl)acrylate using the procedure described for the synthesis of <b>42a</b>, step 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.29 (t, <i>J</i> = 7.07 Hz, 3H), 2.50 (s, 3H), 4.21 (q, <i>J</i> = 7.07 Hz, 2H), 6.33 (d, <i>J</i> = 16.17 Hz, 1H), 6.50 (d, <i>J</i> = 8.08 Hz, 1H), 6.75 (d, <i>J</i> = 8.59 Hz, 2H), 6.79 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.09 (d, <i>J</i> = 8.59 Hz, 1H), 7.16–7.22 (m, 2H), 7.44–7.52 (m, 3H), 7.57 (d, <i>J</i> = 16.17 Hz, 1H). HRMS ESI <i>m</i>/<i>z</i> 447.1278 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 80% yield from ethyl (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-3-methylphenyl)acrylate using the procedure described for the synthesis of <b>42a</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 2.38–2.63 (m, 3H), 6.30 (d, <i>J</i> = 16.17 Hz, 1H), 6.50 (d, <i>J</i> = 8.59 Hz, 1H), 6.73–6.77 (m, 2H), 6.79 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.09 (d, <i>J</i> = 8.59 Hz, 1H), 7.15–7.24 (m, 2H), 7.42–7.53 (m, 3H), 7.57 (d, <i>J</i> = 16.17 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 16.58, 108.96, 114.86, 115.82, 116.74, 117.61, 122.61, 124.98, 127.57, 128.17, 128.32, 128.73, 129.80, 130.01, 132.25, 138.24, 139.87, 146.05, 157.25, 158.74, 159.14, 170.94. HRMS ESI <i>m</i>/<i>z</i> 417.0782 [M – H]<sup>−</sup>.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-methoxyphenyl)acrylic Acid (<b>42c</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 16% yield from ethyl (<i>E</i>)-3-(2-methoxy-4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>42a</b>, step 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.28 (t, <i>J</i> = 7.07 Hz, 3H), 3.75 (s, 3H), 4.20 (q, <i>J</i> = 7.07 Hz, 2H), 6.39 (d, <i>J</i> = 16.17 Hz, 1H), 6.46 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 6.64 (d, <i>J</i> = 2.02 Hz, 1H), 6.76 (d, <i>J</i> = 8.59 Hz, 2H), 6.81 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.14–7.23 (m, 2H), 7.40 (d, <i>J</i> = 8.59 Hz, 1H), 7.49 (d, <i>J</i> = 9.09 Hz, 2H), 7.84 (d, <i>J</i> = 16.17 Hz, 1H). HRMS ESI <i>m</i>/<i>z</i> 463.1185 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 52% yield from ethyl (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)-2-methoxyphenyl)acrylate using the procedure described for the synthesis of <b>42a</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 3.75 (s, 3H), 6.38 (d, <i>J</i> = 16.17 Hz, 1H), 6.46 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 6.65 (d, <i>J</i> = 2.02 Hz, 1H), 6.75–6.79 (m, 2H), 6.79–6.84 (m, 1H), 7.19 (dd, <i>J</i> = 5.31, 3.28 Hz, 2H), 7.41 (d, <i>J</i> = 8.59 Hz, 1H), 7.47–7.54 (m, 2H), 7.84 (d, <i>J</i> = 16.17 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 56.31, 100.56, 108.64, 108.94, 115.82, 116.77, 117.95, 119.07, 122.76, 124.88, 127.81, 128.34, 129.96, 131.35, 138.17, 139.57, 141.09, 157.23, 158.75, 161.43, 162.40, 171.64. LC/MS ESI <i>m</i>/<i>z</i> 435.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-2-methylacrylic Acid (<b>42d</b>)</h4><div class="NLM_p last">The title compound was prepared in 34% yield from (<i>E</i>)-ethyl 3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-2-methyl acrylate using the procedure described for the synthesis of <b>16</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 2.07 (d, <i>J</i> = 1.52 Hz, 3 H), 6.78 (d, <i>J</i> = 9.09 Hz, 2 H), 6.82 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 6.97 (d, <i>J</i> = 8.59 Hz, 2H), 7.16–7.22 (m, 2H), 7.38 (d, <i>J</i> = 9.09 Hz, 2H), 7.53 (d, <i>J</i> = 9.09 Hz, 2H), 7.63 (s, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 14.43, 108.95, 115.77, 116.64, 116.73, 122.80, 124.97, 127.71, 128.41, 128.57, 129.91, 131.63, 132.86, 138.23, 139.47, 139.85, 157.21, 158.71, 159.42, 172.54. HRMS ESI <i>m</i>/<i>z</i> 419.0872 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)but-2-enoic Acid (<b>42e</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 33% yield from methyl (<i>E</i>)-3-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)but-2-enoate using the procedure described for the synthesis of <b>42a</b>, step 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.35–7.46 (m, 4H), 7.01–7.11 (m, 2H), 6.79–6.89 (m, 2H), 6.62–6.71 (m, 3H), 6.02 (d, <i>J</i> = 1.52 Hz, 1H), 3.60 (s, 3H), 2.41 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 431.4 [M – H]<sup>−</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 41% yield from methyl (<i>E</i>)-3-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)but-2-enoate using the procedure described for the synthesis of <b>42a</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.42 (d, <i>J</i> = 9.09 Hz, 2H), 7.27–7.34 (m, <i>J</i> = 8.59 Hz, 2H), 7.00–7.13 (m, 2H), 6.75–6.82 (m, <i>J</i> = 9.09 Hz, 2H), 6.61–6.72 (m, 3H), 6.05 (s, 1H), 2.25 (d, <i>J</i> = 1.01 Hz, 3H). LC/MS ESI <i>m</i>/<i>z</i> 417.4 [M – H]<sup>−</sup>.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (<i>E</i>)-2-(4-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)benzylidene)butanoic Acid (<b>42f</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 68% yield from ethyl (<i>E</i>)-2-(4-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)benzylidene)butanoate using the procedure described for the synthesis of <b>42a</b>, step 1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.14 (t, <i>J</i> = 7.33 Hz, 3H), 1.33 (t, <i>J</i> = 7.33 Hz, 3H), 2.54 (q, <i>J</i> = 7.24 Hz, 2H), 4.25 (q, <i>J</i> = 7.07 Hz, 2H), 6.71–6.85 (m, 3H), 6.92–7.01 (m, 2H), 7.12–7.25 (m, 2H), 7.36 (m, 2H), 7.49–7.63 (m, 3H). LC/MS ESI <i>m</i>/<i>z</i> 461.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 70% yield from ethyl (<i>E</i>)-2-(4-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)benzylidene)butanoate using the procedure described for the synthesis of <b>42a</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.15 (t, <i>J</i> = 7.33 Hz, 3H), 2.53 (q, <i>J</i> = 7.24 Hz, 2H), 6.71–6.85 (m, 3H), 6.92–7.01 (m, 2H), 7.12–7.24 (m, 2H), 7.36 (m, <i>J</i> = 9.09 Hz, 2H), 7.48–7.64 (m, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 14.22, 21.79, 108.95, 115.77, 116.73, 116.74, 122.81, 124.97, 127.70, 128.42, 129.92, 131.43, 132.39, 135.37, 138.23, 138.88, 139.86, 157.21, 158.71, 159.49, 172.30. LC/MS ESI <i>m</i>/<i>z</i> 433.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (5-((6-Methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)methanol (<b>43</b>)</h4><div class="NLM_p">Step 1: To a solution of methyl 5-hydroxypyridine-2-carboxylate (0.273 g, 1.78 mmol) in DMF (6.84 mL) at room temperature was added sodium hydride (60% suspension in oil, 0.043 g, 1.78 mmol), and the resulting mixture was stirred at room temperature for 30 min. After 30 min at room temperature, 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzothiophene 1-oxide (0.5 g, 1.37 mmol) was added and the reaction was heated to 80 °C for 18 h. Upon completion, the reaction was cooled to room temperature, quenched with water, and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were combined, passed through a phase separator, and concentrated <i>in vacuo</i> to give the crude product, which was purified by column chromatography (SiO<sub>2</sub>, 0–75% EtOAc/heptane) to afford methyl 5-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)picolinate (314 mg, 52% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 3.73 (s, 3H), 3.84 (s, 3H), 3.90–3.92 (m, 3H), 6.79–6.86 (m, 2H), 6.91 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 7.03 (d, <i>J</i> = 8.59 Hz, 1H), 7.0 (dd, <i>J</i> = 8.59, 3.03 Hz, 1H), 7.48 (d, <i>J</i> = 2.53 Hz, 1H), 7.55–7.60 (m, 2H), 7.95 (d, <i>J</i> = 8.59 Hz, 1H), 8.55 (d, <i>J</i> = 2.02 Hz, 1H). LC/MS ESI <i>m</i>/<i>z</i> 438.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of methyl 5-((6-methoxy-2-(4-methoxyphenyl)-1-oxidobenzo[<i>b</i>]thiophen-3-yl)oxy)picolinate (0.314 g, 0.718 mmol) in THF (5.98 mL) at 0 °C was added LiAlH<sub>4</sub> (1.0 M in THF, 2.153 mL, 2.15 mmol) dropwise, and the reaction was stirred at 0 °C for 1 h. Upon completion, the reaction was quenched with water and sat. aq. potassium sodium tartrate, and the resulting mixture was stirred for 30 min and then extracted with EtOAc (3×). The organic layers were combined, passed through a phase separator, and concentrated <i>in vacuo</i> to afford crude (5-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)methanol (0.266 g, 93% yield), which was used without further purification. LC/MS ESI <i>m</i>/<i>z</i> 394.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (<i>E</i>)-Methyl 3-(5-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)acrylate (<b>44</b>)</h4><div class="NLM_p">Step 1: To a solution of (5-((6-methoxy-2-(4-methoxyphenyl)-benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)methanol (0.266 g, 0.676 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3.38 mL) was added manganese dioxide (1.176 g, 13.52 mmol), and the reaction was stirred at room temperature for 48 h. Upon completion, the reaction was was filtered over Celite and concentrated <i>in vacuo</i> to afford crude 5-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)picolinaldehyde, which was used without further purification. LC/MS ESI <i>m</i>/<i>z</i> 392.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of 5-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)picolinaldehyde (0.265 g, 0.68 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3.38 mL) at 0 °C was added methyl 2-(triphenylphosphoranylidene)acetate (0.543 g, 1.63 mmol), and the reaction was stirred at room temperature for 18 h. Upon completion, the mixture was concentrated <i>in vacuo</i> to afford crude material, which was purified by column chromatography (SiO<sub>2</sub>, 0–25% EtOAc/heptanes) to afford (<i>E</i>)-methyl 3-(5-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)acrylate (96 mg, 32% yield over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 3.70–3.75 (m, 6H), 3.79–3.83 (m, 3H), 6.70 (d, <i>J</i> = 15.66 Hz, 1H), 6.77–6.88 (m, 3H), 7.02 (dd, <i>J</i> = 8.59, 3.03 Hz, 1H), 7.17 (s, 1H), 7.18–7.22 (m, 2H), 7.48–7.59 (m, 3H), 8.42 (d, <i>J</i> = 2.53 Hz, 1H). LC/MS ESI <i>m</i>/<i>z</i> 448.3 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (<i>E</i>)-3-(5-((6-Hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)acrylic Acid (<b>45</b>)</h4><div class="NLM_p">Step 1: To a solution of (<i>E</i>)-methyl 3-(5-((6-methoxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)acrylate (0.096 g, 0.215 mmol) in DCM (2.145 mL) at room temperature was added BBr<sub>3</sub> (1.0 M in heptane, 0.858 mL, 0.86 mmol), and the reaction was stirred at room temperature for 30 min. Upon completion, the reaction was quenched with MeOH (2.0 mL), stirred for 10 min at room temperature, concentrated <i>in vacuo</i> onto silica gel, and purified by column chromatography (SiO<sub>2</sub>, 0–20% MeOH/DCM) to afford (<i>E</i>)-methyl 3-(5-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)acrylate. LC/MS ESI <i>m</i>/<i>z</i> 420.3 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of (<i>E</i>)-methyl 3-(5-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)acrylate (0.118 g, 0.28 mmol) in THF (2.00 mL) and water (2.00 mL) was added lithium hydroxide (1.0 M aq., 0.844 mL, 0.84 mmol), and the reaction was stirred at room temperature for 2 h. Upon completion, the reaction was quenched with water, diluted with CH<sub>2</sub>Cl<sub>2</sub>, and acidified to pH 1 with 1 N HCl. The mixture was extracted with DCM (3×), and the combined organic layers were passed through a phase separator and concentrated <i>in vacuo</i> to afford the crude product, which was purified by reverse phase HPLC (acidic conditions, 3% TFA in 10–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(5-((6-hydroxy-2-(4-hydroxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)pyridin-2-yl)acrylic acid (14 mg, 9% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 6.66 (d, <i>J</i> = 15.66 Hz, 1H), 6.77–6.81 (m, 2H), 6.84 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.17 (d, <i>J</i> = 8.59 Hz, 1H), 7.22 (dd, <i>J</i> = 8.59, 3.03 Hz, 1H), 7.31 (d, <i>J</i> = 2.02 Hz, 1H), 7.44–7.49 (m, 2H), 7.52 (d, <i>J</i> = 15.66 Hz, 1H), 7.64 (d, <i>J</i> = 8.59 Hz, 1H), 8.45 (d, <i>J</i> = 2.53 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 108.24, 115.22, 116.02, 121.19, 121.25, 122.06, 122.41, 125.42, 125.78, 125.98, 128.50, 136.12, 137.11, 138.90, 142.31, 146.81, 154.18, 156.03, 157.60, 167.42. LC/MS ESI <i>m</i>/<i>z</i> 406.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 2-Bromo-3-(4-bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophene 1,1-Dioxide (<b>48</b>)</h4><div class="NLM_p last">To a solution of 2,3-dibromo-6-methoxybenzo[<i>b</i>]thiophene 1,1-dioxide (2.50 g, 7.06 mmol) in THF (100 mL) at room temperature were added 4-bromophenol (1.344 g, 7.77 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (6.90 g, 21.19 mmol). The mixture was stirred at room temperature for 18 h, after which time the reaction was quenched with water and diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was collected (phase separator) and concentrated to provide 2-bromo-3-(4-bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophene 1,1-dioxide (3.10 g, 98% yield) as a white solid, which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 3.83 (s, 3H), 6.92–7.03 (m, 3H), 7.25–7.35 (m, 2H), 7.39–7.50 (m, 2H). LC/MS ESI <i>m</i>/<i>z</i> 446.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 3-(4-Bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophene (<b>49</b>)</h4><div class="NLM_p">Step 1: To a solution of 2-bromo-3-(4-bromophenoxy)-6-methoxy-benzo[<i>b</i>]thiophene 1,1-dioxide (3.10 g, 6.95 mmol) in MeOH (10 mL) and DMSO (30 mL) was added NaBH<sub>4</sub> (0.789 g, 20.85 mmol). The mixture was stirred at room temperature for 3 h, after which time the reaction was quenched with water and diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was collected (phase separator) and concentrated to provide 3-(4-bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophene 1,1-dioxide (2.47 g, 97% yield) as an off white solid, which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 3.85 (s, 3H), 5.38 (s, 1H), 7.02–7.08 (m, 3H), 7.22 (d, <i>J</i> = 2.53 Hz, 1H), 7.47–7.60 (m, 3H). LC/MS ESI <i>m</i>/<i>z</i> 367.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of 3-(4-bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophene 1,1-dioxide (2.47 g, 6.73 mmol) in THF (90 mL) was added DIBAL-H (1.0 M in CH<sub>2</sub>Cl<sub>2</sub>, 33.6 mL, 33.6 mmol) in one portion. The mixture was heated to 75 °C for 2 h, after which time the reaction was cooled to room temperature and quenched with EtOAc (32.9 mL, 336 mmol). The resulting solution was stirred for 10 min before carefully adding 75 mL of water and potassium sodium tartrate (33.100 g, 117 mmol). The mixture was vigorously stirred for 10 min and diluted with 75 mL of EtOAc. The organic layer was collected, dried with anhydrous MgSO<sub>4</sub>, and concentrated <i>in vacuo</i> to afford 3-(4-bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophene (1.9 g, 84% yield) as a white solid, which was used without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 3.81 (s, 3H), 6.46 (s, 1H), 6.90 (d, <i>J</i> = 9.09 Hz, 3H), 7.16–7.22 (m, 1H), 7.31–7.40 (m, 2H), 7.46 (d, <i>J</i> = 9.09 Hz, 1H). LC/MS ESI <i>m</i>/<i>z</i> 336.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (<i>E</i>)-Methyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>50a</b>)</h4><div class="NLM_p last">To a microwave vial, 3-(4-bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophene (500 mg, 1.49 mmol), methyl acrylate (770 mg, 8.95 mmol), and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (157 mg, 0.22 mmol) were suspended in DMF (12 mL) and triethylamine (1.039 mL, 7.46 mmol). The reaction was heated for 60 min at 120 °C under microwave irradiation. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and water. The organic layer was collected (phase separator) and concentrated to obtain the crude product. The crude material was purified by column chromatography (SiO<sub>2</sub>, 1–20% EtOAc/heptane) to afford (<i>E</i>)-methyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (311 mg, 0.91 mmol, 61% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 1.46 (s, 3H), 3.73 (s, 3H), 6.28 (d, <i>J</i> = 16.17 Hz, 1H), 6.59 (s, 1H), 6.90 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.00 (d, <i>J</i> = 8.59 Hz, 2H), 7.21 (d, <i>J</i> = 2.02 Hz, 1H), 7.37–7.48 (m, 3H), 7.59 (d, <i>J</i> = 16.17 Hz, 1H). LC/MS ESI <i>m</i>/<i>z</i> 341.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (<i>E</i>)-<i>tert</i>-Butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>50b</b>)</h4><div class="NLM_p last">To a microwave vial, 3-(4-bromophenoxy)-6-methoxybenzo[<i>b</i>]thiophene (4 g, 11.93 mmol), <i>tert</i>-butyl acrylate (10.49 mL, 71.6 mmol), and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (1.256 g, 1.79 mmol) were suspended in DMF (12 mL) and triethylamine (8.32 mL, 59.7 mmol). The reaction was heated for 60 min at 120 °C under microwave irradiation. The reaction mixture was diluted with DCM and water. The organic layer was collected (phase separator) and concentrated to obtain the crude product. The crude material was purified by column chromatography (SiO<sub>2</sub>, 1–20% EtOAc/heptane) to afford (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (3 g, 66% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 7.45–7.63 (m, 4H), 7.27–7.33 (m, 1H), 7.03–7.13 (m, 2H), 6.99 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 6.66 (s, 1H), 6.30 (d, <i>J</i> = 16.2 Hz, 1H), 3.90 (s, 3H), 1.55 (s, 9H). LC/MS ESI <i>m</i>/<i>z</i> 383.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (<i>E</i>)-Methyl 3-(4-((2-Bromo-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (<b>51</b>)</h4><div class="NLM_p last">To a solution (<i>E</i>)-methyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (310 mg, 0.911 mmol) in THF (11 mL) at room temperature was added <i>N</i>-bromosuccinimide (170 mg, 0.956 mmol). The resulting solution was stirred vigorously at room temperature for 2 h, after which time the reaction was quenched by addition of sat. aq. sodium thiosulfate solution and extracted with EtOAc (3×). The combined organic layers were dried over anhydrous MgSO4, filtered, and concentrated <i>in vacuo</i>. The resulting crude material was purified by column chromatography (SiO<sub>2</sub>, 0–40% EtOAc/heptane) to afford (<i>E</i>)-methyl 3-(4-((2-bromo-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (343 mg, 90% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 7.65 (d, <i>J</i> = 16.0 Hz, 1H), 7.46 (d, <i>J</i> = 8.7 Hz, 2H), 7.32 (d, <i>J</i> = 8.9 Hz, 1H), 7.20 (d, <i>J</i> = 2.2 Hz, 1H), 6.95 (d, <i>J</i> = 8.7 Hz, 2H), 6.91 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 6.31 (s, 1H), 3.86 (s, 3H), 3.79 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 420.9 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-hydroxy-3-methylphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53a</b>)</h4><div class="NLM_p last">The title compound was prepared using a similar procedure to that described for the synthesis of <b>34</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 2.14 (s, 3H), 6.35 (d, <i>J</i> = 15.66 Hz, 1H), 6.69 (d, <i>J</i> = 8.59 Hz, 1H), 6.79 (dd, <i>J</i> = 8.59, 2.53 Hz, 1H), 6.89–7.00 (m, 2H), 7.15 (d, <i>J</i> = 8.59 Hz, 1H), 7.18 (d, <i>J</i> = 2.02 Hz, 1H), 7.33 (dd, <i>J</i> = 8.34, 2.27 Hz, 1H), 7.39 (d, <i>J</i> = 1.52 Hz, 1H), 7.49–7.55 (m, 2H), 7.60 (d, <i>J</i> = 16.17 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 16.45 108.95, 115.75, 115.87, 117.07, 118.01, 122.65, 124.71, 126.17, 127.26, 128.02, 128.41, 130.27, 131.09, 131.21, 138.19, 139.54, 145.66, 156.88, 157.17, 161.12, 170.93. HRMS ESI <i>m</i>/<i>z</i> 419.0915 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (<i>E</i>)-3-(4-((2-(4-Fluorophenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53b</b>)</h4><div class="NLM_p last">The title compound was prepared using a similar procedure to that described for the synthesis of <b>34</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 6.35 (d, <i>J</i> = 16.17 Hz, 1H), 6.82 (dd, <i>J</i> = 8.84, 2.27 Hz, 1H), 6.95 (d, <i>J</i> = 8.59 Hz, 2H), 7.05–7.13 (m, 2H), 7.19 (d, <i>J</i> = 8.59 Hz, 1H), 7.22 (d, <i>J</i> = 2.02 Hz, 1H), 7.53 (d, <i>J</i> = 8.59 Hz, 2H), 7.60 (d, <i>J</i> = 16.17 Hz, 1H), 7.66–7.73 (m, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 108.85, 116.02, 116.64, 116.86, 116.98, 118.09, 123.09, 125.95, 127.77, 130.32, 130.40, 131.14, 138.62, 140.95, 145.40, 157.64, 160.69, 162.38, 164.84, 170.66. HRMS ESI <i>m</i>/<i>z</i> 406.0675 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (<i>E</i>)-3-(4-((6-Hydroxy-2-phenylbenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-acrylic Acid (<b>53c</b>)</h4><div class="NLM_p last">The title compound was prepared using a similar procedure to that described for the synthesis of <b>34</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 6.28 (d, <i>J</i> = 16.17 Hz, 1H), 6.79 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 6.83–6.93 (m, 2H), 7.09–7.30 (m, 5H), 7.38 (d, <i>J</i> = 8.59 Hz, 2H), 7.54 (d, <i>J</i> = 16.17 Hz, 1H), 7.59–7.68 (m, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 108.98, 116.09, 117.11, 118.11, 123.19, 127.27, 128.07, 128.52, 129.03, 130.01, 130.46, 131.25, 133.63, 138.85, 141.16, 145.61, 157.72, 160.94, 170.80. HRMS ESI <i>m</i>/<i>z</i> 389.0834 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-(trifluoromethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53d</b>)</h4><div class="NLM_p">Step 1: To a 5 mL microwave vial was added a solution of (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (50 mg, 0.13 mmol) in anhydrous DMA (1.5 mL), followed by 1-bromo-4-(trifluoromethyl)benzene (35.3 mg, 0.16 mmol), 1-bromo-4-fluorobenzene (448 mg, 2.56 mmol), chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-tri-i-propyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl]palladium(II) (BrettPhos palladacycle first generation, 10.4 mg, 0.013 mmol), trimethylacetic acid (40.1 mg, 0.392 mmol), and potassium carbonate (54.2 mg, 0.392 mmol). The microwave vial was sealed, purged, and backfilled with nitrogen. The reaction mixture subjected to microwave irradiation for 2 h at 150 °C. Upon completion, the reaction was diluted with EtOAc and washed with water and brine. The combined organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give a red brown residue, which was purified by column chromatography (SiO<sub>2</sub>, 0–30% EtOAc/heptane) to afford (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxy-2-(4-(trifluoromethyl)phenyl)benzo[<i>b</i>]thiophen-3 yl)oxy)phenyl)acrylate (59.4 mg, 86% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.42–1.61 (m, 9H), 3.77–3.98 (m, 3H), 6.31 (d, <i>J</i> = 15.66 Hz, 1H), 6.87–7.04 (m, 3H), 7.28 (d, <i>J</i> = 9.09 Hz, 1H), 7.46 (d, <i>J</i> = 2.53 Hz, 1H), 7.47–7.57 (m, 3H), 7.65 (d, <i>J</i> = 8.08 Hz, 2H), 7.89 (d, <i>J</i> = 8.08 Hz, 2H). LC/MS ESI <i>m</i>/<i>z</i> 471.4 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a 2-dram vial containing (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxy-2-(4-(trifluoromethyl)phenyl)benzo[<i>b</i>]thiophen-3 yl)oxy)phenyl)acrylate (59.4 mg, 0.113 mmol) in anhydrous DCM (1.5 mL) at 0 °C was added BBr<sub>3</sub> (1.0 M in DCM, 451 μL, 0.451 mmol) dropwise. The resulting mixture was stirred at 0 °C for 1 h, after which the reaction was quenched with 3 drops of water, diluted with DCM, and extracted with sat. aq. NaHCO<sub>3</sub> (added a few drops of 2-propanol). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to afford the curde material, which was purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 10–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((6-hydroxy-2-(4-(trifluoromethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (33.8 mg, 66% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 6.36 (d, <i>J</i> = 16.17 Hz, 1H), 6.78–6.89 (m, 1H), 6.98 (d, <i>J</i> = 8.59 Hz, 2H), 7.17–7.30 (m, 2H), 7.51–7.70 (m, 5H), 7.88 (d, <i>J</i> = 8.08 Hz, 2H). HRMS ESI <i>m</i>/<i>z</i> 457.0710 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(o-tolyl)benzo-[<i>b</i>]thiophen-3-yl)oxy)-phenyl)acrylic Acid (<b>53e</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 97% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 1-bromo-2-methylbenzene using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 417.3 [M – <i>t</i>-Bu + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 52% yield from <i>tert</i>-butyl (<i>E</i>)-3-(4-((6-methoxy-2-(<i>o</i>-tolyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>53d</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 2.35 (s, 3H), 6.34 (d, <i>J</i> = 15.66 Hz, 1H), 6.76–6.82 (m, 2H), 6.84 (dd, <i>J</i> = 8.84, 2.27 Hz, 1H), 7.13 (d, <i>J</i> = 8.08 Hz, 1H), 7.16–7.38 (m, 8H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 20.82, 108.88, 115.93, 117.13, 117.85, 123.05, 126.63, 126.83, 127.13, 129.92, 130.11, 130.93, 131.45, 132.18, 132.30, 139.10, 140.03, 141.62, 145.69, 157.37, 161.29, 170.82. HRMS ESI <i>m</i>/<i>z</i> 403.0995 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (<i>E</i>)-3-(4-((2-(2-Ethylphenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-acrylic Acid (<b>53f</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 89% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 1-bromo-2-ethylbenzene using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 431.4 [M – <i>t</i>-Bu + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 42% yield from <i>tert</i>-butyl (<i>E</i>)-3-(4-((2-(2-ethylphenyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>53d</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.14 (t, <i>J</i> = 7.58 Hz, 3H), 2.73 (q, <i>J</i> = 7.58 Hz, 2H), 6.34 (d, <i>J</i> = 15.66 Hz, 1H), 6.79 (d, <i>J</i> = 8.59 Hz, 2H), 6.85 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 7.09–7.17 (m, 1H), 7.22 (d, <i>J</i> = 2.02 Hz, 1H), 7.23–7.30 (m, 5H), 7.34 (d, <i>J</i> = 9.09 Hz, 2H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 16.08, 27.78, 108.83, 115.84, 117.03, 123.17, 124.87, 126.41, 126.75, 127.14, 129.89, 130.02, 130.15, 131.52, 131.63, 132.59, 139.94, 140.50, 141.92, 145.42, 157.28, 160.35, 175.75. HRMS ESI <i>m</i>/<i>z</i> 417.1148 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (<i>E</i>)-3-(4-((2-(2-(<i>tert</i>-Butyl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-acrylic Acid (<b>53g</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 53% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 1-bromo-2-(<i>tert</i>-butyl)benzene using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 459.4 [M – <i>t</i>-Bu + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 20% yield from <i>tert</i>-butyl (<i>E</i>)-3-(4-((2-(2-(<i>tert</i>-butyl)phenyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>53d</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.37 (s, 6H), 3.09 (s, 2H), 6.40 (d, <i>J</i> = 15.66 Hz, 1H), 6.71 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 6.79 (d, <i>J</i> = 8.59 Hz, 2H), 6.98 (d, <i>J</i> = 2.02 Hz, 1H), 7.04 (d, <i>J</i> = 8.59 Hz, 1H), 7.16–7.23 (m, 1H), 7.28 (t, <i>J</i> = 7.58 Hz, 2H), 7.35 (d, <i>J</i> = 16.17 Hz, 1H), 7.37–7.41 (m, 2H), 7.44 (d, <i>J</i> = 9.09 Hz, 2H). HRMS ESI <i>m</i>/<i>z</i> 445.1465 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(2-isopropylphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53h</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 85% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 1-bromo-2-isopropylbenzene using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 445.0 [M – <i>t</i>-Bu + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 35% yield from <i>tert</i>-butyl (<i>E</i>)-3-(4-((2-(2-isopropylphenyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>53d</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.16 (d, <i>J</i> = 6.57 Hz, 6H), 3.23 (m, 1H), 6.31 (d, <i>J</i> = 15.66 Hz, 1H), 6.82–6.88 (m, 3H), 7.09–7.15 (m, 1H), 7.22–7.38 (m, 5H), 7.45 (d, <i>J</i> = 8.59 Hz, 2H), 7.57 (d, <i>J</i> = 16.17 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 24.68, 31.65, 108.86, 115.94, 117.17, 117.84, 123.05, 126.62, 126.82, 126.88, 126.95, 130.05, 130.46, 130.78, 130.95, 132.51, 139.99, 141.70, 145.69, 150.19, 157.33, 161.41, 170.83. HRMS ESI <i>m</i>/<i>z</i> 431.1309 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (<i>E</i>)-3-(4-((2-(4-Fluoro-2-methylphenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-acrylic Acid (<b>53i</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 95% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 1-bromo-4-fluoro-2-methylbenzene using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 435.3 [M – <i>t</i>-Bu + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 63% yield from <i>tert</i>-butyl (<i>E</i>)-3-(4-((2-(4-fluoro-2-methylphenyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>53d</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 2.35 (s, 3H), 6.32 (d, <i>J</i> = 15.66 Hz, 1H), 6.81–6.92 (m, 4H), 6.98 (dd, <i>J</i> = 9.60, 2.53 Hz, 1H), 7.24 (d, <i>J</i> = 2.02 Hz, 1H), 7.27 (d, <i>J</i> = 8.59 Hz, 1H), 7.31 (dd, <i>J</i> = 8.59, 5.56 Hz, 1H), 7.42–7.49 (m, 2H), 7.56 (d, <i>J</i> = 16.17 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 20.87, 108.89, 113.59, 113.80, 116.02, 117.15, 117.80, 117.93, 118.02, 123.10, 125.36, 127.00, 130.98, 134.01, 134.10, 140.04, 142.05, 145.65, 157.49, 161.22, 163.09, 165.54, 170.79. HRMS ESI <i>m</i>/<i>z</i> 421.0911 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(2-(trifluoromethyl)-phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)-acrylic Acid (<b>53j</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 78% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 1-bromo-2-(trifluoromethyl)benzene using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 471.4 [M – <i>t</i>-Bu + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 59% yield from <i>tert</i>-butyl (<i>E</i>)-3-(4-((6-methoxy-2-(2-(trifluoromethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>53d</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 6.32 (d, <i>J</i> = 15.66 Hz, 1H), 6.78–6.91 (m, 3H), 7.16–7.28 (m, 2H), 7.45 (d, <i>J</i> = 9.09 Hz, 2H), 7.49–7.62 (m, 4H), 7.70–7.81 (m, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 108.68, 116.11, 117.42, 118.06, 123.27, 123.39, 126.27, 127.53, 127.58, 127.63, 127.68, 130.27, 130.48, 130.93, 131.33, 131.38, 131.63, 132.95, 135.09, 140.31, 143.10, 145.59, 157.67, 161.24, 170.82. HRMS ESI <i>m</i>/<i>z</i> 457.0702 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> (<i>E</i>)-3-(4-((2-(4-Fluoro-2-(trifluoromethyl)-phenyl)-6-hydroxy-benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53k</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 94% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 1-bromo-4-fluoro-2-(trifluoromethyl)benzene using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 489.3 [M – <i>t</i>-Bu + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 36% yield from <i>tert</i>-butyl (<i>E</i>)-3-(4-((2-(4-fluoro-2-(trifluoromethyl)phenyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>53d</b>, step 2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 6.37 (d, <i>J</i> = 15.66 Hz, 1H), 6.84–6.92 (m, 3H), 7.15 (d, <i>J</i> = 8.59 Hz, 1H), 7.35 (d, <i>J</i> = 2.02 Hz, 1H), 7.49 (d, <i>J</i> = 16.17 Hz, 1H), 7.53–7.62 (m, 3H), 7.68 (dd, <i>J</i> = 8.59, 5.56 Hz, 1H), 7.75 (dd, <i>J</i> = 9.35, 2.78 Hz, 1H), 9.92 (br s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 107.90, 114.31, 114.36, 114.56, 114.61, 115.34, 116.02, 117.79, 119.51, 119.72, 120.06, 122.11, 123.67, 125.64, 128.81, 130.08, 136.27, 136.36, 138.24, 141.46, 143.19, 156.32, 158.84, 160.64, 163.12, 167.73. HRMS ESI <i>m</i>/<i>z</i> 475.0634 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(2-methylpyridin-3-yl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53l</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 78% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 3-bromo-2-methylpyridine using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 474.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 52% yield from <i>tert</i>-butyl (<i>E</i>)-3-(4-((6-methoxy-2-(2-methylpyridin-3-yl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>53d</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 8.56 (d, <i>J</i> = 5.6 Hz, 1H), 8.34 (d, <i>J</i> = 8.0 Hz, 1H), 7.69 (t, <i>J</i> = 7.1 Hz, 1H), 7.56 (d, <i>J</i> = 16.0 Hz, 1H), 7.48 (d, <i>J</i> = 8.8 Hz, 2H), 7.35 (d, <i>J</i> = 8.7 Hz, 1H), 7.31 (d, <i>J</i> = 2.1 Hz, 1H), 6.97–6.86 (m, 3H), 6.33 (d, <i>J</i> = 16.0 Hz, 1H), 2.76 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 20.05, 108.89, 116.73, 117.26, 118.40, 118.73, 123.79, 125.26, 125.98, 130.89, 131.10, 132.65, 140.92, 143.31, 144.47, 145.14, 148.01, 155.36, 158.52, 160.45, 170.34. HRMS ESI <i>m</i>/<i>z</i> 404.0941 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (<i>E</i>)-3-(4-((2-(2-(Dimethylamino)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53m</b>)</h4><div class="NLM_p">Step 1: To a solution of (<i>E</i>)-methyl 3-(4-((2-bromo-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (3.0 g, 7.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) at room temperature was added BBr<sub>3</sub> (1.0 M in heptane, 14.31 mL, 14.31 mmol) dropwise. The resulting mixture was stirred at room temperature for 2 h, after which time the reaction was cooled to 0 °C and carefully quenched by addition of sat. aq. NaHCO<sub>3</sub> solution. The miture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and MeOH (10 mL) to solubilize all solids and then acidified by addition of sat. aq. citric acid solution. The phases were separated, and the combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The crude material was purified by column chromatography (SiO<sub>2</sub>, 0–100% EtOAc/heptane) to afford (<i>E</i>)-methyl 3-(4-((2-bromo-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (1.3 g, 45% yield) as a pale yellow solid and (<i>E</i>)-3-(4-((2-bromo-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (1.1 g, 39% yield) as an orange solid.</div><div id="sec5_1_67_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> (<i>E</i>)-Methyl 3-(4-((2-Bromo-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 3.76 (s, 3H), 6.43 (d, <i>J</i> = 16.17 Hz, 1H), 6.82 (dd, <i>J</i> = 8.84, 2.27 Hz, 1H), 6.90–6.97 (m, 2H), 7.17 (d, <i>J</i> = 2.02 Hz, 1H), 7.22 (d, <i>J</i> = 8.59 Hz, 1H), 7.53–7.62 (m, 2H), 7.65 (d, <i>J</i> = 15.66 Hz, 1H). LC/MS ESI <i>m</i>/<i>z</i> 406.8 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_67_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> (<i>E</i>)-3-(4-((2-Bromo-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid</h5><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 6.38 (d, <i>J</i> = 16.17 Hz, 1H), 6.82 (dd, <i>J</i> = 8.59, 2.02 Hz, 1H), 6.89–6.97 (m, 2H), 7.17 (d, <i>J</i> = 2.02 Hz, 1H), 7.23 (d, <i>J</i> = 8.59 Hz, 1H), 7.53–7.60 (m, 2H), 7.63 (d, <i>J</i> = 15.66 Hz, 1H). LC/MS ESI <i>m</i>/<i>z</i> 392.8 [M + H]<sup>+</sup>.</div><div class="NLM_p">Step 2: To a solution of (<i>E</i>)-methyl 3-(4-((2-bromo-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (75 mg, 0.185 mmol) in dimethoxyethane (1.0 mL) were added (2-(dimethylamino)phenyl)boronic acid (91 mg, 0.370 mmol), Pd(dppf)Cl<sub>2</sub> (13.54 mg, 0.019), and 4 N aqueous K<sub>2</sub>CO<sub>3</sub> solution (0.370 mL, 0.740 mmol). The mixture was subjected to microwave irradiation for 20 min at 110 °C, after which the reaction was quenched with brine and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give the crude product. The crude material was purified by column chromatography (SiO<sub>2</sub>, 0–100% EtOAc/heptane) to afford methyl (<i>E</i>)-3-(4-((2-(2-(dimethylamino)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (72 mg, 87% yield). LC/MS ESI <i>m</i>/<i>z</i> 446.4 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 3: To a solution of (<i>E</i>)-3-(4-((2-(2-(dimethylamino)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (72 mg, 0.162 mmol) in MeOH (3.0 mL) at room temperature was added 2 N aqueous K<sub>2</sub>CO<sub>3</sub> solution (0.646 mL, 1.293 mmol), and the resulting mixture was stirred at room temperature for 16 h. Upon completion, the reaction was concentrated <i>in vacuo</i>, water (5 mL) was added, and the aqueous layer was acidified to pH ∼ 1 by addition of 1 N aqueous HCl. The aqueous layer was then extracted with EtOAc (2 × 10 mL), and the combined organic layers were dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i> to give the crude product. The crude material was purified by reverse phase HPLC (acidic conditions, 3% TFA in 10–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((2-(2-(dimethylamino)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (14.3 mg, 20% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.73–7.45 (m, 6H), 7.41–7.26 (m, 3H), 6.94–6.86 (m, 3H), 6.33 (d, <i>J</i> = 15.9 Hz, 1H), 3.10 (s, 6H). HRMS ESI <i>m</i>/<i>z</i> 432.1279 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> (<i>S</i>,<i>E</i>)-3-(4-((6-Hydroxy-2-(2-(1-hydroxyethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53n</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 39% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and (<i>S</i>)-1-(2-bromophenyl)ethanol using the procedure described for the synthesis of <b>53d</b>, step 1. LC/MS ESI <i>m</i>/<i>z</i> 520.5 [M + H<sub>2</sub>O]<sup>+</sup>.</div><div class="NLM_p">Step 2: To a solution of <i>tert</i>-butyl (<i>S</i>,<i>E</i>)-3-(4-((2-(2-(1-hydroxyethyl)phenyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (59.8 mg, 0.119 mmol) in <i>N</i>-methyl-2-pyrrolidone (1.0 mL) were added thiophenol (0.018 mL, 0.178 mmol) and K<sub>2</sub>CO<sub>3</sub> (16.4 mg, 0.119 mmol). The resulting mixture was subjected to microwave irradiation at 200 °C for 1 h, after which time the reaction was diluted with EtOAc and brine, the layers were separated, and the aqueous layer was further extracted with EtOAc (1×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>, and the crude material was purified by column chromatography (SiO<sub>2</sub>, 0–100% EtOAc/heptane) to afford <i>tert</i>-butyl (<i>S</i>,<i>E</i>)-3-(4-((6-hydroxy-2-(2-(1-hydroxyethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (12.8 mg, 22% yield). LC/MS ESI <i>m</i>/<i>z</i> 487.5 [M – H]<sup>−</sup>.</div><div class="NLM_p last">Step 3: To a solution of <i>tert</i>-butyl (<i>S</i>,<i>E</i>)-3-(4-((6-hydroxy-2-(2-(1-hydroxyethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (12.8 mg, 0.026 mmol) in THF (0.7 mL) at room temperature was added 4.0 N HCl in 1,4-dioxane (200 μL, 0.800 mmol); the resulting mixture was warmed to 80 °C for 18 h. Upon completion, the reaction was quenched by addition of sat. aq. NaHCO<sub>3</sub> and extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>, and the crude material was purified by reverse phase HPLC (neutral conditions, 3% 1-propanol in 10–100% CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>S</i>,<i>E</i>)-3-(4-((6-hydroxy-2-(2-(1-hydroxyethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (3.9 mg, 34% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 1.37 (d, <i>J</i> = 6.57 Hz, 3H), 5.16 (q, <i>J</i> = 6.57 Hz, 1H), 6.32 (d, <i>J</i> = 15.66 Hz, 1H), 6.82–6.90 (m, 3H), 7.17–7.25 (m, 3H), 7.26–7.31 (m, 1H), 7.35–7.41 (m, 1H), 7.45 (d, <i>J</i> = 9.09 Hz, 2H), 7.54 (d, <i>J</i> = 15.66 Hz, 1H), 7.63 (d, <i>J</i> = 7.58 Hz, 1H). LC/MS ESI <i>m</i>/<i>z</i> 431.4 [M – H]<sup>−</sup>.</div></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(2-(methoxymethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53o</b>)</h4><div class="NLM_p">Step 1: To a solution of (<i>E</i>)-methyl 3-(4-((2-bromo-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (100 mg, 0.238 mmol) in 1,2-dimethoxyethane (3.0 mL) was added (2-(methoxymethyl)phenyl)boronic acid (79 mg, 0.477 mmol), Pd(dppf)Cl<sub>2</sub> (17.5 mg, 0.024 mmol), and Na<sub>2</sub>CO<sub>3</sub> (2.0 N aqueous, 0.358 mL, 0.715 mmol). The resulting mixture was subjected to microwave irradiation at 100 °C for 20 min, after which time the reaction was diluted with EtOAc, anhydrous Na<sub>2</sub>SO<sub>4</sub> was added, and the reaction was filtered and concentrated <i>in vacuo</i>. The crude material was purified by column chromatography (SiO<sub>2</sub>, 0–20% EtOAc/heptane) to afford (<i>E</i>)-methyl 3-(4-((6-methoxy-2-(2-(methoxymethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (86.6 mg, 79% yield). LC/MS ESI <i>m</i>/<i>z</i> 478.0 [M + H<sub>2</sub>O]<sup>+</sup>.</div><div class="NLM_p">Step 2: To a solution of (<i>E</i>)-methyl 3-(4-((6-methoxy-2-(2-(methoxymethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (86.6 mg, 0.188 mmol) in MeOH (3.0 mL) was added LiOH (2.0 N aqueous, 0.564 mL, 1.128 mmol). The resulting mixture was stirred at room temperature for 48 h, after which time the reaction was brought to pH 7 by addition of 1 N HCl; the neutralized reaction was then concentrated <i>in vacuo</i> to afford (<i>E</i>)-3-(4-((6-methoxy-2-(2-(methoxymethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (45.9 mg, 55% yield). LC/MS ESI <i>m</i>/<i>z</i> 447.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 3: To a solution of (<i>E</i>)-3-(4-((6-methoxy-2-(2-(methoxymethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (45.9 mg, 0.103 mmol) in <i>N</i>-methyl-2-pyrrolidone (1.0 mL) were added thiophenol (0.016 mL, 0.154 mmol) and K<sub>2</sub>CO<sub>3</sub> (14.21 mg, 0.103 mmol). The resulting mixture was subjected to microwave irradiation at 200 °C for 90 min, after which time the reaction was diluted with EtOAc and filtered. The filtrate was concentrated <i>in vacuo</i>, and the crude material was purified by reverse phase HPLC (basic conditions, 0.1% NH<sub>4</sub>OH in CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((6-hydroxy-2-(2-(methoxymethyl)phenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (3.0 mg, 6% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.47 (d, <i>J</i> = 7.7 Hz, 1H), 7.40–7.31 (m, 4H), 7.31–7.21 (m, 4H), 6.86 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 6.79 (d, <i>J</i> = 8.4 Hz, 2H), 6.35 (d, <i>J</i> = 15.9 Hz, 1H), 4.53 (s, 2H), 3.29 (s, 3H). HRMS ESI <i>m</i>/<i>z</i> 433.1099 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> (<i>E</i>)-3-(4-((2-(2-(Difluoromethyl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53p</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 79% yield from (<i>E</i>)-<i>tert</i>-butyl 3-(4-((6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 1-bromo-2-(difluoromethyl)benzene using the procedure described for the synthesis of <b>53d</b>, step 1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 1.51 (s, 9H), 3.91 (s, 3H), 6.19 (d, <i>J</i> = 16.17 Hz, 1H), 6.82 (d, <i>J</i> = 8.59 Hz, 2H), 6.94 (t, <i>J</i> = 55.06, 1H), 6.98 (dd, <i>J</i> = 8.84, 2.27 Hz, 1H), 7.30–7.35 (m, 3H), 7.37 (d, <i>J</i> = 8.59 Hz, 1H), 7.40–7.51 (m, 4H), 7.69–7.76 (m, 1H).</div><div class="NLM_p">Step 2: To a solution of (<i>E</i>)-<i>tert</i>-butyl 3-(4-((2-(2-(difluoromethyl)phenyl)-6-methoxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (133 mg, 0262 mmol) in <i>N</i>-methyl-2-pyrrolidone (1.5 mL) were added thiophenol (0.040 mL, 0.392 mmol) and K<sub>2</sub>CO<sub>3</sub> (36.1 mg, 0.262 mmol). The resulting mixture was subjected to microwave irradiation at 200 °C for 1 h, after which time the reaction was quenched by addition of water and extracted with EtOAc (2×). The combined organic layers were dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>, and the resulting crude material was purified by column chromatography (SiO<sub>2</sub>, 0–20% EtOAc/heptane) to afford (<i>E</i>)-<i>tert</i>-butyl 3-(4-((2-(2-(difluoromethyl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (100 mg, 77% yield). LC/MS ESI <i>m</i>/<i>z</i> 495.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 3: To a solution of (<i>E</i>)-<i>tert</i>-butyl 3-(4-((2-(2-(difluoromethyl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate (100 mg, 0.202 mmol) in 1,4-dioxane (3.0 mL) was added 4.0 M aq. HCl (0.202 mL, 0.809 mmol). The resulting mixture was warmed to 50 °C and stirred at that temperature for 2 h, after which time the reaction was quenched by addition of sat. aq. NaHCO<sub>3</sub> and extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>, and the resulting crude material was purified by reverse phase HPLC (basic conditions, 0.1% NH<sub>4</sub>OH in CH<sub>3</sub>CN/H<sub>2</sub>O) to afford (<i>E</i>)-3-(4-((2-(2-(difluoromethyl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic acid (16.7 mg, 19% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.72–7.64 (m, 1H), 7.54–7.42 (m, 4H), 7.39 (d, <i>J</i> = 8.7 Hz, 2H), 7.33–7.24 (m, 2H), 7.00 (d, <i>J</i> = 55.2 Hz, 1H), 6.88 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 6.81 (d, <i>J</i> = 8.9 Hz, 2H), 6.30 (d, <i>J</i> = 16.0 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 108.89, 112.32, 114.66, 116.38, 117.01, 117.19, 118.99, 123.09, 123.43, 126.65, 126.92, 126.97, 127.02, 130.52, 130.60, 130.87, 131.91, 132.92, 140.42, 142.46, 144.90, 157.90, 160.86, 171.36. HRMS ESI <i>m</i>/<i>z</i> 439.0776 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> (<i>E</i>)-3-(4-((2-(2-(1-Fluoroethyl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53q</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 42% yield from (<i>E</i>)-methyl 3-(4-((2-bromo-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate and 2-(2-(1-fluoroethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis) using the procedure described for the synthesis of <b>53m</b>, step 2. HRMS ESI <i>m</i>/<i>z</i> 449.4 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Step 2: The title compound was prepared in 11% yield from methyl (<i>E</i>)-3-(4-((2-(2-(1-fluoroethyl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>42a</b>, step 2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ ppm = 7.56 (dd, <i>J</i> = 7.9, 1.2 Hz, 1H), 7.51 (d, <i>J</i> = 15.9 Hz, 1H), 7.47–7.38 (m, 3H), 7.36–7.23 (m, 4H), 6.87 (dd, <i>J</i> = 8.6, 2.1 Hz, 1H), 6.84 (d, <i>J</i> = 8.7 Hz, 2H), 6.32 (d, <i>J</i> = 16.0 Hz, 1H), 5.88 (dq, <i>J</i> = 46.9, 6.3 Hz, 1H), 1.54 (dd, <i>J</i> = 23.6, 6.4 Hz, 3H). HRMS ESI <i>m</i>/<i>z</i> 435.1024 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> (<i>E</i>)-3-(4-((2-(2-(1,1-Difluoroethyl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53r</b>)</h4><div class="NLM_p">Step 1: The intermediate was prepared in 70% yield from (<i>E</i>)-methyl 3-(4-((2-bromo-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate 2-(2-(2-fluoropropan-2-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis) using the procedure described for the synthesis of <b>53m</b>, step 2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm = 7.63–7.56 (m, 2H), 7.44–7.38 (m, H), 7.36 (d, <i>J</i> = 8.8 Hz, 2H), 7.33 (d, <i>J</i> = 4.1 Hz, 2H), 7.28–7.24 (m, 2H), 6.90–6.81 (m, 3H), 6.28 (d, <i>J</i> = 16.1 Hz, 1H), 3.78 (s, 3H), 1.91 (t, <i>J</i> = 18.4 Hz, 3H).</div><div class="NLM_p last">Step 2: The title compound was prepared in 47% yield from methyl (<i>E</i>)-3-(4-((2-(2-(2-fluoropropan-2-yl)phenyl)-6-hydroxybenzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylate using the procedure described for the synthesis of <b>42a</b>, step 2. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 9.94 (s, 1H), 7.63 (d, <i>J</i> = 7.5 Hz, 1H), 7.57 (d, <i>J</i> = 8.7 Hz, 2H), 7.54–7.42 (m, 4H), 7.32 (d, <i>J</i> = 2.1 Hz, 1H), 7.10 (d, <i>J</i> = 8.7 Hz, 1H), 6.88 (d, <i>J</i> = 8.7 Hz, 2H), 6.84 (dd, <i>J</i> = 8.7, 2.2 Hz, 1H), 6.36 (d, <i>J</i> = 16.0 Hz, 1H), 1.94 (t, <i>J</i> = 18.9 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) δ ppm = 26.45, 26.74, 27.04, 108.68, 115.93, 117.40, 117.81, 123.23, 125.73, 126.26, 127.00, 127.08, 127.16, 130.13, 130.31, 130.46, 130.95, 134.74, 139.43, 139.68, 139.93, 140.16, 142.24, 145.75, 157.40, 161.29, 170.71. HRMS ESI <i>m</i>/<i>z</i> 453.0919 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (<i>E</i>)-3-(4-((6-Hydroxy-2-(4-methoxyphenyl)benzo[<i>b</i>]thiophen-3-yl)oxy)phenyl)acrylic Acid (<b>53s</b>)</h4><div class="NLM_p last">The title compound was prepared using a similar procedure to that described for the synthesis of <b>34</b>; see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm = 7.64 (d, <i>J</i> = 8.59 Hz, 2H), 7.55–7.62 (m, 2H), 7.51 (d, <i>J</i> = 16.17 Hz, 1H), 7.30 (d, <i>J</i> = 2.02 Hz, 1H), 7.13 (d, <i>J</i> = 8.59 Hz, 1H), 6.90–7.04 (m, 4H), 6.83 (dd, <i>J</i> = 2.02, 8.59 Hz, 1H), 6.38 (d, <i>J</i> = 16.17 Hz, 1H), 3.75 (s, 3H). LC/MS ESI <i>m</i>/<i>z</i> 417.5 [M – H]<sup>−</sup>.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Cell Culture</h3><div class="NLM_p last">MCF-7 cells were routinely maintained in RPMI 1640 medium (Invitrogen) with 10% fetal bovine serum (FBS) (Invitrogen). To deplete growth factors from cells, MCF-7 cells were cultured in phenol red-free RPMI medium with 10% charcoal-stripped FBS (CSS medium; Invitrogen) for 3 days before the assay.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> MCF-7 ERE Reporter Gene Assays</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> Transient Transfection Assay</h4><div class="NLM_p last">MCF-7 cells were maintained in Dulbecco’s modified Eagle’s Medium (DMEM)/F12 supplemented with 8% fetal bovine serum (FBS). Cells were seeded in 96-well plates and transfected with an estrogen responsive reporter gene (7×-TK-ERE-Luc) and Renilla-luc (to monitor cellular toxicity) using Lipofectin reagent (Invitrogen), as described in the manufacturer’s instructions. After overnight incubation, cells were treated with hormone for 24 h. Cells were then lysed and quantified for luciferase activity using dual luciferase reagent.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> ERE-Luciferase Reporter Stable Cell Line Assay</h4><div class="NLM_p last">Growth factors depleted MCF-7 ERE-luc cells were seeded (10 000 cells/well) in 96-well plates in CSS medium. After overnight incubation, cells were treated with compounds in the presence of estradiol (0.1 nM) for 24 h. Cells were then lysed and quantified for luciferase activity using Bright-Glo assay.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> In-Cell Western To Detect ER Protein Levels</h3><div class="NLM_p last">MCF-7 cells were cultured in CDT growth medium (DMEM/F12 phenol red-free media (Gibco, cat. no. 21041) supplemented with 10% charcoal dextran-stripped serum (Gemini Bio-Products, cat. no. 100-119) 72 h prior to plating cells. The cells were seeded in 100 μL of CDT growth medium at a density of 30 000 cells/well in a black, clear-bottom 96-well assay plate (Greiner, cat. no. 655090) and incubated for 24–36 h at 37 °C with 5% CO<sub>2</sub>. For <b>10</b>, 4-hydroxytamoxifen, and fulvestrant treatment, 11 μL of 10× compound was added to each well in a seven-point, 1:10 dilution series (CSS growth media; normalized for a final assay concentration of 0.1% DMSO), starting at 10 μM, and incubated for 18–24 h at 37 °C with 5% CO<sub>2</sub>. DMSO and fulvestrant were used to determine the baseline for maximal response and ERα degradation, respectively. To fix cells, media was first decanted by inversion, followed immediately by the addition of 100 μL/well of 3.7% formaldehyde (Sigma, cat. no. F8775) in PBS (Gibco, cat. no. 20012), and the cells were incubated for 20 min at room temperature. Cells were then blocked with 50 μL/well of blocking buffer (PBS pH 7.4, 3% goat serum (Life Technologies, cat. no. 16210072), 1% BSA (Sigma, cat. no. A7906), 0.1% cold fish skin gelatin (Sigma, cat. no. G7041), 0.1% Triton X-100 (OmniPur, cat. no. 9410)) for 2 h with shaking at room temperature or at 4 °C overnight. Blocking buffer was then decanted, and 40 μL of ERα primary antibody (Santa Cruz, cat. no. SC543) at 1:3000 in blocking buffer diluted 1:3 with PBS was added to each well, excluding negative control wells used for background subtraction, sealed with film, and incubated at 4 °C overnight. To remove primary antibody, cells were washed three times with 100 μL/well PBS + 0.1% Tween (AMRESCO, cat. no. 0777) (PBST) for 5 min each. 40 μL of polyclonal anti-rabbit IgG (H+L) CF770 antibody (Biotium, cat. no. 20078) at 1:2000 and DRAQ5 DNA stain (Thermo Scientific, cat. no. 62251) at 1:10 000 in blocking buffer diluted 1:3 with PBS was then added to each well and incubated at room temperature with shaking for 2 h. To remove secondary antibody, cells were washed three times with 100 μL/well of PBST for 5 min each. To minimize Tween autofluorescence signaling, the cells were washed once with 100 μL/well of PBS. To prevent drying during detection, 100 μL/well PBS was then added to each well. For detection, the integrated intensities of ERα (700 channel) and DNA stain (800 channel) were measured using a LI-COR Odyssey (LI-COR Biosciences, Lincoln, NE). Data was then normalized by dividing the integrated intensities of the 700 channel (ER) by the integrated intensities of the 800 channel (DNA). Background subtraction was carried out by subtracting the average of the normalized negative control wells (no primary antibody) from all normalized experimental values. Percent response of normalized/background subtracted data was then calculated by dividing each experimental value by the average of the DMSO control values (% response = (value experimental/value DMSO control) × 100). Dose–response curves, IC<sub>50</sub>, and percent ERα remaining values were generated using GraphPad Prism v6.02 software (GraphPad, San Diego, CA).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> MCF-7 Proliferation Assay</h3><div class="NLM_p last">Growth factor-depleted MCF-7 cells were seeded (10 000 cells/well) in 96-well plates in CSS medium. After overnight incubation, cells were treated with compounds in the presence of estradiol (0.1 nM) for 6 days. Cell viability was then measured by CellTiter Glo assay (Promega).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> <i>In Vivo</i> Efficacy in the MCF-7 Breast Cancer Xenograft Model in Mice</h3><div class="NLM_p last">Mice were handled in accordance with Novartis IACUC regulations and guidelines. Female athymic nude mice were used for tumor xenograft studies. Time released 17-β estradiol pellets (0.36 mg E2, 90-day release; Innovative Research of America) were subcutaneously implanted into mice 2 days prior to tumor implantation. MCF-7 cells were grown in EMEM growth medium supplemented with 10% FBS and human insulin (Sigma-Aldrich cat. no. I9278) at 5% CO<sub>2</sub>, 37 °C. Trypsinized cells were pelleted and resuspended in 50% HBSS and 50% Matrigel at 10<sup>7</sup> cells/mL. MCF-7 cells were subcutaneously injected (200 μL/animal) in the right axillary mammary fat pad area. Tumor volume (width<sup>2</sup> × length × π/6) and body weights were measured twice weekly. When tumors reached an average volume of ∼200 mm<sup>3</sup>, mice were randomized into groups and treatment began. Animals were orally administered vehicle alone or 20 mg/kg <b>10</b> daily or 60 mg/kg tamoxifen 5 days per week. Fulvestrant was administered subcutaneously at 5 mg/mouse (corresponds to roughly 250 mg/kg) once weekly, providing a slow release from the depot in the subcutis. The formulations of these three reagents are as follows: 10% ethanol and 90% peanut oil for fulvestrant; 0.5% hydroxypropyl cellulose for tamoxifen; and 10% PEG300, 25% of 20% Solutol, 65% PBS for <b>10</b>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> <i>In Vivo</i> Pharmacodynamics Marker Assessment in the MCF-7 Breast Cancer Xenograft Model</h3><div class="NLM_p last">At the end of the efficacy study on day 48 postimplantation, MCF-7 tumors were collected and snap frozen 7 h post last dose of <b>10</b>, tamoxifen, or fulvestrant.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> Quantitative Reverse Transcriptase-PCR</h3><div class="NLM_p last">For the analysis of progesterone receptor (PgR) mRNA levels from snap-frozen end of efficacy study MCF-7 tumors, total mRNA was isolated using the RNeasy Mini kit (Qiagen, cat. no. 74104), followed by two-step qRT-PCR using an iScript cDNA synthesis kit (BioRad cat. no. 170-8891) for cDNA synthesis and quantitative PCR by Taqman using Taqman Gene Expression Assays (Applied Biosystems). The <i>C</i><sub>T</sub> values were analyzed to assess relative changes in expression of progesterone receptor (PgR) genes, with B2M as an internal control, using the 2<sup>–ΔΔ<i>C</i><sub>T</sub></sup> method.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> Western Blot Analysis</h3><div class="NLM_p last">For the analysis of ERα protein levels in the end of efficacy study MCF-7 tumors, snap frozen tumors were transferred to Lysing Matrix Tubes (MP Biomedicals cat. no. 6913-500), mixed with cold lysis buffer (1× cell lysis buffer; Cell Signaling, cat. no. 9803S) containing Complete Mini (1 tablet to 10 mL) and PhosStop (1 tablet to 10 mL and 1 M Urea), and homogenized by a Fast Prep 24 Tissue Lyser (MP Biomedicals). Total protein concentrations of the lysate were measured (Pierce BCA Protein Assay Kit, cat. no. 23225, Thermo Scientific) according to the manufacturer’s instructions. Lysates were separated by SDS-PAGE, transferred onto membranes, and then immunoblotted using an anti-ERα antibody (Santa Cruz Biotechnology, HC-20), as well as an anti-β-actin antibody (BioLegend, clone 2F<sub>1</sub>-1 cat. no. 643801) as a loading control. Western blots were scanned into (Bio Rad ChemiDoc Imaging Systems) for quantification of the immunoblotted bands. The percent of ERα remaining was determined by comparing tumors from the treated mice versus those from the vehicle control group.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Statistical Analyses for <i>in Vivo</i> Studies</h3><div class="NLM_p last">Statistical analyses of data were generated using GraphPad Prism (San Diego, CA, USA). Tests used are listed in the figure legends.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-9"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i115"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01682" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55723" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55723" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01682" class="ext-link">10.1021/acs.jmedchem.7b01682</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Crystallographic methods and parameters, as well as pharmacokinetic studies (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings as well as IC<sub>50</sub> and percent ERα remaining data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf">jm7b01682_si_001.pdf (1.03 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_002.csv">jm7b01682_si_002.csv (3.37 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for compound <b>10</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F">6B0F</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01682" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30641" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30641" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George S. Tria</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8597-6130" title="Orcid link">http://orcid.org/0000-0001-8597-6130</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3a4959554e4e144e48535b7a54554c5b484e534914595557"><span class="__cf_email__" data-cfemail="ec9f8f839898c2989e858dac82839a8d9e98859fc28f8381">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tinya Abrams</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Baird</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heather E. Burks</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9115-9970" title="Orcid link">http://orcid.org/0000-0001-9115-9970</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brant Firestone</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        (B.F.) Surface Oncology, 50 Hampshire Street, 8th Floor, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">L. Alex Gaither</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence G. Hamann</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        (L.G.H.) Celgene Corporation, 200 Cambridge Park Drive, Suite 3000, Cambridge, Massachusetts 02140 United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guo He</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        (G.H.) Alnylam Pharmaceuticals, 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christina A. Kirby</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sunkyu Kim</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        (S.K.) FORMA Therapeutics, 500 Arsenal Street, No. 100, Watertown, Massachusetts 02472, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Franco Lombardo</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        (F.L.) Alkermes, 852 Winter Street, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kaitlin J. Macchi</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donald P. McDonnell</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Cancer Biology, Duke
University School of Medicine, Durham, North Carolina 27710, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuji Mishina</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. Norris</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Cancer Biology, Duke
University School of Medicine, Durham, North Carolina 27710, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jill Nunez</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clayton Springer</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingchuan Sun</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Noel M. Thomsen</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunrong Wang</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianling Wang</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span>; 
    <span>Present Address:
                        (J.W.) WuXi Apptec, 90 Delin Road, Waigaoqiao Free Trade Zone, Shanghai, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bing Yu</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Choi-Lai Tiong-Yip</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Peukert</span> - <span class="hlFld-Affiliation affiliation">Novartis
Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e9831-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i124">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors gratefully acknowledge Drs. Adam S. Crystal and Andreas Harsch for their help in the preparation of this manuscript. Use of the IMCA-CAT beamline 17-ID at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetate</p></td></tr><tr><td class="NLM_term">Ar</td><td class="NLM_def"><p class="first last">aromatic</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">cmpd</td><td class="NLM_def"><p class="first last">compound</p></td></tr><tr><td class="NLM_term">Bu</td><td class="NLM_def"><p class="first last">butyl</p></td></tr><tr><td class="NLM_term">clogD</td><td class="NLM_def"><p class="first last">calculated logD</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">DIBAL-H</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">1,2-dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">dn</td><td class="NLM_def"><p class="first last">dose normalized</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">ERα</td><td class="NLM_def"><p class="first last">estrogen receptor alpha</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last"><i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hormone receptor</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">per os</p></td></tr><tr><td class="NLM_term">SERD</td><td class="NLM_def"><p class="first last">selective estrogen receptor degrader</p></td></tr><tr><td class="NLM_term">SERM</td><td class="NLM_def"><p class="first last">selective estrogen receptor modulator</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">Sprague–Dawley</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TMS</td><td class="NLM_def"><p class="first last">trimethylsilyl</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i126">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24220" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24220" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Breast Cancer Facts &
Figures 2015–2016</i>; <span class="NLM_publisher-name">American Cancer
Society, Inc</span>: <span class="NLM_publisher-loc">Atlanta</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Breast+Cancer+Facts+%26%0AFigures+2015%E2%80%932016%3B+American+Cancer%0ASociety%2C+Inc%3A+Atlanta%2C+2015."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Facts%2520%2526%250AFigures%25202015%25E2%2580%25932016%26pub%3DAmerican%2520Cancer%250ASociety%252C%2520Inc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentzon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Düring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouridsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroman, N.</span></span> <span> </span><span class="NLM_article-title">Prognostic effect of estrogen receptor status across age in primary breast cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1089</span>– <span class="NLM_lpage">1094</span>, <span class="refDoi"> DOI: 10.1002/ijc.22892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1002%2Fijc.22892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=17960621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslGhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=1089-1094&author=N.+Bentzonauthor=M.+D%C3%BCringauthor=B.+B.+Rasmussenauthor=H.+Mouridsenauthor=N.+Kroman&title=Prognostic+effect+of+estrogen+receptor+status+across+age+in+primary+breast+cancer&doi=10.1002%2Fijc.22892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic effect of estrogen receptor status across age in primary breast cancer</span></div><div class="casAuthors">Bentzon, Niels; During, Maria; Rasmussen, Birgitte Bruun; Mouridsen, Henning; Kroman, Niels</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1089-1094</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Estrogen receptor (ER) status is considered as an important prognostic factor as well as a predictive factor for endocrine responsiveness in breast cancer.  We analyzed the distribution of ER status across age and estd. variations in the prognostic impact of ER status related to patients' age and time since diagnosis.  Overall, 26,944 patients with primary breast cancer diagnosed from 1989 to 2004 were included.  The proportion of ER pos. tumors increased over age from 51 to 82%.  In multivariate anal. of overall survival, ER pos. status was found to be a significantly pos. prognostic factor over all age groups.  This effect was limited to the first 5 years after diagnosis, RR: 2.08 (95% CI: 1.95-2.22, p < 0.0001).  Overall survival during the following 5 years was slightly superior for women with ER neg. tumors, RR of death: 0.89 (95% CI: 0.79-1.00, p = 0.049).  Results were unchanged in patients who did not receive adjuvant systemic therapy (n = 6,272).  Thus, pos. ER status does not confer a neg. impact on survival in young women as has been previously reported.  The inferior prognosis for ER neg. patients during the first 5 years after diagnosis changes into a slightly superior residual prognosis compared to ER pos. patients independent of use of adjuvant systemic therapy.  This may have an impact on future designing of guidelines for adjuvant endocrine therapy beyond 5 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3eNDygp1-2rVg90H21EOLACvtfcHk0lgfI7BHWnduLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslGhu7k%253D&md5=2e9db2ca5d32375c78ce8ae9a6c93e09</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fijc.22892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22892%26sid%3Dliteratum%253Aachs%26aulast%3DBentzon%26aufirst%3DN.%26aulast%3DD%25C3%25BCring%26aufirst%3DM.%26aulast%3DRasmussen%26aufirst%3DB.%2BB.%26aulast%3DMouridsen%26aufirst%3DH.%26aulast%3DKroman%26aufirst%3DN.%26atitle%3DPrognostic%2520effect%2520of%2520estrogen%2520receptor%2520status%2520across%2520age%2520in%2520primary%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D1089%26epage%3D1094%26doi%3D10.1002%2Fijc.22892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deblois, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguère, V.</span></span> <span> </span><span class="NLM_article-title">Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrc3396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2Fnrc3396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=23192231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsleks7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=27-36&author=G.+Debloisauthor=V.+Gigu%C3%A8re&title=Oestrogen-related+receptors+in+breast+cancer%3A+control+of+cellular+metabolism+and+beyond&doi=10.1038%2Fnrc3396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond</span></div><div class="casAuthors">Deblois, Genevieve; Giguere, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Estrogen-related receptors (ERRs) are orphan nuclear receptors that were initially investigated in breast cancer because of their structural relationship to estrogen receptors.  Recent data have shown that the ERRs control vast gene networks that are involved in glycolysis, glutaminolysis, oxidative phosphorylation, nutrient sensing and biosynthesis pathways.  In the context of breast cancer, the ERRs affect cellular metab. in a manner that promotes a Warburg-like phenotype.  The ERRs also modulate breast cancer cell metab., growth and proliferation through the regulation of key oncoproteins.  We discuss the value but also the implications of the complexity of targeting the ERRs for the development of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk41Ox4uzsq7Vg90H21EOLACvtfcHk0lgfI7BHWnduLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsleks7fM&md5=81d9969b61cdaa7e9d04ea3ed008007d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3396%26sid%3Dliteratum%253Aachs%26aulast%3DDeblois%26aufirst%3DG.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DV.%26atitle%3DOestrogen-related%2520receptors%2520in%2520breast%2520cancer%253A%2520control%2520of%2520cellular%2520metabolism%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D27%26epage%3D36%26doi%3D10.1038%2Fnrc3396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, M. J.
K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, A. L.</span></span> <span> </span><span class="NLM_article-title">Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">87</span>, <span class="refDoi"> DOI: 10.1038/212087a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2F212087a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=5965580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADyaF28XltVWitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=1966&pages=87&author=M.+J.%0AK.+Harperauthor=A.+L.+Walpole&title=Contrasting+endocrine+activities+of+cis+and+trans+isomers+in+a+series+of+substituted+triphenylethylenes&doi=10.1038%2F212087a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes</span></div><div class="casAuthors">Harper, M. J. K.; Walpole, A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1966</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">5057</span>),
    <span class="NLM_cas:pages">87</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">cis-1- (p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-2-ethylethylene citrate (I.C.I. 47,699) induced uterine growth in immature rats and vaginal cornification in spayed rats or mice and caused the involution of the prostate and seminal vesicles in intact male rats as a result of inhibition of pituitary gonadotropic activity and (or) direct antiandrogenic action, trans-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-2-ethylethylene citrate (I.C.I. 46,474) was only weakly and atypically estrogenic and caused no involution of intact male rat accessory sex glands. I.C.I. 46,474 was extremely effective in terminating early pregnancy in rats.  While both isomers seemed to be purely estrogenic, the trans isomer was more potent in this respect in mice and the cis isomer was more potent in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW-er5Ofucr7Vg90H21EOLACvtfcHk0lgfI7BHWnduLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF28XltVWitbk%253D&md5=7a1ca8d046aab69ce8e00304712ddea0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F212087a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F212087a0%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DM.%2BJ.%2BK.%26aulast%3DWalpole%26aufirst%3DA.%2BL.%26atitle%3DContrasting%2520endocrine%2520activities%2520of%2520cis%2520and%2520trans%2520isomers%2520in%2520a%2520series%2520of%2520substituted%2520triphenylethylenes%26jtitle%3DNature%26date%3D1966%26volume%3D212%26spage%3D87%26doi%3D10.1038%2F212087a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. N.</span>; <span class="NLM_string-name">Large, M. S.</span></span> <span> </span><span class="NLM_article-title">Preparation and Formulation of (Substituted Aralkyl) Heterocyclic Compounds as Aromatase Inhibitors</span>. Eur. Pat. Appl. <span class="NLM_patent">EP 0296749 B1</span>, <span class="NLM_year">1988</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&author=P.+N.+Edwards&author=M.+S.+Large&title=Preparation+and+Formulation+of+%28Substituted+Aralkyl%29+Heterocyclic+Compounds+as+Aromatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DP.%2BN.%26atitle%3DPreparation%2520and%2520Formulation%2520of%2520%2528Substituted%2520Aralkyl%2529%2520Heterocyclic%2520Compounds%2520as%2520Aromatase%2520Inhibitors%26date%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen resistance in breast cancer</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2012.20.3.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.4062%2Fbiomolther.2012.20.3.256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=256-267&author=M.+Chang&title=Tamoxifen+resistance+in+breast+cancer&doi=10.4062%2Fbiomolther.2012.20.3.256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen resistance in breast cancer</span></div><div class="casAuthors">Chang, Minsun</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">256-267</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">A review.  Tamoxifen is a central component of the treatment of estrogen receptor (ER)-pos. breast cancer as a partial agonist of ER.  It has been clin. used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer.  The most challenging issue with tamoxifen use is the development of resistance in an initially responsive breast tumor.  This review summarizes the roles of ER as the therapeutic target of tamoxifen in cancer treatment, clin. values and issues of tamoxifen use, and mol. mechanisms of tamoxifen resistance.  Emerging knowledge on the mol. mechanisms of tamoxifen resistance will provide insight into the design of regimens to overcome tamoxifen resistance and discovery of novel therapeutic agents with a decreased chance of developing resistance as well as establishing more efficient treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1vLvbFbG_ALVg90H21EOLACvtfcHk0lhQDbpMJ9tohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhtLrP&md5=a852c7664d31f137d8dd4bb1f9918ff5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2012.20.3.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2012.20.3.256%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DM.%26atitle%3DTamoxifen%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DBiomol.%2520Ther.%26date%3D2012%26volume%3D20%26spage%3D256%26epage%3D267%26doi%3D10.4062%2Fbiomolther.2012.20.3.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häusler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieweck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, R.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1027</span>, <span class="refDoi"> DOI: 10.1016/0960-0760(90)90460-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2F0960-0760%2890%2990460-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=2149502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADyaK3MXhtlGltbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1990&pages=1021-1027&author=A.+S.+Bhatnagarauthor=A.+H%C3%A4uslerauthor=K.+Schieweckauthor=M.+Langauthor=R.+Bowman&title=Highly+selective+inhibition+of+estrogen+biosynthesis+by+CGS+20267%2C+a+new+non-steroidal+aromatase+inhibitor&doi=10.1016%2F0960-0760%2890%2990460-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor</span></div><div class="casAuthors">Bhatnagar, A. S.; Haeusler, A.; Schieweck, K.; Lang, M.; Bowman, R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1021-7</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    </div><div class="casAbstract">CGS 20267 (I) is a new nonsteroidal compd. which potently inhibits aromatase in vitro (IC50 of 11.5 nM) and in vivo (ED50 of 1-3 μg/kg p.o.).  CGS 20267 maximally inhibits estradiol prodn. in vitro in LH-stimulated hamster ovarian tissue at 0.1 μM with an IC50 of 0.02 μM and does not significantly affect progesterone prodn. up to 350 μM.  In ACTH-stimulated rat adrenal tissue in vitro, aldosterone prodn. was inhibited with an IC50 of 210 μM (10,000 times higher than the IC50 for estradiol prodn.); no significant effect on corticosterone prodn. was seen at 350 μM.  In vivo, in ACTH-treated rats, CGS 20267 does not affect plasma levels of corticosterone or aldosterone at a dose of 4 mg/kg p.o. (1000 times higher than the ED50 for aromatase inhibition in vivo).  In adult female rats, a 14-day treatment with 1 mg/kg p.o. daily, completely interrupts ovarian cyclicity and suppresses uterine wt. to that seen 14 days after ovariectomy.  In adult female rats bearing estrogen-dependent DMBA-induced mammary tumors, 0.1 mg/kg p.o. given daily for 42 days caused almost complete regression of tumors present at the start of treatment.  Thus compared to each other, CGS 16949A and CGS 20267 are both highly potent in inhibiting estrogen biosynthesis in vitro and in vivo.  The striking difference between them is that unlike CGS 16949A, CGS 20267 does not affect adrenal steroidogenesis in vitro or in vivo, at concns. and doses several orders of magnitude higher than those required to inhibit estrogen biosynthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq83gKMUXDIe7Vg90H21EOLACvtfcHk0lhQDbpMJ9tohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtlGltbs%253D&md5=1f3069c02a2a78083b0a0b1932b660f5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0960-0760%2890%2990460-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-0760%252890%252990460-3%26sid%3Dliteratum%253Aachs%26aulast%3DBhatnagar%26aufirst%3DA.%2BS.%26aulast%3DH%25C3%25A4usler%26aufirst%3DA.%26aulast%3DSchieweck%26aufirst%3DK.%26aulast%3DLang%26aufirst%3DM.%26aulast%3DBowman%26aufirst%3DR.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520estrogen%2520biosynthesis%2520by%2520CGS%252020267%252C%2520a%2520new%2520non-steroidal%2520aromatase%2520inhibitor%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1990%26volume%3D37%26spage%3D1021%26epage%3D1027%26doi%3D10.1016%2F0960-0760%2890%2990460-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goss, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muss, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglione, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therasse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pater, J. L.</span></span> <span> </span><span class="NLM_article-title">A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa032312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1056%2FNEJMoa032312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=14551341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosl2gtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=1793-1802&author=P.+E.+Gossauthor=J.+N.+Ingleauthor=S.+Martinoauthor=N.+J.+Robertauthor=H.+B.+Mussauthor=M.+J.+Piccartauthor=M.+Castiglioneauthor=D.+Tuauthor=L.+E.+Shepherdauthor=K.+I.+Pritchardauthor=R.+B.+Livingstonauthor=N.+E.+Davidsonauthor=L.+Nortonauthor=E.+A.+Perezauthor=J.+S.+Abramsauthor=P.+Therasseauthor=M.+J.+Palmerauthor=J.+L.+Pater&title=A+randomized+trial+of+letrozole+in+postmenopausal+women+after+five+years+of+tamoxifen+therapy+for+early-stage+breast+cancer&doi=10.1056%2FNEJMoa032312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</span></div><div class="casAuthors">Goss, Paul E.; Ingle, James N.; Martino, Silvana; Robert, Nicholas J.; Muss, Hyman B.; Piccart, Martine J.; Castiglione, Monica; Tu, Dongsheng; Shepherd, Lois E.; Pritchard, Kathleen I.; Livingston, Robert B.; Davidson, Nancy E.; Norton, Larry; Perez, Edith A.; Abrams, Jeffrey S.; Therasse, Patrick; Palmer, Michael J.; Pater, Joseph L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy - but not tamoxifen therapy of longer duration - prolongs disease-free and overall survival.  The aromatase inhibitor letrozole, by suppressing estrogen prodn., might improve the outcome after the discontinuation of tamoxifen therapy.  Methods: We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy.  The primary end point was disease-free survival.  Results: A total of 5187 women were enrolled (median follow-up, 2.4 yr).  At the first interim anal., there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast - 75 in the letrozole group and 132 in the placebo group - with estd. four-year disease-free survival rates of 93% and 87%, resp., in the two groups (p ≤ 0.001 for the comparison of disease-free survival).  A total of 42 women in the placebo group and 31 women in the letrozole group died (P = 0.25 for the comparison of overall survival).  Low-grade hot flashes, arthritis, arthralgia, and myalgia were more frequent in the letrozole group, but vaginal bleeding was less frequent.  There were new diagnoses of osteoporosis in 5.8% of the women in the letrozole group and 4.5% of the women in the placebo group (P = 0.07); the rates of fracture were similar.  After the first interim anal., the independent data and safety monitoring committee recommended termination of the trial and prompt communication of the results to the participants.  Conclusions: As compared with placebo, letrozole therapy after the completion of std. tamoxifen treatment significantly improves disease-free survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8Yeh_0VFRbVg90H21EOLACvtfcHk0lhQDbpMJ9tohg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosl2gtbc%253D&md5=b7ccc0fb80f769bc70d2768567a4c31f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032312%26sid%3Dliteratum%253Aachs%26aulast%3DGoss%26aufirst%3DP.%2BE.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DMartino%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DN.%2BJ.%26aulast%3DMuss%26aufirst%3DH.%2BB.%26aulast%3DPiccart%26aufirst%3DM.%2BJ.%26aulast%3DCastiglione%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DShepherd%26aufirst%3DL.%2BE.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DLivingston%26aufirst%3DR.%2BB.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DAbrams%26aufirst%3DJ.%2BS.%26aulast%3DTherasse%26aufirst%3DP.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DPater%26aufirst%3DJ.%2BL.%26atitle%3DA%2520randomized%2520trial%2520of%2520letrozole%2520in%2520postmenopausal%2520women%2520after%2520five%2520years%2520of%2520tamoxifen%2520therapy%2520for%2520early-stage%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D1793%26epage%3D1802%26doi%3D10.1056%2FNEJMoa032312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span> <span> </span><span class="NLM_article-title">Aromatase inhibitors for breast cancer: lessons from the laboratory</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">831</span>, <span class="refDoi"> DOI: 10.1038/nrc1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2Fnrc1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=14668813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFKmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=821-831&author=S.+R.+D.+Johnstonauthor=M.+Dowsett&title=Aromatase+inhibitors+for+breast+cancer%3A+lessons+from+the+laboratory&doi=10.1038%2Fnrc1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors for breast cancer: Lessons from the laboratory</span></div><div class="casAuthors">Johnston, Stephen R. D.; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">821-831</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Endocrine therapy with tamoxifen has been the mainstay of treatment for hormone-sensitive breast cancer for more than 20 yr.  An alternative strategy of estrogen deprivation in postmenopausal women with aromatase inhibitors is set to replace tamoxifen based on better efficacy and a delay in the emergence of endocrine resistance.  There are fundamental differences in how tamoxifen and aromatase inhibitors alter estrogen-receptor signaling.  Understanding the response and resistance to these different therapies is central to further improving therapeutic options for women with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0yq8HDYSRf7Vg90H21EOLACvtfcHk0liORF2KTH3IyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFKmur8%253D&md5=5e187fa66d3912a9c5b151c3c54fb251</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1211%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DAromatase%2520inhibitors%2520for%2520breast%2520cancer%253A%2520lessons%2520from%2520the%2520laboratory%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D821%26epage%3D831%26doi%3D10.1038%2Fnrc1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielewska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of aromatase inhibitor resistance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1038/nrc3920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2Fnrc3920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=25907219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wrur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=261-275&author=C.+X.+Maauthor=T.+Reinertauthor=I.+Chmielewskaauthor=M.+J.+Ellis&title=Mechanisms+of+aromatase+inhibitor+resistance&doi=10.1038%2Fnrc3920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of aromatase inhibitor resistance</span></div><div class="casAuthors">Ma, Cynthia X.; Reinert, Tomas; Chmielewska, Izabela; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">261-275</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor-pos. (ER+) breast cancer is a major cause of cancer death in women.  Although aromatase inhibitors suppress the function of ER and reduce the risk of recurrence, therapeutic resistance is common and essentially inevitable in advanced disease.  This Review considers both genomic and cell biol. explanations as to why ER+ breast cancer cells persist, progress and cause an incurable, lethal, systemic disease.  The design and outcomes of clin. trials are considered with the perspective that resistance mechanisms are heterogeneous, and therefore biomarker and somatic mutation-based stratification and eligibility will be essential for improvements in patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQZc2ZDe2yrVg90H21EOLACvtfcHk0liORF2KTH3IyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wrur3F&md5=8873908dbbf917eece0cdc51d19efea1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc3920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3920%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DReinert%26aufirst%3DT.%26aulast%3DChmielewska%26aufirst%3DI.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DMechanisms%2520of%2520aromatase%2520inhibitor%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D261%26epage%3D275%26doi%3D10.1038%2Fnrc3920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Künzer, H.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of C(7)-Substituted Estra-1,3,5(10)-triene and New Starting Products by this Process</span>. Ger. Offen. <span class="NLM_patent">DE 4218743 C2</span>, <span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=H.+K%C3%BCnzer&title=Process+for+the+Preparation+of+C%287%29-Substituted+Estra-1%2C3%2C5%2810%29-triene+and+New+Starting+Products+by+this+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCnzer%26aufirst%3DH.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520C%25287%2529-Substituted%2520Estra-1%252C3%252C5%252810%2529-triene%2520and%2520New%2520Starting%2520Products%2520by%2520this%2520Process%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart-Cussac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macpherson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4530</span>– <span class="NLM_lpage">4535</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.21.1136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1200%2FJCO.2008.21.1136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=19704066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4530-4535&author=J.+F.+R.+Robertsonauthor=A.+Llombart-Cussacauthor=J.+Rolskiauthor=D.+Feltlauthor=J.+Dewarauthor=E.+Macphersonauthor=J.+Lindemannauthor=M.+J.+Ellis&title=Activity+of+fulvestrant+500+mg+versus+anastrozole+1+mg+as+first-line+treatment+for+advanced+breast+cancer%3A+results+from+the+FIRST+study&doi=10.1200%2FJCO.2008.21.1136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span></div><div class="casAuthors">Robertson, John F. R.; Llombart-Cussac, Antonio; Rolski, Janusz; Feltl, David; Dewar, John; MacPherson, Euan; Lindemann, Justin; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4530-4535</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To compare the clin. activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-pos. breast cancer in postmenopausal women.  Patients and Methods: FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) is a phase II, randomized, open-label, multicenter study of a fulvestrant high-dose (HD) regimen (500 mg/mo plus 500 mg on day 14 of month 1) vs. anastrozole (1 mg/d).  The primary efficacy end point was clin. benefit rate (CBR), defined as the proportion of patients experiencing an objective response (OR) or stable disease for ≥ 24 wk.  The primary anal. was performed 6 mo after the last patient was randomly assigned.  Results: CBR was similar for fulvestrant HD (n = 102) and anastrozole (n = 103), 72.5% v 67.0%, resp. (odds ratio, 1.30; 95% CI, 0.72 to 2.38; P = .386).  Objective response rate (ORR) was also similar between treatments: fulvestrant HD, 36.0%; anastrozole, 35.5%.  Time to progression (TTP) was significantly longer for fulvestrant vs. anastrozole (median TTP not reached for fulvestrant HD v 12.5 mo for anastrozole; hazard ratio, 0.63; 95% CI, 0.39 to 1.00; P = .0496).  Duration of OR and CB also numerically favored fulvestrant HD.  Both treatments were well tolerated, with no significant differences in the incidence of prespecified adverse events.  Conclusion: First-line fulvestrant HD was at least as effective as anastrozole for CBR and ORR and was assocd. with significantly longer TTP.  Fulvestrant HD was generally well tolerated, with a safety profile similar to that of anastrozole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-OU2SQaTsabVg90H21EOLACvtfcHk0liORF2KTH3IyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J&md5=a7a6f5cd7fcdbc8cb6839a2800cd5cb8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.1136%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DActivity%2520of%2520fulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520as%2520first-line%2520treatment%2520for%2520advanced%2520breast%2520cancer%253A%2520results%2520from%2520the%2520FIRST%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4530%26epage%3D4535%26doi%3D10.1200%2FJCO.2008.21.1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0ljPnDCBVSIbCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">9549</span>– <span class="NLM_lpage">9560</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1158%2F0008-5472.CAN-07-1590" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9549-9560&author=B.+M.+Wittmannauthor=A.+Sherkauthor=D.+P.+McDonnell&title=Definition+of+functionally+important+mechanistic+differences+among+selective+estrogen+receptor+down-regulators&doi=10.1158%2F0008-5472.CAN-07-1590"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1590%26sid%3Dliteratum%253Aachs%26aulast%3DWittmann%26aufirst%3DB.%2BM.%26aulast%3DSherk%26aufirst%3DA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DDefinition%2520of%2520functionally%2520important%2520mechanistic%2520differences%2520among%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9549%26epage%3D9560%26doi%3D10.1158%2F0008-5472.CAN-07-1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzelka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khasanov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeven, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrini, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergrass, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J. P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapunar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">4594</span>– <span class="NLM_lpage">4600</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.28.8415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1200%2FJCO.2010.28.8415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=20855825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFaitLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=4594-4600&author=A.+Di%0ALeoauthor=G.+Jerusalemauthor=L.+Petruzelkaauthor=R.+Torresauthor=I.+N.+Bondarenkoauthor=R.+Khasanovauthor=D.+Verhoevenauthor=J.+L.+Pedriniauthor=I.+Smirnovaauthor=M.+R.+Lichinitserauthor=K.+Pendergrassauthor=S.+Garnettauthor=J.+P.+O.+Lindemannauthor=F.+Sapunarauthor=M.+Martin&title=Results+of+the+CONFIRM+phase+III+trial+comparing+fulvestrant+250+mg+with+fulvestrant+500+mg+in+postmenopausal+women+with+estrogen+receptor%E2%80%93positive+advanced+breast+cancer&doi=10.1200%2FJCO.2010.28.8415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer</span></div><div class="casAuthors">di Leo, Angelo; Jerusalem, Guy; Petruzelka, Lubos; Torres, Roberto; Bondarenko, Igor N.; Khasanov, Rustem; Verhoeven, Didier; Pedrini, Jose L.; Smirnova, Iya; Lichinitser, Mikhail R.; Pendergrass, Kelly; Garnett, Sally; Lindemann, Justin P. O.; Sapunar, Francisco; Martin, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4594-4600</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per mo for treatment of postmenopausal women with estrogen receptor-pos. advanced breast cancer who experienced progression after prior endocrine therapy.  Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) is a double-blind, parallel-group, multicenter, phase III study.  Patients were randomly assigned to fulvestrant 500 mg (500 mg i.m. on day 0, then 500 mg i.m. on days 14 and 28 and every 28 days thereafter) or 250 mg every 28 days.  Primary end point was progression-free survival (PFS).  Secondary end points included objective response rate, clin. benefit rate (CBR), duration of clin. benefit (DoCB), overall survival (OS), and quality of life (QOL).  PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% redn. in risk of progression.  Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, resp.).  CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.  DoCB and OS were 16.6 and 25.1 mo, resp., for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 mo, resp., in the 250-mg group.  Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.  QOL was similar for both arms.  Fulvestrant 500 mg was assocd. with a statistically significant increase in PFS and not assocd. with increased toxicity, corresponding to a clin. meaningful improvement in benefit vs. risk compared with fulvestrant 250 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5x_viRvCGrVg90H21EOLACvtfcHk0ljPnDCBVSIbCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFaitLzO&md5=9b82ff995b029df754e4295d3153867e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.28.8415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.28.8415%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DPetruzelka%26aufirst%3DL.%26aulast%3DTorres%26aufirst%3DR.%26aulast%3DBondarenko%26aufirst%3DI.%2BN.%26aulast%3DKhasanov%26aufirst%3DR.%26aulast%3DVerhoeven%26aufirst%3DD.%26aulast%3DPedrini%26aufirst%3DJ.%2BL.%26aulast%3DSmirnova%26aufirst%3DI.%26aulast%3DLichinitser%26aufirst%3DM.%2BR.%26aulast%3DPendergrass%26aufirst%3DK.%26aulast%3DGarnett%26aufirst%3DS.%26aulast%3DLindemann%26aufirst%3DJ.%2BP.%2BO.%26aulast%3DSapunar%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DResults%2520of%2520the%2520CONFIRM%2520phase%2520III%2520trial%2520comparing%2520fulvestrant%2520250%2520mg%2520with%2520fulvestrant%2520500%2520mg%2520in%2520postmenopausal%2520women%2520with%2520estrogen%2520receptor%25E2%2580%2593positive%2520advanced%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D4594%26epage%3D4600%26doi%3D10.1200%2FJCO.2010.28.8415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapunar, F.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant revisited: efficacy and safety of the 500-mg dose</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2011.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2Fj.clbc.2011.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=21729658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKisr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=204-210&author=A.+Howellauthor=F.+Sapunar&title=Fulvestrant+revisited%3A+efficacy+and+safety+of+the+500-mg+dose&doi=10.1016%2Fj.clbc.2011.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant revisited: efficacy and safety of the 500-mg dose</span></div><div class="casAuthors">Howell, Anthony; Sapunar, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">204-210</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Postmenopausal women with hormone receptor-pos. advanced breast cancer are candidates for endocrine therapy.  As the disease will eventually progress in most patients, it is important to investigate agents with novel modes of action to reduce the likelihood of treatment cross-resistance.  Fulvestrant is an estrogen receptor antagonist with no known agonist effects that has been shown to be as effective as anastrozole following failure on tamoxifen, at the approved dose of 250 mg/mo.  However, pharmacokinetic modeling and evidence of clin. efficacy in early trials, together with the favorable tolerability profile of fulvestrant 250 mg, led to suggestions that increasing the fulvestrant dose would lead to an improved benefit-risk profile.  This review describes the rationale behind the development of a 500 mg/mo higher dose of fulvestrant and details relevant clin. trials, including the pivotal phase III COmparisoN of Faslodex In Recurrent or Metastatic breast cancer (CONFIRM) study.  CONFIRM demonstrated a significant improvement in progression-free survival for fulvestrant 500 mg vs. 250 mg in postmenopausal patients who had progressed on previous endocrine therapy.  Here, we present and discuss a pooled safety anal. of CONFIRM and three further clin. studies demonstrating fulvestrant 500 mg to be well-tolerated with no evidence of dose-related adverse events.  Overall, these data indicate an improved benefit-risk profile for fulvestrant 500 mg vs. 250 mg following failure on prior endocrine therapy, and suggest that fulvestrant 500 mg may be considered in future as initial endocrine treatment for advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4U1d7Q6edlbVg90H21EOLACvtfcHk0ljPnDCBVSIbCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKisr7E&md5=0d1063c9546320294193e92d3f2097dd</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2011.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DA.%26aulast%3DSapunar%26aufirst%3DF.%26atitle%3DFulvestrant%2520revisited%253A%2520efficacy%2520and%2520safety%2520of%2520the%2520500-mg%2520dose%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D204%26epage%3D210%26doi%3D10.1016%2Fj.clbc.2011.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momtahen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charifson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batchelor, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubahn, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauls, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triantafillou, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, P. G.</span></span> <span> </span><span class="NLM_article-title">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1021/jm00037a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00037a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1550-1552&author=T.%0AM.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+S.+Charifsonauthor=K.+W.+Batchelorauthor=D.+B.+Lubahnauthor=L.+B.+Mooreauthor=B.+B.+Oliverauthor=H.+R.+Saulsauthor=J.+A.+Triantafillouauthor=S.+G.+Wolfeauthor=P.+G.+Baer&title=3-%5B4-%281%2C2-Diphenylbut-1-enyl%29phenyl%5Dacrylic+acid%3A+a+non-steroidal+estrogen+with+functional+selectivity+for+bone+over+uterus+in+rats&doi=10.1021%2Fjm00037a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Charifson, Paul S.; Batchelor, Kenneth W.; Lubahn, Dennis B.; Moore, Linda B.; Oliver, Beverly B.; Sauls, Howard R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1550-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Exploiting knowledge of the mol. biol. of the estrogen receptor and the existence of two independent transcription activation domains, a series of tissue-selective non-steroidal estrogens was designed.  The ethanolamine side-chain of tamoxifen was targeted for modification, resulting in the identification of a series of α,β-unsatd. acid and amide analogs I [R = OH, NEt2, morpholino, NH(CH2)3OMe, dicyclohexylamino, NEtCH2CH2NMe2, NH(CH2)3OH, N-methyloctylamino, NHEt,NH2].  I [R = OH] profiled as an estrogen with full agonist activity in bone while maintaining antagonist activity in the uterus of rats.  The demonstration that different parts of the triphenylethylene structure control expression of estrogenic activity in bone and uterus has implications in the design of tissue selective ligands for other members of the steroid/retinoid family of intracellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iuXq4R8fm7Vg90H21EOLACvtfcHk0lgCGTtdOfiKsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D&md5=721906b3513f7e8cdc9ae08ecd99a93b</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm00037a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00037a002%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DBatchelor%26aufirst%3DK.%2BW.%26aulast%3DLubahn%26aufirst%3DD.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DTriantafillou%26aufirst%3DJ.%2BA.%26aulast%3DWolfe%26aufirst%3DS.%2BG.%26aulast%3DBaer%26aufirst%3DP.%2BG.%26atitle%3D3-%255B4-%25281%252C2-Diphenylbut-1-enyl%2529phenyl%255Dacrylic%2520acid%253A%2520a%2520non-steroidal%2520estrogen%2520with%2520functional%2520selectivity%2520for%2520bone%2520over%2520uterus%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1550%26epage%3D1552%26doi%3D10.1021%2Fjm00037a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadwater, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewhirst, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Circumventing tamoxifen resistance in breast cancers suing antiestrogens that induce unique conformational changes in the estrogen receptor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2917</span>– <span class="NLM_lpage">2922</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2917-2922&author=C.+E.+Connorauthor=J.+D.+Norrisauthor=G.+Broadwaterauthor=T.+M.+Willsonauthor=M.+M.+Gottardisauthor=M.+W.+Dewhirstauthor=D.+P.+McDonnell&title=Circumventing+tamoxifen+resistance+in+breast+cancers+suing+antiestrogens+that+induce+unique+conformational+changes+in+the+estrogen+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DC.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DCircumventing%2520tamoxifen%2520resistance%2520in%2520breast%2520cancers%2520suing%2520antiestrogens%2520that%2520induce%2520unique%2520conformational%2520changes%2520in%2520the%2520estrogen%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2917%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ERα+ breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2818</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2790-2818&author=H.+E.+Burksauthor=T.+Abramsauthor=C.+A.+Kirbyauthor=J.+Bairdauthor=A.+Feketeauthor=L.+G.+Hamannauthor=S.+Kimauthor=F.+Lombardoauthor=A.+Looauthor=D.+Lubickaauthor=K.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Saranauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=S.+Peukert&title=Discovery+of+an+acrylic+acid+based+tetrahydroisoquinoline+as+an+orally+bioavailable+selective+estrogen+receptor+degrader+for+ER%CE%B1%2B+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01468"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DMacchi%26aufirst%3DK.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSaran%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520an%2520acrylic%2520acid%2520based%2520tetrahydroisoquinoline%2520as%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520for%2520ER%25CE%25B1%252B%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2790%26epage%3D2818%26doi%3D10.1021%2Facs.jmedchem.6b01468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0lhd5tAmDAA3vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, J.</span></span> Roche silently whisks away its lead $1.7B Seragon drug in a Q1 footnote, April 27, 2017. Endpoints News. <a href="https://endpts.com/roche-silently-whisks-away-its-1-7b-seragon-drug-in-a-q1-footnote" class="extLink">https://endpts.com/roche-silently-whisks-away-its-1-7b-seragon-drug-in-a-q1-footnote</a> (accessed Sept. 1, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Carroll%2C+J.+Roche+silently+whisks+away+its+lead+%241.7B+Seragon+drug+in+a+Q1+footnote%2C+April+27%2C+2017.+Endpoints+News.+https%3A%2F%2Fendpts.com%2Froche-silently-whisks-away-its-1-7b-seragon-drug-in-a-q1-footnote+%28accessed+Sept.+1%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DJ.%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, Z.</span></span> <span> </span><span class="NLM_article-title">Syntheses and substituent effects on the properties of unsymmetrical photochromic diarylethenes bearing a benzothiophene unit</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2009&pages=464-474&author=S.+Puauthor=M.+Liauthor=G.+Liuauthor=Z.+Le&title=Syntheses+and+substituent+effects+on+the+properties+of+unsymmetrical+photochromic+diarylethenes+bearing+a+benzothiophene+unit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLe%26aufirst%3DZ.%26atitle%3DSyntheses%2520and%2520substituent%2520effects%2520on%2520the%2520properties%2520of%2520unsymmetrical%2520photochromic%2520diarylethenes%2520bearing%2520a%2520benzothiophene%2520unit%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2009%26volume%3D62%26spage%3D464%26epage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Breemen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-fluoro substitution prevents quinoid formation</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1021/tx049776u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx049776u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=162-173&author=H.+Liuauthor=J.+Liuauthor=R.+B.+van+Breemenauthor=G.+R.+J.+Thatcherauthor=J.+L.+Bolton&title=Bioactivation+of+the+selective+estrogen+receptor+modulator+desmethylated+arzoxifene+to+quinoids%3A+4%E2%80%B2-fluoro+substitution+prevents+quinoid+formation&doi=10.1021%2Ftx049776u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Ftx049776u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx049776u%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3Dvan%2BBreemen%26aufirst%3DR.%2BB.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26atitle%3DBioactivation%2520of%2520the%2520selective%2520estrogen%2520receptor%2520modulator%2520desmethylated%2520arzoxifene%2520to%2520quinoids%253A%25204%25E2%2580%25B2-fluoro%2520substitution%2520prevents%2520quinoid%2520formation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D162%26epage%3D173%26doi%3D10.1021%2Ftx049776u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasena, R. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2692</span>, <span class="refDoi"> DOI: 10.1021/jm070079j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070079j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2682-2692&author=Z.+Qinauthor=I.+Kastratiauthor=R.+E.+P.+Chandrasenaauthor=H.+Liuauthor=P.+Yaoauthor=P.+A.+Petukhovauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Benzothiophene+selective+estrogen+receptor+modulators+with+modulated+oxidative+activity+and+receptor+affinity&doi=10.1021%2Fjm070079j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Chandrasena, R. Esala P.; Liu, Hong; Yao, Ping; Petukhov, Pavel A.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clin. use.  Most SERMs are polyarom. phenols susceptible to oxidative metab. to quinoids, which are proposed to be genotoxic.  Conversely, the redox reactivity of SERMs may contribute to antioxidant and chemopreventive mechanisms, providing a new approach to improve the therapeutic properties of SERMs.  An improved synthetic strategy was developed to generate a family of benzothiophene SERMs.  Using computational modeling methods and measurements of antioxidant activity and estrogen receptor (ER) ligand binding, this SERM family was shown to provide both a range of ERα/ERβ selectivity from 1.2- to 67-fold and a range of redox activity.  Antioxidant activity was successfully modulated by varying a substituent remote from the OH group; the source of the antioxidant capacity.  An efficient synthetic procedure is reported yielding benzothiophene SERMs wherein redox activity and ER affinity are modulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CGhCcopaULVg90H21EOLACvtfcHk0lhd5tAmDAA3vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D&md5=594ddb689931d8629c9f5c9443f88cb4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm070079j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070079j%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DChandrasena%26aufirst%3DR.%2BE.%2BP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520with%2520modulated%2520oxidative%2520activity%2520and%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2682%26epage%3D2692%26doi%3D10.1021%2Fjm070079j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samanen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandeis, E.</span></span> <span> </span><span class="NLM_article-title">The p-(methylsulfinyl)benzyl group: a TFA-stable carboxyl-protecting group readily convertible to a TFA-labile group</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1021/jo00238a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00238a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1988&pages=561-569&author=J.+M.+Samanenauthor=E.+Brandeis&title=The+p-%28methylsulfinyl%29benzyl+group%3A+a+TFA-stable+carboxyl-protecting+group+readily+convertible+to+a+TFA-labile+group&doi=10.1021%2Fjo00238a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjo00238a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00238a016%26sid%3Dliteratum%253Aachs%26aulast%3DSamanen%26aufirst%3DJ.%2BM.%26aulast%3DBrandeis%26aufirst%3DE.%26atitle%3DThe%2520p-%2528methylsulfinyl%2529benzyl%2520group%253A%2520a%2520TFA-stable%2520carboxyl-protecting%2520group%2520readily%2520convertible%2520to%2520a%2520TFA-labile%2520group%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1988%26volume%3D53%26spage%3D561%26epage%3D569%26doi%3D10.1021%2Fjo00238a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T. Y.</span></span> <span> </span><span class="NLM_article-title">Efficient synthesis of 3-oxygenated benzothiophene derivatives</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2349</span>– <span class="NLM_lpage">2352</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2007.01.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2Fj.tetlet.2007.01.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlOku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=2349-2352&author=F.+Zhangauthor=D.+Mitchellauthor=P.+Pollockauthor=T.+Y.+Zhang&title=Efficient+synthesis+of+3-oxygenated+benzothiophene+derivatives&doi=10.1016%2Fj.tetlet.2007.01.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient synthesis of 3-oxygenated benzothiophene derivatives</span></div><div class="casAuthors">Zhang, Fuyao; Mitchell, David; Pollock, Patrick; Zhang, Tony Y.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2349-2352</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient synthesis of 2-bromo-3-(aryloxy)benzothiophene derivs. by a conjugate addn.-elimination sequence of 2,3-dibromobenzothiophene dioxides with phenolic nucleophiles was developed.  These benzothiophene derivs. serve as important intermediates for the synthesis of SERM (selective estrogen receptor modulator) analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobybOZuLGdXbVg90H21EOLACvtfcHk0lj4oyVPOEejAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlOku7s%253D&md5=f5d8f52b8563eff079ea173d2cd89737</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2007.01.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2007.01.141%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DMitchell%26aufirst%3DD.%26aulast%3DPollock%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DT.%2BY.%26atitle%3DEfficient%2520synthesis%2520of%25203-oxygenated%2520benzothiophene%2520derivatives%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D2349%26epage%3D2352%26doi%3D10.1016%2Fj.tetlet.2007.01.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anstead, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinney, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Torsionally and hydrophobically modified 2,3-diarylindenes as estrogen-receptor ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2726</span>– <span class="NLM_lpage">2134</span>, <span class="refDoi"> DOI: 10.1021/jm00172a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00172a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=2726-2134&author=G.+M.+Ansteadauthor=C.+S.+Petersonauthor=K.+G.+Pinneyauthor=S.+R.+Wilsonauthor=J.+A.+Katzenellenbogen&title=Torsionally+and+hydrophobically+modified+2%2C3-diarylindenes+as+estrogen-receptor+ligands&doi=10.1021%2Fjm00172a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm00172a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00172a008%26sid%3Dliteratum%253Aachs%26aulast%3DAnstead%26aufirst%3DG.%2BM.%26aulast%3DPeterson%26aufirst%3DC.%2BS.%26aulast%3DPinney%26aufirst%3DK.%2BG.%26aulast%3DWilson%26aufirst%3DS.%2BR.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DTorsionally%2520and%2520hydrophobically%2520modified%25202%252C3-diarylindenes%2520as%2520estrogen-receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D2726%26epage%3D2134%26doi%3D10.1021%2Fjm00172a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grese, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lugar, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magee, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glasebrook, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, H. U.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1021/jm9606352</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9606352" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=146-167&author=T.+A.+Greseauthor=S.+Choauthor=D.+R.+Finleyauthor=A.+G.+Godfreyauthor=C.+D.+Jonesauthor=C.+W.+Lugarauthor=M.+J.+Martinauthor=K.+Matsumotoauthor=L.+D.+Penningtonauthor=M.+A.+Winterauthor=M.+D.+Adrianauthor=H.+W.+Coleauthor=D.+E.+Mageeauthor=D.+L.+Phillipsauthor=E.+R.+Rowleyauthor=L.+L.+Shortauthor=A.+L.+Glasebrookauthor=H.+U.+Bryant&title=Structure-activity+relationships+of+selective+estrogen+receptor+modulators%3A+modifications+to+the+2-arylbenzothiophene+core+of+raloxifene&doi=10.1021%2Fjm9606352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm9606352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9606352%26sid%3Dliteratum%253Aachs%26aulast%3DGrese%26aufirst%3DT.%2BA.%26aulast%3DCho%26aufirst%3DS.%26aulast%3DFinley%26aufirst%3DD.%2BR.%26aulast%3DGodfrey%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DLugar%26aufirst%3DC.%2BW.%26aulast%3DMartin%26aufirst%3DM.%2BJ.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DWinter%26aufirst%3DM.%2BA.%26aulast%3DAdrian%26aufirst%3DM.%2BD.%26aulast%3DCole%26aufirst%3DH.%2BW.%26aulast%3DMagee%26aufirst%3DD.%2BE.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26aulast%3DRowley%26aufirst%3DE.%2BR.%26aulast%3DShort%26aufirst%3DL.%2BL.%26aulast%3DGlasebrook%26aufirst%3DA.%2BL.%26aulast%3DBryant%26aufirst%3DH.%2BU.%26atitle%3DStructure-activity%2520relationships%2520of%2520selective%2520estrogen%2520receptor%2520modulators%253A%2520modifications%2520to%2520the%25202-arylbenzothiophene%2520core%2520of%2520raloxifene%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D146%26epage%3D167%26doi%3D10.1021%2Fjm9606352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brzozowski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauter, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engström, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J. Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlquist, M.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of agonism and antagonism in the oestrogen receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/39645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2F39645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=9338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=753-758&author=A.+M.+Brzozowskiauthor=A.+C.+W.+Pikeauthor=Z.+Dauterauthor=R.+E.+Hubbardauthor=T.+Bonnauthor=O.+Engstr%C3%B6mauthor=L.+%C3%96hmanauthor=G.+L.+Greeneauthor=J.+%C3%85.+Gustafssonauthor=M.+Carlquist&title=Molecular+basis+of+agonism+and+antagonism+in+the+oestrogen+receptor&doi=10.1038%2F39645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of agonism and antagonism in the estrogen receptor</span></div><div class="casAuthors">Brzozowski, Andrzej M.; Pike, Ashley C. W.; Dauter, Zbigniew; Hubbard, Roderick E.; Bonn, Tomas; Engstrom, Owe; Ohman, Lars; Greene, Geoffrey L.; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6652</span>),
    <span class="NLM_cas:pages">753-758</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Estrogens are involved in the growth, development and homeostasis of a no. of tissues.  The physiol. effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the estrogen receptor (ER).  Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of mol. events culminating in the activation or repression of target genes.  Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery.  Here we report the crystal structures of the LBD of ER in complex with the endogenous estrogen, 17β-estradiol, and the selective antagonist raloxifene, at resolns. of 3.1 and 2.6Å, resp.  The structures provide a mol. basis for the distinctive pharmacophore of the ER and its catholic binding properties.  Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes.  In addn., each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXbSo66V1LrVg90H21EOLACvtfcHk0lhgfUSJpAuvOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D&md5=2a63951b881b329ff142c9fbc82a13e3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2F39645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F39645%26sid%3Dliteratum%253Aachs%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%2BC.%2BW.%26aulast%3DDauter%26aufirst%3DZ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DBonn%26aufirst%3DT.%26aulast%3DEngstr%25C3%25B6m%26aufirst%3DO.%26aulast%3D%25C3%2596hman%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.%2B%25C3%2585.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DMolecular%2520basis%2520of%2520agonism%2520and%2520antagonism%2520in%2520the%2520oestrogen%2520receptor%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D753%26epage%3D758%26doi%3D10.1038%2F39645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span> <i>The PyMOL Molecular
Graphics System</i>, version 1.8.4.2, <span class="NLM_publisher-name">Schrödinger,
LLC</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+PyMOL+Molecular%0AGraphics+System%2C+version+1.8.4.2%2C+Schr%C3%B6dinger%2C%0ALLC."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMOL%2520Molecular%250AGraphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%250ALLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadwater, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewhirst, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2917</span>– <span class="NLM_lpage">2922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=11306468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2917-2922&author=C.+E.+Connorauthor=J.+D.+Norrisauthor=G.+Broadwaterauthor=T.+M.+Willsonauthor=M.+M.+Gottardisauthor=M.+W.+Dewhirstauthor=D.+P.+McDonnell&title=Circumventing+tamoxifen+resistance+in+breast+cancers+using+antiestrogens+that+induce+unique+conformational+changes+in+the+estrogen+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span></div><div class="casAuthors">Connor, Caroline E.; Norris, John D.; Broadwater, Gloria; Willson, Timothy M.; Gottardis, Marco M.; Dewhirst, Mark W.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2917-2922</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tamoxifen inhibits estrogen receptor (ER) transcriptional activity by competitively inhibiting estradiol binding and inducing conformational changes in the receptor that may prevent its interaction with coactivators.  In bone, the cardiovascular system, and some breast tumors, however, tamoxifen exhibits agonist activity, suggesting that the tamoxifen-ER complex is not recognized identically in all cells.  We used phage display to demonstrate that the antiestrogen GW5638 induces a unique structural change in the ER.  The biol. significance of this conformational change was revealed in studies that demonstrated that tamoxifen-resistant breast tumor explants are not cross-resistant to GW5638.  Because of these properties, this drug is currently being developed as a potential therapeutic for tamoxifen-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2YSN94iysMbVg90H21EOLACvtfcHk0lhgfUSJpAuvOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D&md5=d7ecae7d445901e2f2c4f133ebbacdc5</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DC.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DCircumventing%2520tamoxifen%2520resistance%2520in%2520breast%2520cancers%2520using%2520antiestrogens%2520that%2520induce%2520unique%2520conformational%2520changes%2520in%2520the%2520estrogen%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2917%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiRenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span> <span> </span><span class="NLM_article-title">Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00188-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2FS0092-8674%2800%2900188-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=11136970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=843-852&author=Y.+Shangauthor=X.+Huauthor=J.+DiRenzoauthor=M.+A.+Lazarauthor=M.+Brown&title=Cofactor+dynamics+and+sufficiency+in+estrogen+receptor-regulated+transcription&doi=10.1016%2FS0092-8674%2800%2900188-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</span></div><div class="casAuthors">Shang, Yongfeng; Hu, Xiao; DiRenzo, James; Lazar, Mitchell A.; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">843-852</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Many cofactors bind the hormone-activated estrogen receptor (ER), yet the specific regulators of endogenous ER-mediated gene transcription are unknown.  Using chromatin immunopptn. (ChIP), we find that ER and a no. of coactivators rapidly assoc. with estrogen responsive promoters following estrogen treatment in a cyclic fashion that is not predicted by current models of hormone activation.  Cycles of ER complex assembly are followed by transcription.  In contrast, the anti-estrogen tamoxifen (TAM) recruits corepressors but not coactivators.  Using a genetic approach, we show that recruitment of the p160 class of coactivators is sufficient for gene activation and for the growth stimulatory actions of estrogen in breast cancer supporting a model in which ER cofactors play unique roles in estrogen signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6m5Mq-rPwB7Vg90H21EOLACvtfcHk0lhgfUSJpAuvOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFCjt7s%253D&md5=6f5af3762620dfd880758ba9fafcba25</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900188-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900188-4%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDiRenzo%26aufirst%3DJ.%26aulast%3DLazar%26aufirst%3DM.%2BA.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DCofactor%2520dynamics%2520and%2520sufficiency%2520in%2520estrogen%2520receptor-regulated%2520transcription%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D843%26epage%3D852%26doi%3D10.1016%2FS0092-8674%2800%2900188-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2011.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2Fj.bcp.2011.03.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=122-130&author=S.+E.+Wardellauthor=J.+R.+Marksauthor=D.+P.+McDonnell&title=The+turnover+of+estrogen+receptor+%CE%B1+by+the+selective+estrogen+receptor+degrader+%28SERD%29+fulvestrant+is+a+saturable+process+that+is+not+required+for+antagonist+efficacy&doi=10.1016%2Fj.bcp.2011.03.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DMarks%26aufirst%3DJ.%2BR.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DThe%2520turnover%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520by%2520the%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520fulvestrant%2520is%2520a%2520saturable%2520process%2520that%2520is%2520not%2520required%2520for%2520antagonist%2520efficacy%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D122%26epage%3D130%26doi%3D10.1016%2Fj.bcp.2011.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span> </span><span class="NLM_article-title">Phase I/Ib Trial of LSZ102 single agent or LSZ102
+ LEE011 or LSZ102
+ BYL719 in ER+ breast cancers</span>. ClinicalTrials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT02734615" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02734615</a> (accessed Sept. 1, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+I%2FIb+Trial+of+LSZ102+single+agent+or+LSZ102%0A%2B+LEE011+or+LSZ102%0A%2B+BYL719+in+ER%2B+breast+cancers.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02734615+%28accessed+Sept.+1%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPhase%2520I%252FIb%2520Trial%2520of%2520LSZ102%2520single%2520agent%2520or%2520LSZ102%250A%252B%2520LEE011%2520or%2520LSZ102%250A%252B%2520BYL719%2520in%2520ER%252B%2520breast%2520cancers%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span>; <span class="NLM_string-name">Curigliano, G.</span>; <span class="NLM_string-name">Cresta, S.</span>; <span class="NLM_string-name">Yap, Y.
S.</span>; <span class="NLM_string-name">Terret, C.</span>; <span class="NLM_string-name">Duhoux, F. P.</span>; <span class="NLM_string-name">Takahashi, S.</span>; <span class="NLM_string-name">Kundamal, N.</span>; <span class="NLM_string-name">Bhansali, S.</span>; <span class="NLM_string-name">Liao, S.</span>; <span class="NLM_string-name">Crystal, A.</span>; <span class="NLM_string-name">Jhaveri, K.</span></span> <span> </span><span class="NLM_article-title">Phase I/Ib Study of the SERD LSZ102 Alone or in Combination With Ribociclib in ER+ Breast Cancer: Preliminary Single-agent Results</span>.  <i>Abstracts from the 40th Annual SABCS</i>, San Antonio, TX, December 4–9, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Juric&author=G.+Curigliano&author=S.+Cresta&author=Y.%0AS.+Yap&author=C.+Terret&author=F.+P.+Duhoux&author=S.+Takahashi&author=N.+Kundamal&author=S.+Bhansali&author=S.+Liao&author=A.+Crystal&author=K.+Jhaveri&title=Phase+I%2FIb+Study+of+the+SERD+LSZ102+Alone+or+in+Combination+With+Ribociclib+in+ER%2B+Breast+Cancer%3A+Preliminary+Single-agent+Results"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26atitle%3DPhase%2520I%252FIb%2520Study%2520of%2520the%2520SERD%2520LSZ102%2520Alone%2520or%2520in%2520Combination%2520With%2520Ribociclib%2520in%2520ER%252B%2520Breast%2520Cancer%253A%2520Preliminary%2520Single-agent%2520Results%26jtitle%3DAbstracts%2520from%2520the%252040th%2520Annual%2520SABCS%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29a','cit29b'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 55 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Xiaomeng Zhang, Yazhou Wang, Xue Li, Jie Wu, Liwen Zhao, Wei Li, <span class="NLM_string-name hlFld-ContribAuthor">Jian Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7575-7595. <a href="https://doi.org/10.1021/acs.jmedchem.1c00280" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00280</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00280%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDynamics-Based%252BDiscovery%252Bof%252BNovel%25252C%252BPotent%252BBenzoic%252BAcid%252BDerivatives%252Bas%252BOrally%252BBioavailable%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252Bfor%252BER%2525CE%2525B1%25252B%252BBreast%252BCancer%26aulast%3DZhang%26aufirst%3DXiaomeng%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D13022021%26date%3D31052021%26volume%3D64%26issue%3D11%26spage%3D7575%26epage%3D7595" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexandra K. Knox, Christina Kalchschmid, Daniela Schuster, Francesca Gaggia, <span class="NLM_string-name hlFld-ContribAuthor">Ronald Gust</span>. </span><span class="cited-content_cbyCitation_article-title">Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5766-5786. <a href="https://doi.org/10.1021/acs.jmedchem.0c02230" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02230%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHeterodimeric%252BGW7604%252BDerivatives%25253A%252BModification%252Bof%252Bthe%252BPharmacological%252BProfile%252Bby%252BAdditional%252BInteractions%252Bat%252Bthe%252BCoactivator%252BBinding%252BSite%26aulast%3DKnox%26aufirst%3DAlexandra%2BK.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23122020%26date%3D27042021%26volume%3D64%26issue%3D9%26spage%3D5766%26epage%3D5786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yunlong Lu, <span class="NLM_string-name hlFld-ContribAuthor">Wukun Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15094-15114. <a href="https://doi.org/10.1021/acs.jmedchem.0c00913" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00913%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%25253A%252BA%252BPromising%252BStrategy%252Bfor%252BEstrogen%252BReceptor%252BPositive%252BEndocrine-Resistant%252BBreast%252BCancer%26aulast%3DLu%26aufirst%3DYunlong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29052020%26date%3D02112020%26volume%3D63%26issue%3D24%26spage%3D15094%26epage%3D15114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Thomas A. Moss, Amber Balazs, Bernard Barlaam, Jason Breed, Rodrigo J. Carbajo, Elisabetta Chiarparin, Paul R. J. Davey, Oona Delpuech, Stephen Fawell, David I. Fisher, Sladjana Gagrica, Eric T. Gangl, Tyler Grebe, Ryan D. Greenwood, Sudhir Hande, Holia Hatoum-Mokdad, Kara Herlihy, Samantha Hughes, Thomas A. Hunt, Hoan Huynh, Sophie L. M. Janbon, Tony Johnson, Stefan Kavanagh, Teresa Klinowska, Mandy Lawson, Andrew S. Lister, Stacey Marden, Dermot F. McGinnity, Christopher J. Morrow, J. Willem M. Nissink, Daniel H. O’Donovan, Bo Peng, Radoslaw Polanski, Darren S. Stead, Stephen Stokes, Kumar Thakur, Scott R. Throner, Michael J. Tucker, Jeffrey Varnes, Haixia Wang, David M. Wilson, Dedong Wu, Ye Wu, Bin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Wenzhan Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14530-14559. <a href="https://doi.org/10.1021/acs.jmedchem.0c01163" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01163%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BAZD9833%25252C%252Ba%252BPotent%252Band%252BOrally%252BBioavailable%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252Band%252BAntagonist%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07072020%26date%3D29092020%26date%3D10092020%26volume%3D63%26issue%3D23%26spage%3D14530%26epage%3D14559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Emily J. Hanan, Jun Liang, Xiaojing Wang, Robert A. Blake, Nicole Blaquiere, <span class="NLM_string-name hlFld-ContribAuthor">Steven T. Staben</span>. </span><span class="cited-content_cbyCitation_article-title">Monomeric Targeted Protein Degraders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11330-11361. <a href="https://doi.org/10.1021/acs.jmedchem.0c00093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMonomeric%252BTargeted%252BProtein%252BDegraders%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D15062020%26date%3D30042020%26volume%3D63%26issue%3D20%26spage%3D11330%26epage%3D11361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Thomas J. Struble, Juan C. Alvarez, Scott P. Brown, Milan Chytil, Justin Cisar, Renee L. DesJarlais, Ola Engkvist, Scott A. Frank, Daniel R. Greve, Daniel J. Griffin, Xinjun Hou, Jeffrey W. Johannes, Constantine Kreatsoulas, Brian Lahue, Miriam Mathea, Georg Mogk, Christos A. Nicolaou, Andrew D. Palmer, Daniel J. Price, Richard I. Robinson, Sebastian Salentin, Li Xing, Tommi Jaakkola, William. H. Green, Regina Barzilay, Connor W. Coley, <span class="NLM_string-name hlFld-ContribAuthor">Klavs F. Jensen</span>. </span><span class="cited-content_cbyCitation_article-title">Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (16)
                                     , 8667-8682. <a href="https://doi.org/10.1021/acs.jmedchem.9b02120" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02120%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Band%252BFuture%252BRoles%252Bof%252BArtificial%252BIntelligence%252Bin%252BMedicinal%252BChemistry%252BSynthesis%26aulast%3DStruble%26aufirst%3DThomas%2BJ.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19122019%26date%3D14042020%26date%3D03042020%26volume%3D63%26issue%3D16%26spage%3D8667%26epage%3D8682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Markus Baenziger, Marcel Baierl, Krishnaswamy Devanathan, Sumesh Eswaran, Peng Fu, Bjoern Gschwend, Michael Haller, Gopu Kasinathan, Nikola Kovacic, Audrey Langlois, Yongfeng Li, Friedrich Schuerch, Xiaodong Shen, Yinbo Wan, Regina Wickendick, Siwei Xie, <span class="NLM_string-name hlFld-ContribAuthor">Kai Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis Development of the Selective Estrogen Receptor Degrader (SERD) LSZ102 from a Suzuki Coupling to a C–H Activation Strategy. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (8)
                                     , 1405-1419. <a href="https://doi.org/10.1021/acs.oprd.0c00076" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00076%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DSynthesis%252BDevelopment%252Bof%252Bthe%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252B%252528SERD%252529%252BLSZ102%252Bfrom%252Ba%252BSuzuki%252BCoupling%252Bto%252Ba%252BC%2525E2%252580%252593H%252BActivation%252BStrategy%26aulast%3DBaenziger%26aufirst%3DMarkus%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D17072020%26date%3D01072020%26volume%3D24%26issue%3D8%26spage%3D1405%26epage%3D1419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael Parmentier, Mona Wagner, Regina Wickendick, Markus Baenziger, Audrey Langlois, <span class="NLM_string-name hlFld-ContribAuthor">Fabrice Gallou</span>. </span><span class="cited-content_cbyCitation_article-title">A General Kilogram Scale Protocol for Suzuki–Miyaura Cross-Coupling in Water with TPGS-750-M Surfactant. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2020,</strong> <em>24 </em>
                                    (8)
                                     , 1536-1542. <a href="https://doi.org/10.1021/acs.oprd.0c00281" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00281</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00281%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DA%252BGeneral%252BKilogram%252BScale%252BProtocol%252Bfor%252BSuzuki%2525E2%252580%252593Miyaura%252BCross-Coupling%252Bin%252BWater%252Bwith%252BTPGS-750-M%252BSurfactant%26aulast%3DParmentier%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12062020%26date%3D21072020%26date%3D15072020%26volume%3D24%26issue%3D8%26spage%3D1536%26epage%3D1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jun Liang, Robert Blake, Jae Chang, Lori S. Friedman, Simon Goodacre, Steven Hartman, Ellen Rei Ingalla, James R. Kiefer, Tracy Kleinheinz, Sharada Labadie, Jun Li, Kwong Wah Lai, Jiangpeng Liao, Vidhi Mody, Neville McLean, Ciara Metcalfe, Michelle Nannini, Daniel Otwine, Yingqing Ran, Nick Ray, Fabien Roussel, Amy Sambrone, Deepak Sampath, Maia Vinogradova, John Wai, Tao Wang, Kuen Yeap, Amy Young, Jason Zbieg, Birong Zhang, Xiaoping Zheng, Yu Zhong, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojing Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1342-1347. <a href="https://doi.org/10.1021/acsmedchemlett.0c00224" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00224%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BGNE-149%252Bas%252Ba%252BFull%252BAntagonist%252Band%252BEfficient%252BDegrader%252Bof%252BEstrogen%252BReceptor%252Balpha%252Bfor%252BER%25252B%252BBreast%252BCancer%26aulast%3DLiang%26aufirst%3DJun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28042020%26date%3D26052020%26date%3D29052020%26date%3D26052020%26volume%3D11%26issue%3D6%26spage%3D1342%26epage%3D1347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Abed Saady, Melissa Wojtyniak, Eli Varon, Verena Böttner, Noa Kinor, Yaron Shav-Tal, Christian Ducho, <span class="NLM_string-name hlFld-ContribAuthor">Bilha Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Specific, Sensitive, and Quantitative Detection of HER-2 mRNA Breast Cancer Marker by Fluorescent Light-Up Hybridization Probes. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (4)
                                     , 1188-1198. <a href="https://doi.org/10.1021/acs.bioconjchem.0c00130" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.0c00130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.0c00130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.0c00130%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DSpecific%25252C%252BSensitive%25252C%252Band%252BQuantitative%252BDetection%252Bof%252BHER-2%252BmRNA%252BBreast%252BCancer%252BMarker%252Bby%252BFluorescent%252BLight-Up%252BHybridization%252BProbes%26aulast%3DSaady%26aufirst%3DAbed%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05032020%26date%3D24032020%26date%3D31032020%26date%3D25032020%26volume%3D31%26issue%3D4%26spage%3D1188%26epage%3D1198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Youssef El-Ahmad, Michel Tabart, Frank Halley, Victor Certal, Fabienne Thompson, Bruno Filoche-Rommé, Florence Gruss-Leleu, Claire Muller, Maurice Brollo, Laurence Fabien, Véronique Loyau, Luc Bertin, Patrick Richepin, Fabienne Pilorge, Pascal Desmazeau, Chrystelle Girardet, Sylvie Beccari, Audrey Louboutin, Gilles Lebourg, Jacques Le-Roux, Corinne Terrier, François Vallée, Valérie Steier, Magali Mathieu, Alexey Rak, Pierre-Yves Abecassis, Pascale Vicat, Tsiala Benard, Monsif Bouaboula, Fangxian Sun, Maysoun Shomali, Andrew Hebert, Mikhail Levit, Hong Cheng, Albane Courjaud, Celine Ginesty, Christelle Perrault, Carlos Garcia-Echeverria, Gary McCort, <span class="NLM_string-name hlFld-ContribAuthor">Laurent Schio</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (2)
                                     , 512-528. <a href="https://doi.org/10.1021/acs.jmedchem.9b01293" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01293</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01293%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B6-%2525282%25252C4-Dichlorophenyl%252529-5-%25255B4-%25255B%2525283S%252529-1-%2525283-fluoropropyl%252529pyrrolidin-3-yl%25255Doxyphenyl%25255D-8%25252C9-dihydro-7H-benzo%25255B7%25255Dannulene-2-carboxylic%252Bacid%252B%252528SAR439859%252529%25252C%252Ba%252BPotent%252Band%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252B%252528SERD%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BEstrogen-Receptor-Positive%252BBreast%252BCancer%26aulast%3DEl-Ahmad%26aufirst%3DYoussef%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D08082019%26date%3D27112019%26date%3D13112019%26volume%3D63%26issue%3D2%26spage%3D512%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Jason Breed, Rodrigo J. Carbajo, Paul R. Davey, Ryan Greenwood, Hoan K. Huynh, Teresa Klinowska, Christopher J. Morrow, Thomas A. Moss, Radoslaw Polanski, J. Willem M. Nissink, Jeffrey Varnes, <span class="NLM_string-name hlFld-ContribAuthor">Bin Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1492-1497. <a href="https://doi.org/10.1021/acsmedchemlett.9b00370" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00370%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DBuilding%252BBridges%252Bin%252Ba%252BSeries%252Bof%252BEstrogen%252BReceptor%252BDegraders%25253A%252BAn%252BApplication%252Bof%252BMetathesis%252Bin%252BMedicinal%252BChemistry%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08082019%26date%3D23092019%26date%3D25092019%26date%3D23092019%26volume%3D10%26issue%3D10%26spage%3D1492%26epage%3D1497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Manon Réau, Nathalie Lagarde, Jean-François Zagury, <span class="NLM_string-name hlFld-ContribAuthor">Matthieu Montes</span>. </span><span class="cited-content_cbyCitation_article-title">Nuclear Receptors Database Including Negative Data (NR-DBIND): A Database Dedicated to Nuclear Receptors Binding Data Including Negative Data and Pharmacological Profile. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 2894-2904. <a href="https://doi.org/10.1021/acs.jmedchem.8b01105" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01105%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNuclear%252BReceptors%252BDatabase%252BIncluding%252BNegative%252BData%252B%252528NR-DBIND%252529%25253A%252BA%252BDatabase%252BDedicated%252Bto%252BNuclear%252BReceptors%252BBinding%252BData%252BIncluding%252BNegative%252BData%252Band%252BPharmacological%252BProfile%26aulast%3DR%25C3%25A9au%26aufirst%3DManon%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D13072018%26date%3D06112018%26date%3D24102018%26volume%3D62%26issue%3D6%26spage%3D2894%26epage%3D2904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jiantao Hu, Biao Hu, Mingliang Wang, Fuming Xu, Bukeyan Miao, Chao-Yie Yang, Mi Wang, Zhaomin Liu, Daniel F. Hayes, Krishnapriya Chinnaswamy, James Delproposto, Jeanne Stuckey, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (3)
                                     , 1420-1442. <a href="https://doi.org/10.1021/acs.jmedchem.8b01572" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01572</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01572%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BERD-308%252Bas%252Ba%252BHighly%252BPotent%252BProteolysis%252BTargeting%252BChimera%252B%252528PROTAC%252529%252BDegrader%252Bof%252BEstrogen%252BReceptor%252B%252528ER%252529%26aulast%3DHu%26aufirst%3DJiantao%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D09102018%26date%3D18012019%26volume%3D62%26issue%3D3%26spage%3D1420%26epage%3D1442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Andrew Bailey, David Buttar, Rodrigo J. Carbajo, Jon Curwen, Paul R. J. Davey, Robert D. M. Davies, Sébastien L. Degorce, Craig Donald, Eric Gangl, Ryan Greenwood, Sam D. Groombridge, Tony Johnson, Scott Lamont, Mandy Lawson, Andrew Lister, Christopher J. Morrow, Thomas A. Moss, Jennifer H. Pink, <span class="NLM_string-name hlFld-ContribAuthor">Radoslaw Polanski</span>. </span><span class="cited-content_cbyCitation_article-title">Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (3)
                                     , 1593-1608. <a href="https://doi.org/10.1021/acs.jmedchem.8b01837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTricyclic%252BIndazoles%2525E2%252580%252594A%252BNovel%252BClass%252Bof%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252BAntagonists%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D23112018%26date%3D30012019%26date%3D14012019%26volume%3D62%26issue%3D3%26spage%3D1593%26epage%3D1608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Johnny Nagasawa, Steven Govek, Mehmet Kahraman, Andiliy Lai, Celine Bonnefous, Karensa Douglas, John Sensintaffar, Nhin Lu, KyoungJin Lee, Anna Aparicio, Josh Kaufman, Jing Qian, Gang Shao, Rene Prudente, James D. Joseph, Beatrice Darimont, Daniel Brigham, Kate Maheu, Richard Heyman, Peter J. Rix, Jeffrey H. Hager, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (17)
                                     , 7917-7928. <a href="https://doi.org/10.1021/acs.jmedchem.8b00921" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00921</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Ban%252BOrally%252BBioavailable%252BChromene-Based%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252B%252528SERD%252529%252BThat%252BDemonstrates%252BRobust%252BActivity%252Bin%252Ba%252BModel%252Bof%252BTamoxifen-Resistant%252BBreast%252BCancer%26aulast%3DNagasawa%26aufirst%3DJohnny%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09062018%26date%3D04092018%26date%3D07082018%26volume%3D61%26issue%3D17%26spage%3D7917%26epage%3D7928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengfeng  Bai</span>, <span class="hlFld-ContribAuthor ">Shengnan  Ren</span>, <span class="hlFld-ContribAuthor ">Shuangjie  Wu</span>, <span class="hlFld-ContribAuthor ">Meiqi  Zhu</span>, <span class="hlFld-ContribAuthor ">Guoshun  Luo</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113543. <a href="https://doi.org/10.1016/j.ejmech.2021.113543" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113543</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113543%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252Bbenzothiophene%252Banalogs%252Bas%252Bselective%252Bestrogen%252Breceptor%252Bcovalent%252Bantagonists%252Bagainst%252Bbreast%252Bcancer%26aulast%3DBai%26aufirst%3DChengfeng%26date%3D2021%26volume%3D221%26spage%3D113543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Hernando</span>, <span class="hlFld-ContribAuthor ">Belén  Ortega-Morillo</span>, <span class="hlFld-ContribAuthor ">Marta  Tapia</span>, <span class="hlFld-ContribAuthor ">Santiago  Moragón</span>, <span class="hlFld-ContribAuthor ">María Teresa  Martínez</span>, <span class="hlFld-ContribAuthor ">Pilar  Eroles</span>, <span class="hlFld-ContribAuthor ">Iris  Garrido-Cano</span>, <span class="hlFld-ContribAuthor ">Anna  Adam-Artigues</span>, <span class="hlFld-ContribAuthor ">Ana  Lluch</span>, <span class="hlFld-ContribAuthor ">Begoña  Bermejo</span>, <span class="hlFld-ContribAuthor ">Juan Miguel  Cejalvo</span>. </span><span class="cited-content_cbyCitation_article-title">Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (15)
                                     , 7812. <a href="https://doi.org/10.3390/ijms22157812" title="DOI URL">https://doi.org/10.3390/ijms22157812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22157812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22157812%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DOral%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%252Bas%252Ba%252BNovel%252BBreast%252BCancer%252BTherapy%25253A%252BPresent%252Band%252BFuture%252Bfrom%252Ba%252BClinical%252BPerspective%26aulast%3DHernando%26aufirst%3DCristina%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D15%26spage%3D7812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xi  Liu</span>, <span class="hlFld-ContribAuthor ">Qian  Hu</span>, <span class="hlFld-ContribAuthor ">Wanyan  Wang</span>, <span class="hlFld-ContribAuthor ">Hui  Ma</span>, <span class="hlFld-ContribAuthor ">Jiaqian  Pu</span>, <span class="hlFld-ContribAuthor ">Jiayan  Cui</span>, <span class="hlFld-ContribAuthor ">Ting  Gong</span>, <span class="hlFld-ContribAuthor ">Yu  Wu</span>, <span class="hlFld-ContribAuthor ">Weiqiang  Lu</span>, <span class="hlFld-ContribAuthor ">Jin  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>188 </em>, 114583. <a href="https://doi.org/10.1016/j.bcp.2021.114583" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114583</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114583%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DA%252Bprotein-fragment%252Bcomplementation%252Bassay%252Breveals%252Bthat%252Bcelastrol%252Band%252Bgambogic%252Bacid%252Bsuppress%252BER%2525CE%2525B1%252Bmutants%252Bin%252Bbreast%252Bcancer%26aulast%3DLiu%26aufirst%3DXi%26date%3D2021%26volume%3D188%26spage%3D114583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erika  Araujo</span>. </span><span class="cited-content_cbyCitation_article-title">Cancer Targets Involving the Ubiquitin Proteasome System. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-27. <a href="https://doi.org/10.1002/0471266949.bmc282" title="DOI URL">https://doi.org/10.1002/0471266949.bmc282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc282%26sid%3Dliteratum%253Aachs%26atitle%3DCancer%252BTargets%252BInvolving%252Bthe%252BUbiquitin%252BProteasome%252BSystem%26aulast%3DAraujo%26aufirst%3DErika%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D27%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carlo I.  Rosales</span>, <span class="hlFld-ContribAuthor ">Lauren M.  Gutgesell</span>, <span class="hlFld-ContribAuthor ">Kiira M.  Ratia</span>, <span class="hlFld-ContribAuthor ">Gregory R.J.  Thatcher</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen Receptor Modulators. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-74. <a href="https://doi.org/10.1002/0471266949.bmc054.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc054.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc054.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc054.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DEstrogen%252BReceptor%252BModulators%26aulast%3DRosales%26aufirst%3DCarlo%2BI.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D74%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang  Lu</span>, <span class="hlFld-ContribAuthor ">Yu  Teng</span>, <span class="hlFld-ContribAuthor ">Xin  Lin</span>, <span class="hlFld-ContribAuthor ">Maoxu  Xiao</span>, <span class="hlFld-ContribAuthor ">Chenna  Liu</span>, <span class="hlFld-ContribAuthor ">Xinglong  Chi</span>, <span class="hlFld-ContribAuthor ">Yulan  Zhang</span>, <span class="hlFld-ContribAuthor ">Guoshun  Luo</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104714. <a href="https://doi.org/10.1016/j.bioorg.2021.104714" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104714</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104714%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B2H-chromene-3-carbonyl%252Bderivatives%252Bas%252Bselective%252Bestrogen%252Breceptor%252Bdegraders%252B%252528SERDs%252529%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DLu%26aufirst%3DXiang%26date%3D2021%26volume%3D109%26spage%3D104714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nitish  Kumar</span>, <span class="hlFld-ContribAuthor ">Harmandeep Kaur  Gulati</span>, <span class="hlFld-ContribAuthor ">Aakriti  Sharma</span>, <span class="hlFld-ContribAuthor ">Shilpa  Heer</span>, <span class="hlFld-ContribAuthor ">Anupmjot Kaur  Jassal</span>, <span class="hlFld-ContribAuthor ">Lovenish  Arora</span>, <span class="hlFld-ContribAuthor ">Simranpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">Atamjit  Singh</span>, <span class="hlFld-ContribAuthor ">Kavita  Bhagat</span>, <span class="hlFld-ContribAuthor ">Arshmeet  Kaur</span>, <span class="hlFld-ContribAuthor ">Harbinder  Singh</span>, <span class="hlFld-ContribAuthor ">Jatinder Vir  Singh</span>, <span class="hlFld-ContribAuthor ">Preet Mohinder Singh  Bedi</span>. </span><span class="cited-content_cbyCitation_article-title">Most recent strategies targeting estrogen receptor alpha for the treatment of breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>25 </em>
                                    (1)
                                     , 603-624. <a href="https://doi.org/10.1007/s11030-020-10133-y" title="DOI URL">https://doi.org/10.1007/s11030-020-10133-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10133-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10133-y%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DMost%252Brecent%252Bstrategies%252Btargeting%252Bestrogen%252Breceptor%252Balpha%252Bfor%252Bthe%252Btreatment%252Bof%252Bbreast%252Bcancer%26aulast%3DKumar%26aufirst%3DNitish%26date%3D2021%26date%3D2020%26volume%3D25%26issue%3D1%26spage%3D603%26epage%3D624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alan  Carrasco-Carballo</span>, <span class="hlFld-ContribAuthor ">María  Guadalupe Hernández-Linares</span>, <span class="hlFld-ContribAuthor ">Maura  Cárdenas-García</span>, <span class="hlFld-ContribAuthor ">Jesús  Sandoval-Ramírez</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological in vitro evaluation of the effect of hydroxyimino steroidal derivatives on breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Steroids</span><span> <strong>2021,</strong> <em>166 </em>, 108787. <a href="https://doi.org/10.1016/j.steroids.2020.108787" title="DOI URL">https://doi.org/10.1016/j.steroids.2020.108787</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.steroids.2020.108787&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.steroids.2020.108787%26sid%3Dliteratum%253Aachs%26jtitle%3DSteroids%26atitle%3DSynthesis%252Band%252Bbiological%252Bin%252Bvitro%252Bevaluation%252Bof%252Bthe%252Beffect%252Bof%252Bhydroxyimino%252Bsteroidal%252Bderivatives%252Bon%252Bbreast%252Bcancer%252Bcells%26aulast%3DCarrasco-Carballo%26aufirst%3DAlan%26date%3D2021%26volume%3D166%26spage%3D108787" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maysoun  Shomali</span>, <span class="hlFld-ContribAuthor ">Jane  Cheng</span>, <span class="hlFld-ContribAuthor ">Fangxian  Sun</span>, <span class="hlFld-ContribAuthor ">Malvika  Koundinya</span>, <span class="hlFld-ContribAuthor ">Zhuyan  Guo</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Hebert</span>, <span class="hlFld-ContribAuthor ">Jessica  McManus</span>, <span class="hlFld-ContribAuthor ">Mikhail N.  Levit</span>, <span class="hlFld-ContribAuthor ">Dietmar  Hoffmann</span>, <span class="hlFld-ContribAuthor ">Albane  Courjaud</span>, <span class="hlFld-ContribAuthor ">Rosalia  Arrebola</span>, <span class="hlFld-ContribAuthor ">Hui  Cao</span>, <span class="hlFld-ContribAuthor ">Jack  Pollard</span>, <span class="hlFld-ContribAuthor ">Joon Sang  Lee</span>, <span class="hlFld-ContribAuthor ">Laurent  Besret</span>, <span class="hlFld-ContribAuthor ">Anne  Caron</span>, <span class="hlFld-ContribAuthor ">Dinesh S.  Bangari</span>, <span class="hlFld-ContribAuthor ">Pierre-Yves  Abecassis</span>, <span class="hlFld-ContribAuthor ">Laurent  Schio</span>, <span class="hlFld-ContribAuthor ">Youssef  El-Ahmad</span>, <span class="hlFld-ContribAuthor ">Frank  Halley</span>, <span class="hlFld-ContribAuthor ">Michel  Tabart</span>, <span class="hlFld-ContribAuthor ">Victor  Certal</span>, <span class="hlFld-ContribAuthor ">Fabienne  Thompson</span>, <span class="hlFld-ContribAuthor ">Gary  McCort</span>, <span class="hlFld-ContribAuthor ">Bruno  Filoche-Rommé</span>, <span class="hlFld-ContribAuthor ">Hong  Cheng</span>, <span class="hlFld-ContribAuthor ">Carlos  Garcia-Echeverria</span>, <span class="hlFld-ContribAuthor ">Laurent  Debussche</span>, <span class="hlFld-ContribAuthor ">Monsif  Bouaboula</span>. </span><span class="cited-content_cbyCitation_article-title">SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (2)
                                     , 250-262. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0390" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0390%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DSAR439859%25252C%252Ba%252BNovel%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252B%252528SERD%252529%25252C%252BDemonstrates%252BEffective%252Band%252BBroad%252BAntitumor%252BActivity%252Bin%252BWild-Type%252Band%252BMutant%252BER-Positive%252BBreast%252BCancer%252BModels%26aulast%3DShomali%26aufirst%3DMaysoun%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D2%26spage%3D250%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Davide  Cirillo</span>, <span class="hlFld-ContribAuthor ">Francesco  Angelucci</span>, <span class="hlFld-ContribAuthor ">Hans‐René  Bjørsvik</span>. </span><span class="cited-content_cbyCitation_article-title">Functionalization of the Imidazole Backbone by Means of a Tailored and Optimized Oxidative Heck Cross‐Coupling. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (22)
                                     , 5079-5092. <a href="https://doi.org/10.1002/adsc.202000909" title="DOI URL">https://doi.org/10.1002/adsc.202000909</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000909%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DFunctionalization%252Bof%252Bthe%252BImidazole%252BBackbone%252Bby%252BMeans%252Bof%252Ba%252BTailored%252Band%252BOptimized%252BOxidative%252BHeck%252BCross%2525E2%252580%252590Coupling%26aulast%3DCirillo%26aufirst%3DDavide%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D22%26spage%3D5079%26epage%3D5092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Wang</span>, <span class="hlFld-ContribAuthor ">Abhishek  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (22)
                                     , 2072-2097. <a href="https://doi.org/10.1002/cmdc.202000473" title="DOI URL">https://doi.org/10.1002/cmdc.202000473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000473%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThe%252BQuest%252Bfor%252BOrally%252BAvailable%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%26aulast%3DWang%26aufirst%3DLucia%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D22%26spage%3D2072%26epage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiaqiang  Dong</span>, <span class="hlFld-ContribAuthor ">Tie-lin  Wang</span>, <span class="hlFld-ContribAuthor ">Jianyu  Lu</span>, <span class="hlFld-ContribAuthor ">Charles Z.  Ding</span>, <span class="hlFld-ContribAuthor ">Lihong  Hu</span>, <span class="hlFld-ContribAuthor ">Guoping  Hu</span>, <span class="hlFld-ContribAuthor ">Huijun  He</span>, <span class="hlFld-ContribAuthor ">Xu  Zeng</span>, <span class="hlFld-ContribAuthor ">Xiaoting  Li</span>, <span class="hlFld-ContribAuthor ">Deheng  Sun</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhu</span>, <span class="hlFld-ContribAuthor ">Liang  Shen</span>, <span class="hlFld-ContribAuthor ">Qingyang  Gu</span>, <span class="hlFld-ContribAuthor ">Chi-chung  Chan</span>, <span class="hlFld-ContribAuthor ">Yuanfeng  Xia</span>, <span class="hlFld-ContribAuthor ">Jian  Li</span>, <span class="hlFld-ContribAuthor ">Shuhui  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, syntheses and evaluations of novel indole derivatives as orally selective estrogen receptor degraders (SERD). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (22)
                                     , 127601. <a href="https://doi.org/10.1016/j.bmcl.2020.127601" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127601%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsyntheses%252Band%252Bevaluations%252Bof%252Bnovel%252Bindole%252Bderivatives%252Bas%252Borally%252Bselective%252Bestrogen%252Breceptor%252Bdegraders%252B%252528SERD%252529%26aulast%3DDong%26aufirst%3DJiaqiang%26date%3D2020%26volume%3D30%26issue%3D22%26spage%3D127601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaitlyn J.  Andreano</span>, <span class="hlFld-ContribAuthor ">Jennifer G.  Baker</span>, <span class="hlFld-ContribAuthor ">Sunghee  Park</span>, <span class="hlFld-ContribAuthor ">Rachid  Safi</span>, <span class="hlFld-ContribAuthor ">Sandeep  Artham</span>, <span class="hlFld-ContribAuthor ">Steffi  Oesterreich</span>, <span class="hlFld-ContribAuthor ">Rinath  Jeselsohn</span>, <span class="hlFld-ContribAuthor ">Myles  Brown</span>, <span class="hlFld-ContribAuthor ">Sarah  Sammons</span>, <span class="hlFld-ContribAuthor ">Suzanne E.  Wardell</span>, <span class="hlFld-ContribAuthor ">Ching-yi  Chang</span>, <span class="hlFld-ContribAuthor ">John D.  Norris</span>, <span class="hlFld-ContribAuthor ">Donald P.  McDonnell</span>. </span><span class="cited-content_cbyCitation_article-title">The Dysregulated Pharmacology of Clinically Relevant
              ESR1
              Mutants is Normalized by Ligand-activated WT Receptor. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (7)
                                     , 1395-1405. <a href="https://doi.org/10.1158/1535-7163.MCT-19-1148" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-1148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-1148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-1148%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DThe%252BDysregulated%252BPharmacology%252Bof%252BClinically%252BRelevant%252BESR1%252BMutants%252Bis%252BNormalized%252Bby%252BLigand-activated%252BWT%252BReceptor%26aulast%3DAndreano%26aufirst%3DKaitlyn%2BJ.%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D7%26spage%3D1395%26epage%3D1405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Divya  Bafna</span>, <span class="hlFld-ContribAuthor ">Fuqiang  Ban</span>, <span class="hlFld-ContribAuthor ">Paul S.  Rennie</span>, <span class="hlFld-ContribAuthor ">Kriti  Singh</span>, <span class="hlFld-ContribAuthor ">Artem  Cherkasov</span>. </span><span class="cited-content_cbyCitation_article-title">Computer-Aided Ligand Discovery for Estrogen Receptor Alpha. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (12)
                                     , 4193. <a href="https://doi.org/10.3390/ijms21124193" title="DOI URL">https://doi.org/10.3390/ijms21124193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21124193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21124193%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DComputer-Aided%252BLigand%252BDiscovery%252Bfor%252BEstrogen%252BReceptor%252BAlpha%26aulast%3DBafna%26aufirst%3DDivya%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D12%26spage%3D4193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shagufta</span>, <span class="hlFld-ContribAuthor ">Irshad  Ahmad</span>, <span class="hlFld-ContribAuthor ">Shimy  Mathew</span>, <span class="hlFld-ContribAuthor ">Sofia  Rahman</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (4)
                                     , 438-454. <a href="https://doi.org/10.1039/C9MD00570F" title="DOI URL">https://doi.org/10.1039/C9MD00570F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MD00570F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MD00570F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bselective%252Bestrogen%252Breceptor%252Bdownregulators%252B%252528SERDs%252529%252Bfor%252Bthe%252Btreatment%252Bof%252Bbreast%252Bcancer%26aulast%3DShagufta%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D4%26spage%3D438%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cuihua  Zhang</span>, <span class="hlFld-ContribAuthor ">Qunlin  Li</span>, <span class="hlFld-ContribAuthor ">Yujie  Ren</span>, <span class="hlFld-ContribAuthor ">Fei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling studies of benzothiophene-containing derivatives as promising selective estrogen receptor downregulators: a combination of 3D-QSAR, molecular docking and molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em> </em>, 1-22. <a href="https://doi.org/10.1080/07391102.2020.1751717" title="DOI URL">https://doi.org/10.1080/07391102.2020.1751717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1751717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1751717%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DMolecular%252Bmodeling%252Bstudies%252Bof%252Bbenzothiophene-containing%252Bderivatives%252Bas%252Bpromising%252Bselective%252Bestrogen%252Breceptor%252Bdownregulators%25253A%252Ba%252Bcombination%252Bof%252B3D-QSAR%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DZhang%26aufirst%3DCuihua%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shanchun  Guo</span>, <span class="hlFld-ContribAuthor ">Changde  Zhang</span>, <span class="hlFld-ContribAuthor ">Madhusoodanan  Mottamal</span>, <span class="hlFld-ContribAuthor ">Ahamed  Hossain</span>, <span class="hlFld-ContribAuthor ">Jiawang  Liu</span>, <span class="hlFld-ContribAuthor ">Guangdi  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2020,</strong> <em>180 </em>
                                    (2)
                                     , 359-368. <a href="https://doi.org/10.1007/s10549-020-05558-w" title="DOI URL">https://doi.org/10.1007/s10549-020-05558-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-020-05558-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-020-05558-w%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DGLL398%25252C%252Ban%252Boral%252Bselective%252Bestrogen%252Breceptor%252Bdegrader%252B%252528SERD%252529%25252C%252Bblocks%252Btumor%252Bgrowth%252Bin%252Bxenograft%252Bbreast%252Bcancer%252Bmodels%26aulast%3DGuo%26aufirst%3DShanchun%26date%3D2020%26date%3D2020%26volume%3D180%26issue%3D2%26spage%3D359%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaitlyn J.  Andreano</span>, <span class="hlFld-ContribAuthor ">Suzanne E.  Wardell</span>, <span class="hlFld-ContribAuthor ">Jennifer G.  Baker</span>, <span class="hlFld-ContribAuthor ">Taylor K.  Desautels</span>, <span class="hlFld-ContribAuthor ">Robert  Baldi</span>, <span class="hlFld-ContribAuthor ">Christina A.  Chao</span>, <span class="hlFld-ContribAuthor ">Kendall A.  Heetderks</span>, <span class="hlFld-ContribAuthor ">Yeeun  Bae</span>, <span class="hlFld-ContribAuthor ">Rui  Xiong</span>, <span class="hlFld-ContribAuthor ">Debra A.  Tonetti</span>, <span class="hlFld-ContribAuthor ">Lauren M.  Gutgesell</span>, <span class="hlFld-ContribAuthor ">Jiong  Zhao</span>, <span class="hlFld-ContribAuthor ">Jessica A.  Sorrentino</span>, <span class="hlFld-ContribAuthor ">Delita A.  Thompson</span>, <span class="hlFld-ContribAuthor ">John E.  Bisi</span>, <span class="hlFld-ContribAuthor ">Jay C.  Strum</span>, <span class="hlFld-ContribAuthor ">Gregory R. J.  Thatcher</span>, <span class="hlFld-ContribAuthor ">John D.  Norris</span>. </span><span class="cited-content_cbyCitation_article-title">G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2020,</strong> <em>180 </em>
                                    (3)
                                     , 635-646. <a href="https://doi.org/10.1007/s10549-020-05575-9" title="DOI URL">https://doi.org/10.1007/s10549-020-05575-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-020-05575-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-020-05575-9%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DG1T48%25252C%252Ban%252Boral%252Bselective%252Bestrogen%252Breceptor%252Bdegrader%25252C%252Band%252Bthe%252BCDK4%25252F6%252Binhibitor%252Blerociclib%252Binhibit%252Btumor%252Bgrowth%252Bin%252Banimal%252Bmodels%252Bof%252Bendocrine-resistant%252Bbreast%252Bcancer%26aulast%3DAndreano%26aufirst%3DKaitlyn%2BJ.%26date%3D2020%26date%3D2020%26volume%3D180%26issue%3D3%26spage%3D635%26epage%3D646" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiang  Lu</span>, <span class="hlFld-ContribAuthor ">Ali  Huang</span>, <span class="hlFld-ContribAuthor ">Maoxu  Xiao</span>, <span class="hlFld-ContribAuthor ">Liang  Sun</span>, <span class="hlFld-ContribAuthor ">Jiashun  Mao</span>, <span class="hlFld-ContribAuthor ">Guoshun  Luo</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>97 </em>, 103666. <a href="https://doi.org/10.1016/j.bioorg.2020.103666" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103666%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Bnew%252Bclass%252Bof%252B1%25252C3%25252C5-triazine-based%252Bselective%252Bestrogen%252Breceptor%252Bdegraders%252B%252528SERDs%252529%25253A%252BLead%252Boptimization%25252C%252Bmolecular%252Bdocking%252Band%252Bdynamic%252Bsimulation%26aulast%3DLu%26aufirst%3DXiang%26date%3D2020%26volume%3D97%26spage%3D103666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandra  Knox</span>, <span class="hlFld-ContribAuthor ">Christina  Kalchschmid</span>, <span class="hlFld-ContribAuthor ">Daniela  Schuster</span>, <span class="hlFld-ContribAuthor ">Francesca  Gaggia</span>, <span class="hlFld-ContribAuthor ">Claudia  Manzl</span>, <span class="hlFld-ContribAuthor ">Daniel  Baecker</span>, <span class="hlFld-ContribAuthor ">Ronald  Gust</span>. </span><span class="cited-content_cbyCitation_article-title">Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>192 </em>, 112191. <a href="https://doi.org/10.1016/j.ejmech.2020.112191" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112191</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112191%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bbivalent%252Btriarylalkene-%252Band%252Bcyclofenil-derived%252Bdual%252Bestrogen%252Breceptor%252Bantagonists%252Band%252Bdownregulators%26aulast%3DKnox%26aufirst%3DAlexandra%26date%3D2020%26volume%3D192%26spage%3D112191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ariella B.  Hanker</span>, <span class="hlFld-ContribAuthor ">Dhivya R.  Sudhan</span>, <span class="hlFld-ContribAuthor ">Carlos L.  Arteaga</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming Endocrine Resistance in Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2020,</strong> <em>37 </em>
                                    (4)
                                     , 496-513. <a href="https://doi.org/10.1016/j.ccell.2020.03.009" title="DOI URL">https://doi.org/10.1016/j.ccell.2020.03.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2020.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2020.03.009%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DOvercoming%252BEndocrine%252BResistance%252Bin%252BBreast%252BCancer%26aulast%3DHanker%26aufirst%3DAriella%2BB.%26date%3D2020%26volume%3D37%26issue%3D4%26spage%3D496%26epage%3D513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianchang  Liu</span>, <span class="hlFld-ContribAuthor ">Jida  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiangye  Li</span>, <span class="hlFld-ContribAuthor ">Chaolin  Wu</span>, <span class="hlFld-ContribAuthor ">Hefu  Liu</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Fenggang  Sun</span>, <span class="hlFld-ContribAuthor ">Yueyun  Li</span>, <span class="hlFld-ContribAuthor ">Yuying  Liu</span>, <span class="hlFld-ContribAuthor ">Xinjin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Nickel‐Catalyzed 1,1‐Difluoroethylation of (Hetero)aryl Halides with 1,1‐Difluoroethyl Chloride (CH
              3
              CF
              2
              Cl). </span><span class="cited-content_cbyCitation_journal-name">Asian Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>9 </em>
                                    (3)
                                     , 391-394. <a href="https://doi.org/10.1002/ajoc.202000004" title="DOI URL">https://doi.org/10.1002/ajoc.202000004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ajoc.202000004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fajoc.202000004%26sid%3Dliteratum%253Aachs%26jtitle%3DAsian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DNickel%2525E2%252580%252590Catalyzed%252B1%25252C1%2525E2%252580%252590Difluoroethylation%252Bof%252B%252528Hetero%252529aryl%252BHalides%252Bwith%252B1%25252C1%2525E2%252580%252590Difluoroethyl%252BChloride%252B%252528CH%252B3%252BCF%252B2%252BCl%252529%26aulast%3DLiu%26aufirst%3DJianchang%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D3%26spage%3D391%26epage%3D394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abed  Saady</span>, <span class="hlFld-ContribAuthor ">Noam Y.  Steinman</span>, <span class="hlFld-ContribAuthor ">Melissa  Wojtyniak</span>, <span class="hlFld-ContribAuthor ">Christian  Ducho</span>, <span class="hlFld-ContribAuthor ">Bilha  Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2′‐Deoxyuridine Modified with a 3,5‐Difluoro‐4‐Methoxybenzylidene Imidazolinone Derivative for Incorporation into Oligonucleotide Probes for Detection of HER2 Breast Cancer Marker. </span><span class="cited-content_cbyCitation_journal-name">Current Protocols in Nucleic Acid Chemistry</span><span> <strong>2020,</strong> <em>80 </em>
                                    (1)
                                     <a href="https://doi.org/10.1002/cpnc.104" title="DOI URL">https://doi.org/10.1002/cpnc.104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpnc.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpnc.104%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Protocols%2520in%2520Nucleic%2520Acid%2520Chemistry%26atitle%3DSynthesis%252Bof%252B2%2525E2%252580%2525B2%2525E2%252580%252590Deoxyuridine%252BModified%252Bwith%252Ba%252B3%25252C5%2525E2%252580%252590Difluoro%2525E2%252580%2525904%2525E2%252580%252590Methoxybenzylidene%252BImidazolinone%252BDerivative%252Bfor%252BIncorporation%252Binto%252BOligonucleotide%252BProbes%252Bfor%252BDetection%252Bof%252BHER2%252BBreast%252BCancer%252BMarker%26aulast%3DSaady%26aufirst%3DAbed%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suzanne E.  Wardell</span>, <span class="hlFld-ContribAuthor ">Alexander P.  Yllanes</span>, <span class="hlFld-ContribAuthor ">Christina A.  Chao</span>, <span class="hlFld-ContribAuthor ">Yeeun  Bae</span>, <span class="hlFld-ContribAuthor ">Kaitlyn J.  Andreano</span>, <span class="hlFld-ContribAuthor ">Taylor K.  Desautels</span>, <span class="hlFld-ContribAuthor ">Kendall A.  Heetderks</span>, <span class="hlFld-ContribAuthor ">Jeremy T.  Blitzer</span>, <span class="hlFld-ContribAuthor ">John D.  Norris</span>, <span class="hlFld-ContribAuthor ">Donald P.  McDonnell</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research and Treatment</span><span> <strong>2020,</strong> <em>179 </em>
                                    (1)
                                     , 67-77. <a href="https://doi.org/10.1007/s10549-019-05454-y" title="DOI URL">https://doi.org/10.1007/s10549-019-05454-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10549-019-05454-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10549-019-05454-y%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%2520and%2520Treatment%26atitle%3DPharmacokinetic%252Band%252Bpharmacodynamic%252Banalysis%252Bof%252Bfulvestrant%252Bin%252Bpreclinical%252Bmodels%252Bof%252Bbreast%252Bcancer%252Bto%252Bassess%252Bthe%252Bimportance%252Bof%252Bits%252Bestrogen%252Breceptor-%2525CE%2525B1%252Bdegrader%252Bactivity%252Bin%252Bantitumor%252Befficacy%26aulast%3DWardell%26aufirst%3DSuzanne%2BE.%26date%3D2020%26date%3D2019%26volume%3D179%26issue%3D1%26spage%3D67%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John A.  Joule</span>. </span><span class="cited-content_cbyCitation_article-title">Five-Membered Ring Systems: Thiophenes and Selenium/Tellurium Analogs and Benzo Analogs. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 177-222. <a href="https://doi.org/10.1016/B978-0-12-819962-6.00005-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-819962-6.00005-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819962-6.00005-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819962-6.00005-1%26sid%3Dliteratum%253Aachs%26atitle%3DFive-Membered%252BRing%252BSystems%25253A%252BThiophenes%252Band%252BSelenium%25252FTellurium%252BAnalogs%252Band%252BBenzo%252BAnalogs%26aulast%3DJoule%26aufirst%3DJohn%2BA.%26date%3D2020%26spage%3D177%26epage%3D222%26pub%3DElsevier%26date%3D2020%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Subhajit  Makar</span>, <span class="hlFld-ContribAuthor ">Tanmay  Saha</span>, <span class="hlFld-ContribAuthor ">Rayala  Swetha</span>, <span class="hlFld-ContribAuthor ">Gopichand  Gutti</span>, <span class="hlFld-ContribAuthor ">Ashok  Kumar</span>, <span class="hlFld-ContribAuthor ">Sushil K.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103380. <a href="https://doi.org/10.1016/j.bioorg.2019.103380" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103380</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103380%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DRational%252Bapproaches%252Bof%252Bdrug%252Bdesign%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bselective%252Bestrogen%252Breceptor%252Bmodulators%252B%252528SERMs%252529%25252C%252Bimplicated%252Bin%252Bbreast%252Bcancer%26aulast%3DMakar%26aufirst%3DSubhajit%26date%3D2020%26volume%3D94%26spage%3D103380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Pepermans</span>, <span class="hlFld-ContribAuthor ">Eric R.  Prossnitz</span>. </span><span class="cited-content_cbyCitation_article-title">ERα-targeted endocrine therapy, resistance and the role of GPER. </span><span class="cited-content_cbyCitation_journal-name">Steroids</span><span> <strong>2019,</strong> <em>152 </em>, 108493. <a href="https://doi.org/10.1016/j.steroids.2019.108493" title="DOI URL">https://doi.org/10.1016/j.steroids.2019.108493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.steroids.2019.108493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.steroids.2019.108493%26sid%3Dliteratum%253Aachs%26jtitle%3DSteroids%26atitle%3DER%2525CE%2525B1-targeted%252Bendocrine%252Btherapy%25252C%252Bresistance%252Band%252Bthe%252Brole%252Bof%252BGPER%26aulast%3DPepermans%26aufirst%3DRichard%2BA.%26date%3D2019%26volume%3D152%26spage%3D108493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Campos</span>, <span class="hlFld-ContribAuthor ">Berteina-Raboin</span>. </span><span class="cited-content_cbyCitation_article-title">Eucalyptol as a Bio-Based Solvent for Buchwald-Hartwig Reaction on O,S,N-Heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Catalysts</span><span> <strong>2019,</strong> <em>9 </em>
                                    (10)
                                     , 840. <a href="https://doi.org/10.3390/catal9100840" title="DOI URL">https://doi.org/10.3390/catal9100840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/catal9100840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcatal9100840%26sid%3Dliteratum%253Aachs%26jtitle%3DCatalysts%26atitle%3DEucalyptol%252Bas%252Ba%252BBio-Based%252BSolvent%252Bfor%252BBuchwald-Hartwig%252BReaction%252Bon%252BO%25252CS%25252CN-Heterocycles%26aulast%3DCampos%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D10%26spage%3D840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianchang  Liu</span>, <span class="hlFld-ContribAuthor ">Jida  Zhang</span>, <span class="hlFld-ContribAuthor ">Chaolin  Wu</span>, <span class="hlFld-ContribAuthor ">Hefu  Liu</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Fenggang  Sun</span>, <span class="hlFld-ContribAuthor ">Yueyun  Li</span>, <span class="hlFld-ContribAuthor ">Yuying  Liu</span>, <span class="hlFld-ContribAuthor ">Yunhui  Dong</span>, <span class="hlFld-ContribAuthor ">Xinjin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">1,1-Difluoroethyl chloride (CH
              3
              CF
              2
              Cl), a novel difluoroalkylating reagent for 1,1-difluoroethylation of arylboronic acids. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (49)
                                     , 28409-28413. <a href="https://doi.org/10.1039/C9RA06406K" title="DOI URL">https://doi.org/10.1039/C9RA06406K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA06406K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA06406K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3D1%25252C1-Difluoroethyl%252Bchloride%252B%252528CH%252B3%252BCF%252B2%252BCl%252529%25252C%252Ba%252Bnovel%252Bdifluoroalkylating%252Breagent%252Bfor%252B1%25252C1-difluoroethylation%252Bof%252Barylboronic%252Bacids%26aulast%3DLiu%26aufirst%3DJianchang%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D49%26spage%3D28409%26epage%3D28413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Enguang  Yu</span>, <span class="hlFld-ContribAuthor ">Yueping  Xu</span>, <span class="hlFld-ContribAuthor ">Yanbo  Shi</span>, <span class="hlFld-ContribAuthor ">Qiuyan  Yu</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2019,</strong> <em>25 </em>
                                    (9)
                                     <a href="https://doi.org/10.1007/s00894-019-4156-7" title="DOI URL">https://doi.org/10.1007/s00894-019-4156-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-019-4156-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-019-4156-7%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DDiscovery%252Bof%252Bnovel%252Bnatural%252Bcompound%252Binhibitors%252Btargeting%252Bestrogen%252Breceptor%252B%2525CE%2525B1%252Bby%252Ban%252Bintegrated%252Bvirtual%252Bscreening%252Bstrategy%26aulast%3DYu%26aufirst%3DEnguang%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tanmay  Saha</span>, <span class="hlFld-ContribAuthor ">Subhajit  Makar</span>, <span class="hlFld-ContribAuthor ">Rayala  Swetha</span>, <span class="hlFld-ContribAuthor ">Gopichand  Gutti</span>, <span class="hlFld-ContribAuthor ">Sushil K.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen signaling: An emanating therapeutic target for breast cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>177 </em>, 116-143. <a href="https://doi.org/10.1016/j.ejmech.2019.05.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEstrogen%252Bsignaling%25253A%252BAn%252Bemanating%252Btherapeutic%252Btarget%252Bfor%252Bbreast%252Bcancer%252Btreatment%26aulast%3DSaha%26aufirst%3DTanmay%26date%3D2019%26volume%3D177%26spage%3D116%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sharada S.  Labadie</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Robert A.  Blake</span>, <span class="hlFld-ContribAuthor ">Jae H.  Chang</span>, <span class="hlFld-ContribAuthor ">Simon  Goodacre</span>, <span class="hlFld-ContribAuthor ">Steven J.  Hartman</span>, <span class="hlFld-ContribAuthor ">Weiling  Liang</span>, <span class="hlFld-ContribAuthor ">James R.  Kiefer</span>, <span class="hlFld-ContribAuthor ">Tracy  Kleinheinz</span>, <span class="hlFld-ContribAuthor ">Tommy  Lai</span>, <span class="hlFld-ContribAuthor ">Jiangpeng  Liao</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Vidhi  Mody</span>, <span class="hlFld-ContribAuthor ">Nicholas C.  Ray</span>, <span class="hlFld-ContribAuthor ">Fabien  Roussel</span>, <span class="hlFld-ContribAuthor ">Maia  Vinogradova</span>, <span class="hlFld-ContribAuthor ">Siew Kuen  Yeap</span>, <span class="hlFld-ContribAuthor ">Birong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Zheng</span>, <span class="hlFld-ContribAuthor ">Jason R.  Zbieg</span>, <span class="hlFld-ContribAuthor ">Jun  Liang</span>, <span class="hlFld-ContribAuthor ">Xiaojing  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (16)
                                     , 2090-2093. <a href="https://doi.org/10.1016/j.bmcl.2019.07.013" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.07.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.07.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BC-8%252Bhydroxychromene%252Bas%252Ba%252Bpotent%252Bdegrader%252Bof%252Bestrogen%252Breceptor%252Balpha%252Bwith%252Bimproved%252Brat%252Boral%252Bexposure%252Bover%252BGDC-0927%26aulast%3DLabadie%26aufirst%3DSharada%2BS.%26date%3D2019%26volume%3D29%26issue%3D16%26spage%3D2090%26epage%3D2093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuanyuan  Li</span>, <span class="hlFld-ContribAuthor ">Silong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhiye  Hu</span>, <span class="hlFld-ContribAuthor ">Yuan  Xiao</span>, <span class="hlFld-ContribAuthor ">Jian  Huang</span>, <span class="hlFld-ContribAuthor ">Chune  Dong</span>, <span class="hlFld-ContribAuthor ">Shengtang  Huang</span>, <span class="hlFld-ContribAuthor ">Hai-Bing  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>172 </em>, 48-61. <a href="https://doi.org/10.1016/j.ejmech.2019.03.058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DExploring%252Bthe%252BPROTAC%252Bdegron%252Bcandidates%25253A%252BOBHSA%252Bwith%252Bdifferent%252Bside%252Bchains%252Bas%252Bnovel%252Bselective%252Bestrogen%252Breceptor%252Bdegraders%252B%252528SERDs%252529%26aulast%3DLi%26aufirst%3DYuanyuan%26date%3D2019%26volume%3D172%26spage%3D48%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mary  Barber</span>, <span class="hlFld-ContribAuthor ">Lee S  Nguyen</span>, <span class="hlFld-ContribAuthor ">Johanna  Wassermann</span>, <span class="hlFld-ContribAuthor ">Jean-Philippe  Spano</span>, <span class="hlFld-ContribAuthor ">Christian  Funck-Brentano</span>, <span class="hlFld-ContribAuthor ">Joe-Elie  Salem</span>. </span><span class="cited-content_cbyCitation_article-title">Cardiac arrhythmia considerations of hormone cancer therapies. </span><span class="cited-content_cbyCitation_journal-name">Cardiovascular Research</span><span> <strong>2019,</strong> <em>115 </em>
                                    (5)
                                     , 878-894. <a href="https://doi.org/10.1093/cvr/cvz020" title="DOI URL">https://doi.org/10.1093/cvr/cvz020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/cvr/cvz020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fcvr%2Fcvz020%26sid%3Dliteratum%253Aachs%26jtitle%3DCardiovascular%2520Research%26atitle%3DCardiac%252Barrhythmia%252Bconsiderations%252Bof%252Bhormone%252Bcancer%252Btherapies%26aulast%3DBarber%26aufirst%3DMary%26date%3D2019%26date%3D2019%26volume%3D115%26issue%3D5%26spage%3D878%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean W  Fanning</span>, <span class="hlFld-ContribAuthor ">Geoffrey L  Greene</span>. </span><span class="cited-content_cbyCitation_article-title">Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Endocrinology</span><span> <strong>2019,</strong> <em>160 </em>
                                    (4)
                                     , 759-769. <a href="https://doi.org/10.1210/en.2018-01095" title="DOI URL">https://doi.org/10.1210/en.2018-01095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1210/en.2018-01095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1210%2Fen.2018-01095%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrinology%26atitle%3DNext-Generation%252BER%2525CE%2525B1%252BInhibitors%252Bfor%252BEndocrine-Resistant%252BER%25252B%252BBreast%252BCancer%26aulast%3DFanning%26aufirst%3DSean%2BW%26date%3D2019%26date%3D2019%26volume%3D160%26issue%3D4%26spage%3D759%26epage%3D769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angeles C.  Tecalco-Cruz</span>, <span class="hlFld-ContribAuthor ">Josué O.  Ramírez-Jarquín</span>, <span class="hlFld-ContribAuthor ">Eduardo  Cruz-Ramos</span>. </span><span class="cited-content_cbyCitation_article-title">Estrogen Receptor Alpha and its Ubiquitination in Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Targets</span><span> <strong>2019,</strong> <em>20 </em>
                                    (6)
                                     , 690-704. <a href="https://doi.org/10.2174/1389450119666181015114041" title="DOI URL">https://doi.org/10.2174/1389450119666181015114041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389450119666181015114041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389450119666181015114041%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Targets%26atitle%3DEstrogen%252BReceptor%252BAlpha%252Band%252Bits%252BUbiquitination%252Bin%252BBreast%252BCancer%252BCells%26aulast%3DTecalco-Cruz%26aufirst%3DAngeles%2BC.%26date%3D2019%26volume%3D20%26issue%3D6%26spage%3D690%26epage%3D704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinjin  Li</span>, <span class="hlFld-ContribAuthor ">Jianchang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiangye  Li</span>, <span class="hlFld-ContribAuthor ">Hefu  Liu</span>, <span class="hlFld-ContribAuthor ">Hui  Liu</span>, <span class="hlFld-ContribAuthor ">Yueyun  Li</span>, <span class="hlFld-ContribAuthor ">Yuying  Liu</span>, <span class="hlFld-ContribAuthor ">Yunhui  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advance in the synthesis of (1,1-difluoroethyl)arenes. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2018,</strong> <em>216 </em>, 102-106. <a href="https://doi.org/10.1016/j.jfluchem.2018.10.011" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2018.10.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2018.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2018.10.011%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DRecent%252Badvance%252Bin%252Bthe%252Bsynthesis%252Bof%252B%2525281%25252C1-difluoroethyl%252529arenes%26aulast%3DLi%26aufirst%3DXinjin%26date%3D2018%26volume%3D216%26spage%3D102%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean W  Fanning</span>, <span class="hlFld-ContribAuthor ">Rinath  Jeselsohn</span>, <span class="hlFld-ContribAuthor ">Venkatasubramanian  Dharmarajan</span>, <span class="hlFld-ContribAuthor ">Christopher G  Mayne</span>, <span class="hlFld-ContribAuthor ">Mostafa  Karimi</span>, <span class="hlFld-ContribAuthor ">Gilles  Buchwalter</span>, <span class="hlFld-ContribAuthor ">René  Houtman</span>, <span class="hlFld-ContribAuthor ">Weiyi  Toy</span>, <span class="hlFld-ContribAuthor ">Colin E  Fowler</span>, <span class="hlFld-ContribAuthor ">Ross  Han</span>, <span class="hlFld-ContribAuthor ">Muriel  Lainé</span>, <span class="hlFld-ContribAuthor ">Kathryn E  Carlson</span>, <span class="hlFld-ContribAuthor ">Teresa A  Martin</span>, <span class="hlFld-ContribAuthor ">Jason  Nowak</span>, <span class="hlFld-ContribAuthor ">Jerome C  Nwachukwu</span>, <span class="hlFld-ContribAuthor ">David J  Hosfield</span>, <span class="hlFld-ContribAuthor ">Sarat  Chandarlapaty</span>, <span class="hlFld-ContribAuthor ">Emad  Tajkhorshid</span>, <span class="hlFld-ContribAuthor ">Kendall W  Nettles</span>, <span class="hlFld-ContribAuthor ">Patrick R  Griffin</span>, <span class="hlFld-ContribAuthor ">Yang  Shen</span>, <span class="hlFld-ContribAuthor ">John A  Katzenellenbogen</span>, <span class="hlFld-ContribAuthor ">Myles  Brown</span>, <span class="hlFld-ContribAuthor ">Geoffrey L  Greene</span>. </span><span class="cited-content_cbyCitation_article-title">The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2018,</strong> <em>7 </em><a href="https://doi.org/10.7554/eLife.37161" title="DOI URL">https://doi.org/10.7554/eLife.37161</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.37161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.37161%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DThe%252BSERM%25252FSERD%252Bbazedoxifene%252Bdisrupts%252BESR1%252Bhelix%252B12%252Bto%252Bovercome%252Bacquired%252Bhormone%252Bresistance%252Bin%252Bbreast%252Bcancer%252Bcells%26aulast%3DFanning%26aufirst%3DSean%2BW%26date%3D2018%26date%3D2018%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0028.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0029.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of tamoxifen, its bioactive metabolite 4-hydroxytamoxifen, and aromatase inhibitors anastrazole and letrozole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0001.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of fulvestrant, GW-5638, active metabolite GW-7604, arzoxifene, GDC-0810, and <b>10</b> (LSZ102).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Ether-Linked Benzothiophene Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>-bromosuccinimide, THF, 0 → 25 °C, 97%; (b) H<sub>2</sub>O<sub>2</sub>, TFA, CH<sub>2</sub>Cl<sub>2</sub>, 88%; (c) 4-bromophenol, NaH, DMF, 87%; (d) LiAlH<sub>4</sub>, THF, 0 °C, 91%; (e) <i>tert</i>-butyl acrylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 120 °C, 63%; (f) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 53%; (g) H<sub>2</sub> (balloon), 10% Pd/C, CH<sub>2</sub>Cl<sub>2</sub>/MeOH (4:1), 99%; (h) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 31%; (i) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 77%; (j) for <b>18</b>: 4-vinyl-1-methyl imidazole, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 150 °C, 58%; for <b>19</b>: <i>tert</i>-butyl 4-vinyl-1<i>H</i>-imidazole-1-carboxylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 150 °C, 15%. THF = tetrahydrofuran, TFA = trifluoroacetic acid, DMF = <i>N</i>,<i>N</i>-dimethylformamide.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Amine-Linked Compounds <b>24</b> and <b>25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethyl 4-aminocinnamate, K<sub>3</sub>PO<sub>4</sub>, RuPhos palladacycle, 1,4-dioxane, 120 °C, 15%; (b) methyl iodide, NaH, DMF, 36%; (c) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (d) LiOH, EtOH, 21% (two steps); (e) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C; (f) NaOH, EtOH, 22% (two steps). DMF = <i>N</i>,<i>N</i>-dimethylformamide.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Ketone-Linked Compound <b>29</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) AlCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 → 25 °C, 96%; (b) <i>tert</i>-butyl acrylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 120 °C, 88%; (c) BBr<sub>3</sub> (1.0 M in CH<sub>2</sub>Cl<sub>2</sub>), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 42%. DMF = <i>N</i>,<i>N</i>-dimethylformamide.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>33</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Na<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, dimethoxyethane/water (4:1), 100 °C, 65%; (b) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 46%; (c) LiOH (2.0 N aqueous), THF/water (4:1), 60 °C, 88%. THF = tetrahydrofuran</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Ether-Linked Compounds <b>35a</b>–<b>e</b> and Tetrazoles <b>37</b>–<b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) R<sup>1</sup> = H for <b>35a</b>, <b>35c</b>, and <b>35d</b> and R<sup>1</sup> = Me for <b>35b</b>, HATU, DIEA, DMF, 30–80%; (b) R<sup>1</sup> = Me for <b>35e</b>, HATU, DIEA, DMF, 72%; (c) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 86%; (d) Bu<sub>2</sub>SnO, TMSN<sub>3</sub>, dimethoxyethane, 180 °C, 83%; (e) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 40%; (f) methyl iodide, K<sub>2</sub>CO<sub>3</sub>, DMF, 91% (combined yield of both 1- and 2-methyl tetrazole); (g) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 32–35%. HATU = <i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate, DIEA = <i>N</i>,<i>N</i>-diisopropylethylamine, DMF = <i>N</i>,<i>N</i>-dimethylformamide, Me = methyl, Bu = butyl, TMS = trimethysilyl.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0014.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Linker-Substituted Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaH, DMF, 43–86%; (b) TMSCl, PPh<sub>3</sub>, THF, 75 °C, 65–98%; (c) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 16–93% (<b>42d</b> was obtained directly from this step); (d) LiOH (2 N aqueous), EtOH, 41–80% (for <b>42a</b>–<b>c</b> and <b>42e</b>–<b>f</b>); (e) 5-hydroxypyridine-2-carboxylate, NaH, DMF, 80 °C, 52%; (f) LiAlH<sub>4</sub>, THF, 0 °C, 93%; (g) MnO<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (h) methyl 2-triphenylphosphoranylidene)acetate, CH<sub>2</sub>Cl<sub>2</sub>, 32% (2 steps); (i) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (j) LiOH, THF/water (1:1), 9% (two steps). Ac = acetate, DMF = <i>N</i>,<i>N</i>-dimethylformamide, TMS = trimethylsilyl, Ph = phenyl, THF = tetrahydrofuran.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0015.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Key Intermediate <b>49</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-bromophenol, Cs<sub>2</sub>CO<sub>3</sub>, THF, 98%; (b) NaBH<sub>4</sub>, DMSO/MeOH (3:1), 97%; (c) DIBAL-H, THF, 75 °C, 84%. THF = tetrahydrofuran, DMSO = dimethyl sulfoxide, DIBAL-H = diisobutylaluminum hydride.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0016.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Phenyl-Substituted Benzothiophene Analogues <b>53d</b>–<b>r</b> and LSZ102 (<b>10</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl acrylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 120 °C, 61%; (b) <i>tert</i>-butyl acrylate, Et<sub>3</sub>N, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, DMF, 120 °C, 66%; (c) <i>N</i>-bromosuccinimide, THF, 90%; (d) 2-(methoxymethyl)benzeneboronic acid, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, 110 °C, 79% (only <b>53o</b> was made in this manner); (e) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 45%; (f) boronic acid/ester, Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, 110 °C, 42–87%; (g) LiOH, MeOH/water (3:1), 11–70%; (h) LiOH, MeOH, 55% (compound <b>53o</b> only); (i) thiophenol, K<sub>2</sub>CO<sub>3</sub>, <i>N</i>-methyl-2-pyrrolidone, 190 °C, 6% (compound <b>53o</b> only); (j) K<sub>2</sub>CO<sub>3</sub>, trimethylacetic acid, BrettPhos palladacycle (first generation), DMA, 150 °C, 39–97%; (k) BBr<sub>3</sub> (1.0 M in heptane), CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 20–66%; (l) thiophenol, K<sub>2</sub>CO<sub>3</sub>, <i>N</i>-methyl-2-pyrrolidone, 200 °C, 22–77%; (m) HCl (4 N in 1,4-dioxane), THF, 50 °C, 19–34%.</p><p class="last"><span class="fn-label"><sup>b</sup></span>Compounds <b>53a</b>–<b>c</b> were synthesized in a similar sequence to <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>; for full details see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf" class="ext-link">Supporting Information</a>. DMF = <i>N</i>,<i>N</i>-dimethylformamide, THF = tetrahydrofuran, dppf = 1,1′-bis(diphenylphosphino)ferrocene, DME = 1,2-dimethoxyethane, DMA = <i>N</i>,<i>N</i>-dimethylacetamide.</p></p></figure><figure data-id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0002.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Benzothiophene-based linker exploration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0003.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Binding pocket of ERα in complex with <b>10</b> (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F">6B0F</a>) highlighting residues that form the ligand-binding pocket. (B) van der Waals excluded surface of the ligand-binding pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0004.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proteasome-dependent ERα degradation by <b>10</b>. Western blot analysis of the effect of <b>10</b>, THIQ 40, and fulvestrant (10 μM, 24 h) on ERα levels with or without MG132 pretreatment for 24 h. IB = immunoblot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0005.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Measurement of ERα reduction by <b>10</b>, fulvestrant, and 4-hydroxytamoxifen (<b>2</b>) in MCF-7 cells grown in 10% charcoal dextran-stripped serum supplemented media. For the in-cell western, cells were incubated with compounds for 18 h followed by fixation and processing to determine the amount of ERα protein remaining.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0006.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Proliferation of MCF-7 cells. Cells were incubated in RPMI (without phenol red) plus 10% charcoal dextran-stripped serum and treated with compounds in the presence of 0.1 nM estradiol for 6 days. Cell viability was determined by CellTiter-Glo assay. IC<sub>50</sub> values were calculated using the XLfit software and are defined as the inflection point of the fitted inhibition curves. RPMI = Roswell Park Memorial Institute.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0007.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of ER-mediated gene transcription by <b>10</b>. MCF-7-EREluc and MCF-7 cells were incubated in phenol-red free RPMI plus 10% charcoal dextran-stripped serum and treated with compounds in the presence of 0.1 nM E2 for 24 h. (A) Cell luciferase signal from MCF-7-EREluc was measured using Bright-Glo assay and normalized to DMSO control. (B) mRNA of ER target gene GREB1 from treated MCF-7 cells was quantified by TaqMan assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/medium/jm-2017-01682c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0008.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Anti-tumor efficacy of <b>10</b> in the ER+ human breast cancer MCF-7 xenograft model. Tumors were established in female NSG mice by injection of 10<sup>7</sup> cells into the axillary mammary fat pad area of each mouse. Mice were implanted with 0.72 mg estradiol/90-day release pellets several days prior to cell implantation. When tumors reached an average of 200 mm<sup>3</sup>, mice were randomized according to tumor volume into treatment groups (<i>n</i> = 8). Test agents were administered at the dose levels and schedules indicated. <b>10</b> or its vehicle alone was orally administred once daily, and tamoxifen was orally administered 5 times a week. Fulvestrant was administered subcutaneously (sc) once a week (5 mg/mouse). (A) Tumor volumes of treatment groups vs days post randomization. <i>p</i> < 0.05, ANOVA, Holm–Sidak posthoc test, versus vehicle control. Inhibition of progesterone receptor mRNA levels as analyzed by RT-PCR (B) and ER protein levels as analyzed by quantification of a western blot (C) as compared to the vehicle control at the end of the efficacy study at 7 h post last dose are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-7/acs.jmedchem.7b01682/20180406/images/large/jm-2017-01682c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01682&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i126">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48320" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48320" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Breast Cancer Facts &
Figures 2015–2016</i>; <span class="NLM_publisher-name">American Cancer
Society, Inc</span>: <span class="NLM_publisher-loc">Atlanta</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Breast+Cancer+Facts+%26%0AFigures+2015%E2%80%932016%3B+American+Cancer%0ASociety%2C+Inc%3A+Atlanta%2C+2015."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Facts%2520%2526%250AFigures%25202015%25E2%2580%25932016%26pub%3DAmerican%2520Cancer%250ASociety%252C%2520Inc%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bentzon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Düring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasmussen, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouridsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroman, N.</span></span> <span> </span><span class="NLM_article-title">Prognostic effect of estrogen receptor status across age in primary breast cancer</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">1089</span>– <span class="NLM_lpage">1094</span>, <span class="refDoi"> DOI: 10.1002/ijc.22892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1002%2Fijc.22892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=17960621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslGhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=1089-1094&author=N.+Bentzonauthor=M.+D%C3%BCringauthor=B.+B.+Rasmussenauthor=H.+Mouridsenauthor=N.+Kroman&title=Prognostic+effect+of+estrogen+receptor+status+across+age+in+primary+breast+cancer&doi=10.1002%2Fijc.22892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Prognostic effect of estrogen receptor status across age in primary breast cancer</span></div><div class="casAuthors">Bentzon, Niels; During, Maria; Rasmussen, Birgitte Bruun; Mouridsen, Henning; Kroman, Niels</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1089-1094</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Estrogen receptor (ER) status is considered as an important prognostic factor as well as a predictive factor for endocrine responsiveness in breast cancer.  We analyzed the distribution of ER status across age and estd. variations in the prognostic impact of ER status related to patients' age and time since diagnosis.  Overall, 26,944 patients with primary breast cancer diagnosed from 1989 to 2004 were included.  The proportion of ER pos. tumors increased over age from 51 to 82%.  In multivariate anal. of overall survival, ER pos. status was found to be a significantly pos. prognostic factor over all age groups.  This effect was limited to the first 5 years after diagnosis, RR: 2.08 (95% CI: 1.95-2.22, p < 0.0001).  Overall survival during the following 5 years was slightly superior for women with ER neg. tumors, RR of death: 0.89 (95% CI: 0.79-1.00, p = 0.049).  Results were unchanged in patients who did not receive adjuvant systemic therapy (n = 6,272).  Thus, pos. ER status does not confer a neg. impact on survival in young women as has been previously reported.  The inferior prognosis for ER neg. patients during the first 5 years after diagnosis changes into a slightly superior residual prognosis compared to ER pos. patients independent of use of adjuvant systemic therapy.  This may have an impact on future designing of guidelines for adjuvant endocrine therapy beyond 5 years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3eNDygp1-2rVg90H21EOLACvtfcHk0lgZc7Mffu4LgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslGhu7k%253D&md5=2e9db2ca5d32375c78ce8ae9a6c93e09</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fijc.22892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.22892%26sid%3Dliteratum%253Aachs%26aulast%3DBentzon%26aufirst%3DN.%26aulast%3DD%25C3%25BCring%26aufirst%3DM.%26aulast%3DRasmussen%26aufirst%3DB.%2BB.%26aulast%3DMouridsen%26aufirst%3DH.%26aulast%3DKroman%26aufirst%3DN.%26atitle%3DPrognostic%2520effect%2520of%2520estrogen%2520receptor%2520status%2520across%2520age%2520in%2520primary%2520breast%2520cancer%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D1089%26epage%3D1094%26doi%3D10.1002%2Fijc.22892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deblois, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giguère, V.</span></span> <span> </span><span class="NLM_article-title">Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.1038/nrc3396</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2Fnrc3396" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=23192231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsleks7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=27-36&author=G.+Debloisauthor=V.+Gigu%C3%A8re&title=Oestrogen-related+receptors+in+breast+cancer%3A+control+of+cellular+metabolism+and+beyond&doi=10.1038%2Fnrc3396"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond</span></div><div class="casAuthors">Deblois, Genevieve; Giguere, Vincent</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Estrogen-related receptors (ERRs) are orphan nuclear receptors that were initially investigated in breast cancer because of their structural relationship to estrogen receptors.  Recent data have shown that the ERRs control vast gene networks that are involved in glycolysis, glutaminolysis, oxidative phosphorylation, nutrient sensing and biosynthesis pathways.  In the context of breast cancer, the ERRs affect cellular metab. in a manner that promotes a Warburg-like phenotype.  The ERRs also modulate breast cancer cell metab., growth and proliferation through the regulation of key oncoproteins.  We discuss the value but also the implications of the complexity of targeting the ERRs for the development of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk41Ox4uzsq7Vg90H21EOLACvtfcHk0lgZc7Mffu4LgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsleks7fM&md5=81d9969b61cdaa7e9d04ea3ed008007d</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3396&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3396%26sid%3Dliteratum%253Aachs%26aulast%3DDeblois%26aufirst%3DG.%26aulast%3DGigu%25C3%25A8re%26aufirst%3DV.%26atitle%3DOestrogen-related%2520receptors%2520in%2520breast%2520cancer%253A%2520control%2520of%2520cellular%2520metabolism%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D27%26epage%3D36%26doi%3D10.1038%2Fnrc3396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, M. J.
K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, A. L.</span></span> <span> </span><span class="NLM_article-title">Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_volume"><i>212</i></span>,  <span class="NLM_fpage">87</span>, <span class="refDoi"> DOI: 10.1038/212087a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2F212087a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=5965580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADyaF28XltVWitbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=1966&pages=87&author=M.+J.%0AK.+Harperauthor=A.+L.+Walpole&title=Contrasting+endocrine+activities+of+cis+and+trans+isomers+in+a+series+of+substituted+triphenylethylenes&doi=10.1038%2F212087a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes</span></div><div class="casAuthors">Harper, M. J. K.; Walpole, A. L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1966</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue">5057</span>),
    <span class="NLM_cas:pages">87</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">cis-1- (p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-2-ethylethylene citrate (I.C.I. 47,699) induced uterine growth in immature rats and vaginal cornification in spayed rats or mice and caused the involution of the prostate and seminal vesicles in intact male rats as a result of inhibition of pituitary gonadotropic activity and (or) direct antiandrogenic action, trans-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-2-ethylethylene citrate (I.C.I. 46,474) was only weakly and atypically estrogenic and caused no involution of intact male rat accessory sex glands. I.C.I. 46,474 was extremely effective in terminating early pregnancy in rats.  While both isomers seemed to be purely estrogenic, the trans isomer was more potent in this respect in mice and the cis isomer was more potent in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoW-er5Ofucr7Vg90H21EOLACvtfcHk0lj5369BQHTuJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF28XltVWitbk%253D&md5=7a1ca8d046aab69ce8e00304712ddea0</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F212087a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F212087a0%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DM.%2BJ.%2BK.%26aulast%3DWalpole%26aufirst%3DA.%2BL.%26atitle%3DContrasting%2520endocrine%2520activities%2520of%2520cis%2520and%2520trans%2520isomers%2520in%2520a%2520series%2520of%2520substituted%2520triphenylethylenes%26jtitle%3DNature%26date%3D1966%26volume%3D212%26spage%3D87%26doi%3D10.1038%2F212087a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, P. N.</span>; <span class="NLM_string-name">Large, M. S.</span></span> <span> </span><span class="NLM_article-title">Preparation and Formulation of (Substituted Aralkyl) Heterocyclic Compounds as Aromatase Inhibitors</span>. Eur. Pat. Appl. <span class="NLM_patent">EP 0296749 B1</span>, <span class="NLM_year">1988</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&author=P.+N.+Edwards&author=M.+S.+Large&title=Preparation+and+Formulation+of+%28Substituted+Aralkyl%29+Heterocyclic+Compounds+as+Aromatase+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DP.%2BN.%26atitle%3DPreparation%2520and%2520Formulation%2520of%2520%2528Substituted%2520Aralkyl%2529%2520Heterocyclic%2520Compounds%2520as%2520Aromatase%2520Inhibitors%26date%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, M.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen resistance in breast cancer</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">267</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2012.20.3.256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.4062%2Fbiomolther.2012.20.3.256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWhtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=256-267&author=M.+Chang&title=Tamoxifen+resistance+in+breast+cancer&doi=10.4062%2Fbiomolther.2012.20.3.256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen resistance in breast cancer</span></div><div class="casAuthors">Chang, Minsun</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">256-267</span>CODEN:
                <span class="NLM_cas:coden">BTIHA3</span>;
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    
            (<span class="NLM_cas:orgname">Korean Society of Applied Pharmacology</span>)
        </div><div class="casAbstract">A review.  Tamoxifen is a central component of the treatment of estrogen receptor (ER)-pos. breast cancer as a partial agonist of ER.  It has been clin. used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer.  The most challenging issue with tamoxifen use is the development of resistance in an initially responsive breast tumor.  This review summarizes the roles of ER as the therapeutic target of tamoxifen in cancer treatment, clin. values and issues of tamoxifen use, and mol. mechanisms of tamoxifen resistance.  Emerging knowledge on the mol. mechanisms of tamoxifen resistance will provide insight into the design of regimens to overcome tamoxifen resistance and discovery of novel therapeutic agents with a decreased chance of developing resistance as well as establishing more efficient treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1vLvbFbG_ALVg90H21EOLACvtfcHk0lj5369BQHTuJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWhtLrP&md5=a852c7664d31f137d8dd4bb1f9918ff5</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2012.20.3.256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2012.20.3.256%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DM.%26atitle%3DTamoxifen%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DBiomol.%2520Ther.%26date%3D2012%26volume%3D20%26spage%3D256%26epage%3D267%26doi%3D10.4062%2Fbiomolther.2012.20.3.256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatnagar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Häusler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schieweck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, R.</span></span> <span> </span><span class="NLM_article-title">Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1021</span>– <span class="NLM_lpage">1027</span>, <span class="refDoi"> DOI: 10.1016/0960-0760(90)90460-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2F0960-0760%2890%2990460-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=2149502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADyaK3MXhtlGltbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1990&pages=1021-1027&author=A.+S.+Bhatnagarauthor=A.+H%C3%A4uslerauthor=K.+Schieweckauthor=M.+Langauthor=R.+Bowman&title=Highly+selective+inhibition+of+estrogen+biosynthesis+by+CGS+20267%2C+a+new+non-steroidal+aromatase+inhibitor&doi=10.1016%2F0960-0760%2890%2990460-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor</span></div><div class="casAuthors">Bhatnagar, A. S.; Haeusler, A.; Schieweck, K.; Lang, M.; Bowman, R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1021-7</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    </div><div class="casAbstract">CGS 20267 (I) is a new nonsteroidal compd. which potently inhibits aromatase in vitro (IC50 of 11.5 nM) and in vivo (ED50 of 1-3 μg/kg p.o.).  CGS 20267 maximally inhibits estradiol prodn. in vitro in LH-stimulated hamster ovarian tissue at 0.1 μM with an IC50 of 0.02 μM and does not significantly affect progesterone prodn. up to 350 μM.  In ACTH-stimulated rat adrenal tissue in vitro, aldosterone prodn. was inhibited with an IC50 of 210 μM (10,000 times higher than the IC50 for estradiol prodn.); no significant effect on corticosterone prodn. was seen at 350 μM.  In vivo, in ACTH-treated rats, CGS 20267 does not affect plasma levels of corticosterone or aldosterone at a dose of 4 mg/kg p.o. (1000 times higher than the ED50 for aromatase inhibition in vivo).  In adult female rats, a 14-day treatment with 1 mg/kg p.o. daily, completely interrupts ovarian cyclicity and suppresses uterine wt. to that seen 14 days after ovariectomy.  In adult female rats bearing estrogen-dependent DMBA-induced mammary tumors, 0.1 mg/kg p.o. given daily for 42 days caused almost complete regression of tumors present at the start of treatment.  Thus compared to each other, CGS 16949A and CGS 20267 are both highly potent in inhibiting estrogen biosynthesis in vitro and in vivo.  The striking difference between them is that unlike CGS 16949A, CGS 20267 does not affect adrenal steroidogenesis in vitro or in vivo, at concns. and doses several orders of magnitude higher than those required to inhibit estrogen biosynthesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq83gKMUXDIe7Vg90H21EOLACvtfcHk0lj5369BQHTuJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhtlGltbs%253D&md5=1f3069c02a2a78083b0a0b1932b660f5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2F0960-0760%2890%2990460-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-0760%252890%252990460-3%26sid%3Dliteratum%253Aachs%26aulast%3DBhatnagar%26aufirst%3DA.%2BS.%26aulast%3DH%25C3%25A4usler%26aufirst%3DA.%26aulast%3DSchieweck%26aufirst%3DK.%26aulast%3DLang%26aufirst%3DM.%26aulast%3DBowman%26aufirst%3DR.%26atitle%3DHighly%2520selective%2520inhibition%2520of%2520estrogen%2520biosynthesis%2520by%2520CGS%252020267%252C%2520a%2520new%2520non-steroidal%2520aromatase%2520inhibitor%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1990%26volume%3D37%26spage%3D1021%26epage%3D1027%26doi%3D10.1016%2F0960-0760%2890%2990460-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goss, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muss, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglione, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livingston, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therasse, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pater, J. L.</span></span> <span> </span><span class="NLM_article-title">A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">1793</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa032312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1056%2FNEJMoa032312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=14551341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD3sXosl2gtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=1793-1802&author=P.+E.+Gossauthor=J.+N.+Ingleauthor=S.+Martinoauthor=N.+J.+Robertauthor=H.+B.+Mussauthor=M.+J.+Piccartauthor=M.+Castiglioneauthor=D.+Tuauthor=L.+E.+Shepherdauthor=K.+I.+Pritchardauthor=R.+B.+Livingstonauthor=N.+E.+Davidsonauthor=L.+Nortonauthor=E.+A.+Perezauthor=J.+S.+Abramsauthor=P.+Therasseauthor=M.+J.+Palmerauthor=J.+L.+Pater&title=A+randomized+trial+of+letrozole+in+postmenopausal+women+after+five+years+of+tamoxifen+therapy+for+early-stage+breast+cancer&doi=10.1056%2FNEJMoa032312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer</span></div><div class="casAuthors">Goss, Paul E.; Ingle, James N.; Martino, Silvana; Robert, Nicholas J.; Muss, Hyman B.; Piccart, Martine J.; Castiglione, Monica; Tu, Dongsheng; Shepherd, Lois E.; Pritchard, Kathleen I.; Livingston, Robert B.; Davidson, Nancy E.; Norton, Larry; Perez, Edith A.; Abrams, Jeffrey S.; Therasse, Patrick; Palmer, Michael J.; Pater, Joseph L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1793-1802</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy - but not tamoxifen therapy of longer duration - prolongs disease-free and overall survival.  The aromatase inhibitor letrozole, by suppressing estrogen prodn., might improve the outcome after the discontinuation of tamoxifen therapy.  Methods: We conducted a double-blind, placebo-controlled trial to test the effectiveness of five years of letrozole therapy in postmenopausal women with breast cancer who have completed five years of tamoxifen therapy.  The primary end point was disease-free survival.  Results: A total of 5187 women were enrolled (median follow-up, 2.4 yr).  At the first interim anal., there were 207 local or metastatic recurrences of breast cancer or new primary cancers in the contralateral breast - 75 in the letrozole group and 132 in the placebo group - with estd. four-year disease-free survival rates of 93% and 87%, resp., in the two groups (p ≤ 0.001 for the comparison of disease-free survival).  A total of 42 women in the placebo group and 31 women in the letrozole group died (P = 0.25 for the comparison of overall survival).  Low-grade hot flashes, arthritis, arthralgia, and myalgia were more frequent in the letrozole group, but vaginal bleeding was less frequent.  There were new diagnoses of osteoporosis in 5.8% of the women in the letrozole group and 4.5% of the women in the placebo group (P = 0.07); the rates of fracture were similar.  After the first interim anal., the independent data and safety monitoring committee recommended termination of the trial and prompt communication of the results to the participants.  Conclusions: As compared with placebo, letrozole therapy after the completion of std. tamoxifen treatment significantly improves disease-free survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn8Yeh_0VFRbVg90H21EOLACvtfcHk0lhveR7E8sO-Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXosl2gtbc%253D&md5=b7ccc0fb80f769bc70d2768567a4c31f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032312%26sid%3Dliteratum%253Aachs%26aulast%3DGoss%26aufirst%3DP.%2BE.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DMartino%26aufirst%3DS.%26aulast%3DRobert%26aufirst%3DN.%2BJ.%26aulast%3DMuss%26aufirst%3DH.%2BB.%26aulast%3DPiccart%26aufirst%3DM.%2BJ.%26aulast%3DCastiglione%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DShepherd%26aufirst%3DL.%2BE.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DLivingston%26aufirst%3DR.%2BB.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DNorton%26aufirst%3DL.%26aulast%3DPerez%26aufirst%3DE.%2BA.%26aulast%3DAbrams%26aufirst%3DJ.%2BS.%26aulast%3DTherasse%26aufirst%3DP.%26aulast%3DPalmer%26aufirst%3DM.%2BJ.%26aulast%3DPater%26aufirst%3DJ.%2BL.%26atitle%3DA%2520randomized%2520trial%2520of%2520letrozole%2520in%2520postmenopausal%2520women%2520after%2520five%2520years%2520of%2520tamoxifen%2520therapy%2520for%2520early-stage%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D1793%26epage%3D1802%26doi%3D10.1056%2FNEJMoa032312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span> <span> </span><span class="NLM_article-title">Aromatase inhibitors for breast cancer: lessons from the laboratory</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">831</span>, <span class="refDoi"> DOI: 10.1038/nrc1211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2Fnrc1211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=14668813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFKmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=821-831&author=S.+R.+D.+Johnstonauthor=M.+Dowsett&title=Aromatase+inhibitors+for+breast+cancer%3A+lessons+from+the+laboratory&doi=10.1038%2Fnrc1211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors for breast cancer: Lessons from the laboratory</span></div><div class="casAuthors">Johnston, Stephen R. D.; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">821-831</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Endocrine therapy with tamoxifen has been the mainstay of treatment for hormone-sensitive breast cancer for more than 20 yr.  An alternative strategy of estrogen deprivation in postmenopausal women with aromatase inhibitors is set to replace tamoxifen based on better efficacy and a delay in the emergence of endocrine resistance.  There are fundamental differences in how tamoxifen and aromatase inhibitors alter estrogen-receptor signaling.  Understanding the response and resistance to these different therapies is central to further improving therapeutic options for women with breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0yq8HDYSRf7Vg90H21EOLACvtfcHk0lhveR7E8sO-Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFKmur8%253D&md5=5e187fa66d3912a9c5b151c3c54fb251</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc1211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1211%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DS.%2BR.%2BD.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DAromatase%2520inhibitors%2520for%2520breast%2520cancer%253A%2520lessons%2520from%2520the%2520laboratory%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D821%26epage%3D831%26doi%3D10.1038%2Fnrc1211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielewska, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of aromatase inhibitor resistance</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1038/nrc3920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2Fnrc3920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=25907219" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Wrur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=261-275&author=C.+X.+Maauthor=T.+Reinertauthor=I.+Chmielewskaauthor=M.+J.+Ellis&title=Mechanisms+of+aromatase+inhibitor+resistance&doi=10.1038%2Fnrc3920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of aromatase inhibitor resistance</span></div><div class="casAuthors">Ma, Cynthia X.; Reinert, Tomas; Chmielewska, Izabela; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">261-275</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Estrogen receptor-pos. (ER+) breast cancer is a major cause of cancer death in women.  Although aromatase inhibitors suppress the function of ER and reduce the risk of recurrence, therapeutic resistance is common and essentially inevitable in advanced disease.  This Review considers both genomic and cell biol. explanations as to why ER+ breast cancer cells persist, progress and cause an incurable, lethal, systemic disease.  The design and outcomes of clin. trials are considered with the perspective that resistance mechanisms are heterogeneous, and therefore biomarker and somatic mutation-based stratification and eligibility will be essential for improvements in patient outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQZc2ZDe2yrVg90H21EOLACvtfcHk0lhveR7E8sO-Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Wrur3F&md5=8873908dbbf917eece0cdc51d19efea1</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc3920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3920%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DReinert%26aufirst%3DT.%26aulast%3DChmielewska%26aufirst%3DI.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DMechanisms%2520of%2520aromatase%2520inhibitor%2520resistance%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D261%26epage%3D275%26doi%3D10.1038%2Fnrc3920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Künzer, H.</span></span> <span> </span><span class="NLM_article-title">Process for the Preparation of C(7)-Substituted Estra-1,3,5(10)-triene and New Starting Products by this Process</span>. Ger. Offen. <span class="NLM_patent">DE 4218743 C2</span>, <span class="NLM_year">1993</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&author=H.+K%C3%BCnzer&title=Process+for+the+Preparation+of+C%287%29-Substituted+Estra-1%2C3%2C5%2810%29-triene+and+New+Starting+Products+by+this+Process"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCnzer%26aufirst%3DH.%26atitle%3DProcess%2520for%2520the%2520Preparation%2520of%2520C%25287%2529-Substituted%2520Estra-1%252C3%252C5%252810%2529-triene%2520and%2520New%2520Starting%2520Products%2520by%2520this%2520Process%26date%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, J. F. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llombart-Cussac, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macpherson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4530</span>– <span class="NLM_lpage">4535</span>, <span class="refDoi"> DOI: 10.1200/JCO.2008.21.1136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1200%2FJCO.2008.21.1136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=19704066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=4530-4535&author=J.+F.+R.+Robertsonauthor=A.+Llombart-Cussacauthor=J.+Rolskiauthor=D.+Feltlauthor=J.+Dewarauthor=E.+Macphersonauthor=J.+Lindemannauthor=M.+J.+Ellis&title=Activity+of+fulvestrant+500+mg+versus+anastrozole+1+mg+as+first-line+treatment+for+advanced+breast+cancer%3A+results+from+the+FIRST+study&doi=10.1200%2FJCO.2008.21.1136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study</span></div><div class="casAuthors">Robertson, John F. R.; Llombart-Cussac, Antonio; Rolski, Janusz; Feltl, David; Dewar, John; MacPherson, Euan; Lindemann, Justin; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">4530-4535</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To compare the clin. activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor-pos. breast cancer in postmenopausal women.  Patients and Methods: FIRST (Fulvestrant First-Line Study Comparing Endocrine Treatments) is a phase II, randomized, open-label, multicenter study of a fulvestrant high-dose (HD) regimen (500 mg/mo plus 500 mg on day 14 of month 1) vs. anastrozole (1 mg/d).  The primary efficacy end point was clin. benefit rate (CBR), defined as the proportion of patients experiencing an objective response (OR) or stable disease for ≥ 24 wk.  The primary anal. was performed 6 mo after the last patient was randomly assigned.  Results: CBR was similar for fulvestrant HD (n = 102) and anastrozole (n = 103), 72.5% v 67.0%, resp. (odds ratio, 1.30; 95% CI, 0.72 to 2.38; P = .386).  Objective response rate (ORR) was also similar between treatments: fulvestrant HD, 36.0%; anastrozole, 35.5%.  Time to progression (TTP) was significantly longer for fulvestrant vs. anastrozole (median TTP not reached for fulvestrant HD v 12.5 mo for anastrozole; hazard ratio, 0.63; 95% CI, 0.39 to 1.00; P = .0496).  Duration of OR and CB also numerically favored fulvestrant HD.  Both treatments were well tolerated, with no significant differences in the incidence of prespecified adverse events.  Conclusion: First-line fulvestrant HD was at least as effective as anastrozole for CBR and ORR and was assocd. with significantly longer TTP.  Fulvestrant HD was generally well tolerated, with a safety profile similar to that of anastrozole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-OU2SQaTsabVg90H21EOLACvtfcHk0ljLWHPIENF_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCns77J&md5=a7a6f5cd7fcdbc8cb6839a2800cd5cb8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.21.1136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.21.1136%26sid%3Dliteratum%253Aachs%26aulast%3DRobertson%26aufirst%3DJ.%2BF.%2BR.%26aulast%3DLlombart-Cussac%26aufirst%3DA.%26aulast%3DRolski%26aufirst%3DJ.%26aulast%3DFeltl%26aufirst%3DD.%26aulast%3DDewar%26aufirst%3DJ.%26aulast%3DMacpherson%26aufirst%3DE.%26aulast%3DLindemann%26aufirst%3DJ.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DActivity%2520of%2520fulvestrant%2520500%2520mg%2520versus%2520anastrozole%25201%2520mg%2520as%2520first-line%2520treatment%2520for%2520advanced%2520breast%2520cancer%253A%2520results%2520from%2520the%2520FIRST%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D4530%26epage%3D4535%26doi%3D10.1200%2FJCO.2008.21.1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0ljLWHPIENF_CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">9549</span>– <span class="NLM_lpage">9560</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1590</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1158%2F0008-5472.CAN-07-1590" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9549-9560&author=B.+M.+Wittmannauthor=A.+Sherkauthor=D.+P.+McDonnell&title=Definition+of+functionally+important+mechanistic+differences+among+selective+estrogen+receptor+down-regulators&doi=10.1158%2F0008-5472.CAN-07-1590"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1590%26sid%3Dliteratum%253Aachs%26aulast%3DWittmann%26aufirst%3DB.%2BM.%26aulast%3DSherk%26aufirst%3DA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DDefinition%2520of%2520functionally%2520important%2520mechanistic%2520differences%2520among%2520selective%2520estrogen%2520receptor%2520down-regulators%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9549%26epage%3D9560%26doi%3D10.1158%2F0008-5472.CAN-07-1590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petruzelka, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khasanov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhoeven, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrini, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smirnova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pendergrass, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindemann, J. P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapunar, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span> <span> </span><span class="NLM_article-title">Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor–positive advanced breast cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">4594</span>– <span class="NLM_lpage">4600</span>, <span class="refDoi"> DOI: 10.1200/JCO.2010.28.8415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1200%2FJCO.2010.28.8415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=20855825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFaitLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=4594-4600&author=A.+Di%0ALeoauthor=G.+Jerusalemauthor=L.+Petruzelkaauthor=R.+Torresauthor=I.+N.+Bondarenkoauthor=R.+Khasanovauthor=D.+Verhoevenauthor=J.+L.+Pedriniauthor=I.+Smirnovaauthor=M.+R.+Lichinitserauthor=K.+Pendergrassauthor=S.+Garnettauthor=J.+P.+O.+Lindemannauthor=F.+Sapunarauthor=M.+Martin&title=Results+of+the+CONFIRM+phase+III+trial+comparing+fulvestrant+250+mg+with+fulvestrant+500+mg+in+postmenopausal+women+with+estrogen+receptor%E2%80%93positive+advanced+breast+cancer&doi=10.1200%2FJCO.2010.28.8415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer</span></div><div class="casAuthors">di Leo, Angelo; Jerusalem, Guy; Petruzelka, Lubos; Torres, Roberto; Bondarenko, Igor N.; Khasanov, Rustem; Verhoeven, Didier; Pedrini, Jose L.; Smirnova, Iya; Lichinitser, Mikhail R.; Pendergrass, Kelly; Garnett, Sally; Lindemann, Justin P. O.; Sapunar, Francisco; Martin, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">4594-4600</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per mo for treatment of postmenopausal women with estrogen receptor-pos. advanced breast cancer who experienced progression after prior endocrine therapy.  Comparison of Faslodex in Recurrent or Metastatic Breast Cancer (CONFIRM) is a double-blind, parallel-group, multicenter, phase III study.  Patients were randomly assigned to fulvestrant 500 mg (500 mg i.m. on day 0, then 500 mg i.m. on days 14 and 28 and every 28 days thereafter) or 250 mg every 28 days.  Primary end point was progression-free survival (PFS).  Secondary end points included objective response rate, clin. benefit rate (CBR), duration of clin. benefit (DoCB), overall survival (OS), and quality of life (QOL).  PFS was significantly longer for fulvestrant 500 mg (n = 362) than 250 mg (n = 374) (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.94; P = .006), corresponding to a 20% redn. in risk of progression.  Objective response rate was similar for fulvestrant 500 mg and 250 mg (9.1% v 10.2%, resp.).  CBR was 45.6% for fulvestrant 500 mg and 39.6% for fulvestrant 250 mg.  DoCB and OS were 16.6 and 25.1 mo, resp., for the 500-mg group, whereas DoCB and OS were 13.9 and 22.8 mo, resp., in the 250-mg group.  Fulvestrant 500 mg was well tolerated with no dose-dependent adverse events.  QOL was similar for both arms.  Fulvestrant 500 mg was assocd. with a statistically significant increase in PFS and not assocd. with increased toxicity, corresponding to a clin. meaningful improvement in benefit vs. risk compared with fulvestrant 250 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5x_viRvCGrVg90H21EOLACvtfcHk0lgHUoAN5YY5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFaitLzO&md5=9b82ff995b029df754e4295d3153867e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.28.8415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.28.8415%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DPetruzelka%26aufirst%3DL.%26aulast%3DTorres%26aufirst%3DR.%26aulast%3DBondarenko%26aufirst%3DI.%2BN.%26aulast%3DKhasanov%26aufirst%3DR.%26aulast%3DVerhoeven%26aufirst%3DD.%26aulast%3DPedrini%26aufirst%3DJ.%2BL.%26aulast%3DSmirnova%26aufirst%3DI.%26aulast%3DLichinitser%26aufirst%3DM.%2BR.%26aulast%3DPendergrass%26aufirst%3DK.%26aulast%3DGarnett%26aufirst%3DS.%26aulast%3DLindemann%26aufirst%3DJ.%2BP.%2BO.%26aulast%3DSapunar%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DResults%2520of%2520the%2520CONFIRM%2520phase%2520III%2520trial%2520comparing%2520fulvestrant%2520250%2520mg%2520with%2520fulvestrant%2520500%2520mg%2520in%2520postmenopausal%2520women%2520with%2520estrogen%2520receptor%25E2%2580%2593positive%2520advanced%2520breast%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D4594%26epage%3D4600%26doi%3D10.1200%2FJCO.2010.28.8415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapunar, F.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant revisited: efficacy and safety of the 500-mg dose</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">204</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2011.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2Fj.clbc.2011.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=21729658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKisr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=204-210&author=A.+Howellauthor=F.+Sapunar&title=Fulvestrant+revisited%3A+efficacy+and+safety+of+the+500-mg+dose&doi=10.1016%2Fj.clbc.2011.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant revisited: efficacy and safety of the 500-mg dose</span></div><div class="casAuthors">Howell, Anthony; Sapunar, Francisco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Breast Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">204-210</span>CODEN:
                <span class="NLM_cas:coden">CBCLB7</span>;
        ISSN:<span class="NLM_cas:issn">1526-8209</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Postmenopausal women with hormone receptor-pos. advanced breast cancer are candidates for endocrine therapy.  As the disease will eventually progress in most patients, it is important to investigate agents with novel modes of action to reduce the likelihood of treatment cross-resistance.  Fulvestrant is an estrogen receptor antagonist with no known agonist effects that has been shown to be as effective as anastrozole following failure on tamoxifen, at the approved dose of 250 mg/mo.  However, pharmacokinetic modeling and evidence of clin. efficacy in early trials, together with the favorable tolerability profile of fulvestrant 250 mg, led to suggestions that increasing the fulvestrant dose would lead to an improved benefit-risk profile.  This review describes the rationale behind the development of a 500 mg/mo higher dose of fulvestrant and details relevant clin. trials, including the pivotal phase III COmparisoN of Faslodex In Recurrent or Metastatic breast cancer (CONFIRM) study.  CONFIRM demonstrated a significant improvement in progression-free survival for fulvestrant 500 mg vs. 250 mg in postmenopausal patients who had progressed on previous endocrine therapy.  Here, we present and discuss a pooled safety anal. of CONFIRM and three further clin. studies demonstrating fulvestrant 500 mg to be well-tolerated with no evidence of dose-related adverse events.  Overall, these data indicate an improved benefit-risk profile for fulvestrant 500 mg vs. 250 mg following failure on prior endocrine therapy, and suggest that fulvestrant 500 mg may be considered in future as initial endocrine treatment for advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4U1d7Q6edlbVg90H21EOLACvtfcHk0lgHUoAN5YY5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKisr7E&md5=0d1063c9546320294193e92d3f2097dd</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2011.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DHowell%26aufirst%3DA.%26aulast%3DSapunar%26aufirst%3DF.%26atitle%3DFulvestrant%2520revisited%253A%2520efficacy%2520and%2520safety%2520of%2520the%2520500-mg%2520dose%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D204%26epage%3D210%26doi%3D10.1016%2Fj.clbc.2011.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Momtahen, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charifson, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batchelor, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubahn, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauls, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Triantafillou, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baer, P. G.</span></span> <span> </span><span class="NLM_article-title">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1021/jm00037a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00037a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1550-1552&author=T.%0AM.+Willsonauthor=B.+R.+Henkeauthor=T.+M.+Momtahenauthor=P.+S.+Charifsonauthor=K.+W.+Batchelorauthor=D.+B.+Lubahnauthor=L.+B.+Mooreauthor=B.+B.+Oliverauthor=H.+R.+Saulsauthor=J.+A.+Triantafillouauthor=S.+G.+Wolfeauthor=P.+G.+Baer&title=3-%5B4-%281%2C2-Diphenylbut-1-enyl%29phenyl%5Dacrylic+acid%3A+a+non-steroidal+estrogen+with+functional+selectivity+for+bone+over+uterus+in+rats&doi=10.1021%2Fjm00037a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats</span></div><div class="casAuthors">Willson, Timothy M.; Henke, Brad R.; Momtahen, Tanya M.; Charifson, Paul S.; Batchelor, Kenneth W.; Lubahn, Dennis B.; Moore, Linda B.; Oliver, Beverly B.; Sauls, Howard R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1550-2</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Exploiting knowledge of the mol. biol. of the estrogen receptor and the existence of two independent transcription activation domains, a series of tissue-selective non-steroidal estrogens was designed.  The ethanolamine side-chain of tamoxifen was targeted for modification, resulting in the identification of a series of α,β-unsatd. acid and amide analogs I [R = OH, NEt2, morpholino, NH(CH2)3OMe, dicyclohexylamino, NEtCH2CH2NMe2, NH(CH2)3OH, N-methyloctylamino, NHEt,NH2].  I [R = OH] profiled as an estrogen with full agonist activity in bone while maintaining antagonist activity in the uterus of rats.  The demonstration that different parts of the triphenylethylene structure control expression of estrogenic activity in bone and uterus has implications in the design of tissue selective ligands for other members of the steroid/retinoid family of intracellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4iuXq4R8fm7Vg90H21EOLACvtfcHk0lgHUoAN5YY5Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlCqt7g%253D&md5=721906b3513f7e8cdc9ae08ecd99a93b</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm00037a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00037a002%26sid%3Dliteratum%253Aachs%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DHenke%26aufirst%3DB.%2BR.%26aulast%3DMomtahen%26aufirst%3DT.%2BM.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26aulast%3DBatchelor%26aufirst%3DK.%2BW.%26aulast%3DLubahn%26aufirst%3DD.%2BB.%26aulast%3DMoore%26aufirst%3DL.%2BB.%26aulast%3DOliver%26aufirst%3DB.%2BB.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DTriantafillou%26aufirst%3DJ.%2BA.%26aulast%3DWolfe%26aufirst%3DS.%2BG.%26aulast%3DBaer%26aufirst%3DP.%2BG.%26atitle%3D3-%255B4-%25281%252C2-Diphenylbut-1-enyl%2529phenyl%255Dacrylic%2520acid%253A%2520a%2520non-steroidal%2520estrogen%2520with%2520functional%2520selectivity%2520for%2520bone%2520over%2520uterus%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1550%26epage%3D1552%26doi%3D10.1021%2Fjm00037a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadwater, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewhirst, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Circumventing tamoxifen resistance in breast cancers suing antiestrogens that induce unique conformational changes in the estrogen receptor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2917</span>– <span class="NLM_lpage">2922</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2917-2922&author=C.+E.+Connorauthor=J.+D.+Norrisauthor=G.+Broadwaterauthor=T.+M.+Willsonauthor=M.+M.+Gottardisauthor=M.+W.+Dewhirstauthor=D.+P.+McDonnell&title=Circumventing+tamoxifen+resistance+in+breast+cancers+suing+antiestrogens+that+induce+unique+conformational+changes+in+the+estrogen+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DC.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DCircumventing%2520tamoxifen%2520resistance%2520in%2520breast%2520cancers%2520suing%2520antiestrogens%2520that%2520induce%2520unique%2520conformational%2520changes%2520in%2520the%2520estrogen%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2917%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burks, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of an acrylic acid based tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for ERα+ breast cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2790</span>– <span class="NLM_lpage">2818</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01468</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01468" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2790-2818&author=H.+E.+Burksauthor=T.+Abramsauthor=C.+A.+Kirbyauthor=J.+Bairdauthor=A.+Feketeauthor=L.+G.+Hamannauthor=S.+Kimauthor=F.+Lombardoauthor=A.+Looauthor=D.+Lubickaauthor=K.+Macchiauthor=D.+P.+McDonnellauthor=Y.+Mishinaauthor=J.+D.+Norrisauthor=J.+Nunezauthor=C.+Saranauthor=Y.+Sunauthor=N.+M.+Thomsenauthor=C.+Wangauthor=J.+Wangauthor=S.+Peukert&title=Discovery+of+an+acrylic+acid+based+tetrahydroisoquinoline+as+an+orally+bioavailable+selective+estrogen+receptor+degrader+for+ER%CE%B1%2B+breast+cancer&doi=10.1021%2Facs.jmedchem.6b01468"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01468%26sid%3Dliteratum%253Aachs%26aulast%3DBurks%26aufirst%3DH.%2BE.%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DKirby%26aufirst%3DC.%2BA.%26aulast%3DBaird%26aufirst%3DJ.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DMacchi%26aufirst%3DK.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DSaran%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPeukert%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520an%2520acrylic%2520acid%2520based%2520tetrahydroisoquinoline%2520as%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520for%2520ER%25CE%25B1%252B%2520breast%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2790%26epage%3D2818%26doi%3D10.1021%2Facs.jmedchem.6b01468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillot, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4888</span>– <span class="NLM_lpage">4904</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00054</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00054" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4888-4904&author=A.+Laiauthor=M.+Kahramanauthor=S.+Govekauthor=J.+Nagasawaauthor=C.+Bonnefousauthor=J.+Julienauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=M.+J.+Moonauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Grillotauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+GDC-0810+%28ARN-810%29%2C+an+orally+bioavailable+selective+estrogen+receptor+degrader+%28SERD%29+that+demonstrates+robust+activity+in+tamoxifen-resistant+breast+cancer+xenografts&doi=10.1021%2Facs.jmedchem.5b00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts</span></div><div class="casAuthors">Lai, Andiliy; Kahraman, Mehmet; Govek, Steven; Nagasawa, Johnny; Bonnefous, Celine; Julien, Jackie; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, Kyoung-jin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Moon, Michael J.; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Grillot, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4888-4904</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. 80% of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α and is active in patients who have progressed on antihormonal agents.  However, fulvestrant suffers from poor pharmaceutical properties and must be administered by i.m. injections that limit the total amt. of drug that can be administered and hence lead to the potential for incomplete receptor blockade.  The authors describe the identification and characterization of a series of small-mol., orally bioavailable SERDs which are potent antagonists and degraders of ER-α and in which the ER-α degrading properties were prospectively optimized.  The lead compd. I (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clin. trials in women with locally advanced or metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOegJFz-sqwbVg90H21EOLACvtfcHk0ljaf-CZn35ZQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFyisb4%253D&md5=e836ec4d593ce6ed2d9622da5cd898e6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00054%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DJulien%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DMoon%26aufirst%3DM.%2BJ.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DGrillot%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520GDC-0810%2520%2528ARN-810%2529%252C%2520an%2520orally%2520bioavailable%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520that%2520demonstrates%2520robust%2520activity%2520in%2520tamoxifen-resistant%2520breast%2520cancer%2520xenografts%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4888%26epage%3D4904%26doi%3D10.1021%2Facs.jmedchem.5b00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, J.</span></span> Roche silently whisks away its lead $1.7B Seragon drug in a Q1 footnote, April 27, 2017. Endpoints News. <a href="https://endpts.com/roche-silently-whisks-away-its-1-7b-seragon-drug-in-a-q1-footnote" class="extLink">https://endpts.com/roche-silently-whisks-away-its-1-7b-seragon-drug-in-a-q1-footnote</a> (accessed Sept. 1, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Carroll%2C+J.+Roche+silently+whisks+away+its+lead+%241.7B+Seragon+drug+in+a+Q1+footnote%2C+April+27%2C+2017.+Endpoints+News.+https%3A%2F%2Fendpts.com%2Froche-silently-whisks-away-its-1-7b-seragon-drug-in-a-q1-footnote+%28accessed+Sept.+1%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3DCarroll%26aufirst%3DJ.%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, Z.</span></span> <span> </span><span class="NLM_article-title">Syntheses and substituent effects on the properties of unsymmetrical photochromic diarylethenes bearing a benzothiophene unit</span>. <i>Aust. J. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">464</span>– <span class="NLM_lpage">474</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2009&pages=464-474&author=S.+Puauthor=M.+Liauthor=G.+Liuauthor=Z.+Le&title=Syntheses+and+substituent+effects+on+the+properties+of+unsymmetrical+photochromic+diarylethenes+bearing+a+benzothiophene+unit"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DLe%26aufirst%3DZ.%26atitle%3DSyntheses%2520and%2520substituent%2520effects%2520on%2520the%2520properties%2520of%2520unsymmetrical%2520photochromic%2520diarylethenes%2520bearing%2520a%2520benzothiophene%2520unit%26jtitle%3DAust.%2520J.%2520Chem.%26date%3D2009%26volume%3D62%26spage%3D464%26epage%3D474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Breemen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span> <span> </span><span class="NLM_article-title">Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-fluoro substitution prevents quinoid formation</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1021/tx049776u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx049776u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=162-173&author=H.+Liuauthor=J.+Liuauthor=R.+B.+van+Breemenauthor=G.+R.+J.+Thatcherauthor=J.+L.+Bolton&title=Bioactivation+of+the+selective+estrogen+receptor+modulator+desmethylated+arzoxifene+to+quinoids%3A+4%E2%80%B2-fluoro+substitution+prevents+quinoid+formation&doi=10.1021%2Ftx049776u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Ftx049776u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx049776u%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3Dvan%2BBreemen%26aufirst%3DR.%2BB.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26atitle%3DBioactivation%2520of%2520the%2520selective%2520estrogen%2520receptor%2520modulator%2520desmethylated%2520arzoxifene%2520to%2520quinoids%253A%25204%25E2%2580%25B2-fluoro%2520substitution%2520prevents%2520quinoid%2520formation%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2005%26volume%3D18%26spage%3D162%26epage%3D173%26doi%3D10.1021%2Ftx049776u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasena, R. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2692</span>, <span class="refDoi"> DOI: 10.1021/jm070079j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070079j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2682-2692&author=Z.+Qinauthor=I.+Kastratiauthor=R.+E.+P.+Chandrasenaauthor=H.+Liuauthor=P.+Yaoauthor=P.+A.+Petukhovauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Benzothiophene+selective+estrogen+receptor+modulators+with+modulated+oxidative+activity+and+receptor+affinity&doi=10.1021%2Fjm070079j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Chandrasena, R. Esala P.; Liu, Hong; Yao, Ping; Petukhov, Pavel A.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clin. use.  Most SERMs are polyarom. phenols susceptible to oxidative metab. to quinoids, which are proposed to be genotoxic.  Conversely, the redox reactivity of SERMs may contribute to antioxidant and chemopreventive mechanisms, providing a new approach to improve the therapeutic properties of SERMs.  An improved synthetic strategy was developed to generate a family of benzothiophene SERMs.  Using computational modeling methods and measurements of antioxidant activity and estrogen receptor (ER) ligand binding, this SERM family was shown to provide both a range of ERα/ERβ selectivity from 1.2- to 67-fold and a range of redox activity.  Antioxidant activity was successfully modulated by varying a substituent remote from the OH group; the source of the antioxidant capacity.  An efficient synthetic procedure is reported yielding benzothiophene SERMs wherein redox activity and ER affinity are modulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CGhCcopaULVg90H21EOLACvtfcHk0ljnHYSB2ulPqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D&md5=594ddb689931d8629c9f5c9443f88cb4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm070079j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070079j%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DChandrasena%26aufirst%3DR.%2BE.%2BP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520selective%2520estrogen%2520receptor%2520modulators%2520with%2520modulated%2520oxidative%2520activity%2520and%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2682%26epage%3D2692%26doi%3D10.1021%2Fjm070079j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samanen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandeis, E.</span></span> <span> </span><span class="NLM_article-title">The p-(methylsulfinyl)benzyl group: a TFA-stable carboxyl-protecting group readily convertible to a TFA-labile group</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1021/jo00238a016</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00238a016" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1988&pages=561-569&author=J.+M.+Samanenauthor=E.+Brandeis&title=The+p-%28methylsulfinyl%29benzyl+group%3A+a+TFA-stable+carboxyl-protecting+group+readily+convertible+to+a+TFA-labile+group&doi=10.1021%2Fjo00238a016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjo00238a016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00238a016%26sid%3Dliteratum%253Aachs%26aulast%3DSamanen%26aufirst%3DJ.%2BM.%26aulast%3DBrandeis%26aufirst%3DE.%26atitle%3DThe%2520p-%2528methylsulfinyl%2529benzyl%2520group%253A%2520a%2520TFA-stable%2520carboxyl-protecting%2520group%2520readily%2520convertible%2520to%2520a%2520TFA-labile%2520group%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1988%26volume%3D53%26spage%3D561%26epage%3D569%26doi%3D10.1021%2Fjo00238a016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T. Y.</span></span> <span> </span><span class="NLM_article-title">Efficient synthesis of 3-oxygenated benzothiophene derivatives</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">2349</span>– <span class="NLM_lpage">2352</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2007.01.141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2Fj.tetlet.2007.01.141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlOku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=2349-2352&author=F.+Zhangauthor=D.+Mitchellauthor=P.+Pollockauthor=T.+Y.+Zhang&title=Efficient+synthesis+of+3-oxygenated+benzothiophene+derivatives&doi=10.1016%2Fj.tetlet.2007.01.141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient synthesis of 3-oxygenated benzothiophene derivatives</span></div><div class="casAuthors">Zhang, Fuyao; Mitchell, David; Pollock, Patrick; Zhang, Tony Y.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2349-2352</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient synthesis of 2-bromo-3-(aryloxy)benzothiophene derivs. by a conjugate addn.-elimination sequence of 2,3-dibromobenzothiophene dioxides with phenolic nucleophiles was developed.  These benzothiophene derivs. serve as important intermediates for the synthesis of SERM (selective estrogen receptor modulator) analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobybOZuLGdXbVg90H21EOLACvtfcHk0ljnHYSB2ulPqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlOku7s%253D&md5=f5d8f52b8563eff079ea173d2cd89737</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2007.01.141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2007.01.141%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DMitchell%26aufirst%3DD.%26aulast%3DPollock%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DT.%2BY.%26atitle%3DEfficient%2520synthesis%2520of%25203-oxygenated%2520benzothiophene%2520derivatives%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D2349%26epage%3D2352%26doi%3D10.1016%2Fj.tetlet.2007.01.141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anstead, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinney, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Torsionally and hydrophobically modified 2,3-diarylindenes as estrogen-receptor ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">2726</span>– <span class="NLM_lpage">2134</span>, <span class="refDoi"> DOI: 10.1021/jm00172a008</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00172a008" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=2726-2134&author=G.+M.+Ansteadauthor=C.+S.+Petersonauthor=K.+G.+Pinneyauthor=S.+R.+Wilsonauthor=J.+A.+Katzenellenbogen&title=Torsionally+and+hydrophobically+modified+2%2C3-diarylindenes+as+estrogen-receptor+ligands&doi=10.1021%2Fjm00172a008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm00172a008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00172a008%26sid%3Dliteratum%253Aachs%26aulast%3DAnstead%26aufirst%3DG.%2BM.%26aulast%3DPeterson%26aufirst%3DC.%2BS.%26aulast%3DPinney%26aufirst%3DK.%2BG.%26aulast%3DWilson%26aufirst%3DS.%2BR.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DTorsionally%2520and%2520hydrophobically%2520modified%25202%252C3-diarylindenes%2520as%2520estrogen-receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D2726%26epage%3D2134%26doi%3D10.1021%2Fjm00172a008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grese, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lugar, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adrian, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magee, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glasebrook, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, H. U.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">167</span>, <span class="refDoi"> DOI: 10.1021/jm9606352</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9606352" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=146-167&author=T.+A.+Greseauthor=S.+Choauthor=D.+R.+Finleyauthor=A.+G.+Godfreyauthor=C.+D.+Jonesauthor=C.+W.+Lugarauthor=M.+J.+Martinauthor=K.+Matsumotoauthor=L.+D.+Penningtonauthor=M.+A.+Winterauthor=M.+D.+Adrianauthor=H.+W.+Coleauthor=D.+E.+Mageeauthor=D.+L.+Phillipsauthor=E.+R.+Rowleyauthor=L.+L.+Shortauthor=A.+L.+Glasebrookauthor=H.+U.+Bryant&title=Structure-activity+relationships+of+selective+estrogen+receptor+modulators%3A+modifications+to+the+2-arylbenzothiophene+core+of+raloxifene&doi=10.1021%2Fjm9606352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm9606352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9606352%26sid%3Dliteratum%253Aachs%26aulast%3DGrese%26aufirst%3DT.%2BA.%26aulast%3DCho%26aufirst%3DS.%26aulast%3DFinley%26aufirst%3DD.%2BR.%26aulast%3DGodfrey%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DC.%2BD.%26aulast%3DLugar%26aufirst%3DC.%2BW.%26aulast%3DMartin%26aufirst%3DM.%2BJ.%26aulast%3DMatsumoto%26aufirst%3DK.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DWinter%26aufirst%3DM.%2BA.%26aulast%3DAdrian%26aufirst%3DM.%2BD.%26aulast%3DCole%26aufirst%3DH.%2BW.%26aulast%3DMagee%26aufirst%3DD.%2BE.%26aulast%3DPhillips%26aufirst%3DD.%2BL.%26aulast%3DRowley%26aufirst%3DE.%2BR.%26aulast%3DShort%26aufirst%3DL.%2BL.%26aulast%3DGlasebrook%26aufirst%3DA.%2BL.%26aulast%3DBryant%26aufirst%3DH.%2BU.%26atitle%3DStructure-activity%2520relationships%2520of%2520selective%2520estrogen%2520receptor%2520modulators%253A%2520modifications%2520to%2520the%25202-arylbenzothiophene%2520core%2520of%2520raloxifene%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D146%26epage%3D167%26doi%3D10.1021%2Fjm9606352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brzozowski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauter, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engström, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J. Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlquist, M.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of agonism and antagonism in the oestrogen receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/39645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1038%2F39645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=9338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=753-758&author=A.+M.+Brzozowskiauthor=A.+C.+W.+Pikeauthor=Z.+Dauterauthor=R.+E.+Hubbardauthor=T.+Bonnauthor=O.+Engstr%C3%B6mauthor=L.+%C3%96hmanauthor=G.+L.+Greeneauthor=J.+%C3%85.+Gustafssonauthor=M.+Carlquist&title=Molecular+basis+of+agonism+and+antagonism+in+the+oestrogen+receptor&doi=10.1038%2F39645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of agonism and antagonism in the estrogen receptor</span></div><div class="casAuthors">Brzozowski, Andrzej M.; Pike, Ashley C. W.; Dauter, Zbigniew; Hubbard, Roderick E.; Bonn, Tomas; Engstrom, Owe; Ohman, Lars; Greene, Geoffrey L.; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6652</span>),
    <span class="NLM_cas:pages">753-758</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Estrogens are involved in the growth, development and homeostasis of a no. of tissues.  The physiol. effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the estrogen receptor (ER).  Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of mol. events culminating in the activation or repression of target genes.  Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery.  Here we report the crystal structures of the LBD of ER in complex with the endogenous estrogen, 17β-estradiol, and the selective antagonist raloxifene, at resolns. of 3.1 and 2.6Å, resp.  The structures provide a mol. basis for the distinctive pharmacophore of the ER and its catholic binding properties.  Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes.  In addn., each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXbSo66V1LrVg90H21EOLACvtfcHk0lgg8m_uLr_twg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D&md5=2a63951b881b329ff142c9fbc82a13e3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2F39645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F39645%26sid%3Dliteratum%253Aachs%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%2BC.%2BW.%26aulast%3DDauter%26aufirst%3DZ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DBonn%26aufirst%3DT.%26aulast%3DEngstr%25C3%25B6m%26aufirst%3DO.%26aulast%3D%25C3%2596hman%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.%2B%25C3%2585.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DMolecular%2520basis%2520of%2520agonism%2520and%2520antagonism%2520in%2520the%2520oestrogen%2520receptor%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D753%26epage%3D758%26doi%3D10.1038%2F39645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span> <i>The PyMOL Molecular
Graphics System</i>, version 1.8.4.2, <span class="NLM_publisher-name">Schrödinger,
LLC</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The+PyMOL+Molecular%0AGraphics+System%2C+version+1.8.4.2%2C+Schr%C3%B6dinger%2C%0ALLC."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520PyMOL%2520Molecular%250AGraphics%2520System%26pub%3DSchr%25C3%25B6dinger%252C%250ALLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadwater, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottardis, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewhirst, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2917</span>– <span class="NLM_lpage">2922</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=11306468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=2917-2922&author=C.+E.+Connorauthor=J.+D.+Norrisauthor=G.+Broadwaterauthor=T.+M.+Willsonauthor=M.+M.+Gottardisauthor=M.+W.+Dewhirstauthor=D.+P.+McDonnell&title=Circumventing+tamoxifen+resistance+in+breast+cancers+using+antiestrogens+that+induce+unique+conformational+changes+in+the+estrogen+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor</span></div><div class="casAuthors">Connor, Caroline E.; Norris, John D.; Broadwater, Gloria; Willson, Timothy M.; Gottardis, Marco M.; Dewhirst, Mark W.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2917-2922</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Tamoxifen inhibits estrogen receptor (ER) transcriptional activity by competitively inhibiting estradiol binding and inducing conformational changes in the receptor that may prevent its interaction with coactivators.  In bone, the cardiovascular system, and some breast tumors, however, tamoxifen exhibits agonist activity, suggesting that the tamoxifen-ER complex is not recognized identically in all cells.  We used phage display to demonstrate that the antiestrogen GW5638 induces a unique structural change in the ER.  The biol. significance of this conformational change was revealed in studies that demonstrated that tamoxifen-resistant breast tumor explants are not cross-resistant to GW5638.  Because of these properties, this drug is currently being developed as a potential therapeutic for tamoxifen-resistant breast cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2YSN94iysMbVg90H21EOLACvtfcHk0lgg8m_uLr_twg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGqsrw%253D&md5=d7ecae7d445901e2f2c4f133ebbacdc5</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DConnor%26aufirst%3DC.%2BE.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DBroadwater%26aufirst%3DG.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGottardis%26aufirst%3DM.%2BM.%26aulast%3DDewhirst%26aufirst%3DM.%2BW.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DCircumventing%2520tamoxifen%2520resistance%2520in%2520breast%2520cancers%2520using%2520antiestrogens%2520that%2520induce%2520unique%2520conformational%2520changes%2520in%2520the%2520estrogen%2520receptor%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D2917%26epage%3D2922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiRenzo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span> <span> </span><span class="NLM_article-title">Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">852</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00188-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2FS0092-8674%2800%2900188-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=11136970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovFCjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=843-852&author=Y.+Shangauthor=X.+Huauthor=J.+DiRenzoauthor=M.+A.+Lazarauthor=M.+Brown&title=Cofactor+dynamics+and+sufficiency+in+estrogen+receptor-regulated+transcription&doi=10.1016%2FS0092-8674%2800%2900188-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription</span></div><div class="casAuthors">Shang, Yongfeng; Hu, Xiao; DiRenzo, James; Lazar, Mitchell A.; Brown, Myles</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">843-852</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Many cofactors bind the hormone-activated estrogen receptor (ER), yet the specific regulators of endogenous ER-mediated gene transcription are unknown.  Using chromatin immunopptn. (ChIP), we find that ER and a no. of coactivators rapidly assoc. with estrogen responsive promoters following estrogen treatment in a cyclic fashion that is not predicted by current models of hormone activation.  Cycles of ER complex assembly are followed by transcription.  In contrast, the anti-estrogen tamoxifen (TAM) recruits corepressors but not coactivators.  Using a genetic approach, we show that recruitment of the p160 class of coactivators is sufficient for gene activation and for the growth stimulatory actions of estrogen in breast cancer supporting a model in which ER cofactors play unique roles in estrogen signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6m5Mq-rPwB7Vg90H21EOLACvtfcHk0lh4M7lR1o9RMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovFCjt7s%253D&md5=6f5af3762620dfd880758ba9fafcba25</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900188-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900188-4%26sid%3Dliteratum%253Aachs%26aulast%3DShang%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDiRenzo%26aufirst%3DJ.%26aulast%3DLazar%26aufirst%3DM.%2BA.%26aulast%3DBrown%26aufirst%3DM.%26atitle%3DCofactor%2520dynamics%2520and%2520sufficiency%2520in%2520estrogen%2520receptor-regulated%2520transcription%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D843%26epage%3D852%26doi%3D10.1016%2FS0092-8674%2800%2900188-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">130</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2011.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;key=10.1016%2Fj.bcp.2011.03.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2011&pages=122-130&author=S.+E.+Wardellauthor=J.+R.+Marksauthor=D.+P.+McDonnell&title=The+turnover+of+estrogen+receptor+%CE%B1+by+the+selective+estrogen+receptor+degrader+%28SERD%29+fulvestrant+is+a+saturable+process+that+is+not+required+for+antagonist+efficacy&doi=10.1016%2Fj.bcp.2011.03.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2011.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2011.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DMarks%26aufirst%3DJ.%2BR.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DThe%2520turnover%2520of%2520estrogen%2520receptor%2520%25CE%25B1%2520by%2520the%2520selective%2520estrogen%2520receptor%2520degrader%2520%2528SERD%2529%2520fulvestrant%2520is%2520a%2520saturable%2520process%2520that%2520is%2520not%2520required%2520for%2520antagonist%2520efficacy%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2011%26volume%3D82%26spage%3D122%26epage%3D130%26doi%3D10.1016%2Fj.bcp.2011.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span> </span><span class="NLM_article-title">Phase I/Ib Trial of LSZ102 single agent or LSZ102
+ LEE011 or LSZ102
+ BYL719 in ER+ breast cancers</span>. ClinicalTrials.gov. <a href="https://clinicaltrials.gov/ct2/show/NCT02734615" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02734615</a> (accessed Sept. 1, <span class="NLM_year">2017</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Phase+I%2FIb+Trial+of+LSZ102+single+agent+or+LSZ102%0A%2B+LEE011+or+LSZ102%0A%2B+BYL719+in+ER%2B+breast+cancers.+ClinicalTrials.gov.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02734615+%28accessed+Sept.+1%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPhase%2520I%252FIb%2520Trial%2520of%2520LSZ102%2520single%2520agent%2520or%2520LSZ102%250A%252B%2520LEE011%2520or%2520LSZ102%250A%252B%2520BYL719%2520in%2520ER%252B%2520breast%2520cancers%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span>; <span class="NLM_string-name">Curigliano, G.</span>; <span class="NLM_string-name">Cresta, S.</span>; <span class="NLM_string-name">Yap, Y.
S.</span>; <span class="NLM_string-name">Terret, C.</span>; <span class="NLM_string-name">Duhoux, F. P.</span>; <span class="NLM_string-name">Takahashi, S.</span>; <span class="NLM_string-name">Kundamal, N.</span>; <span class="NLM_string-name">Bhansali, S.</span>; <span class="NLM_string-name">Liao, S.</span>; <span class="NLM_string-name">Crystal, A.</span>; <span class="NLM_string-name">Jhaveri, K.</span></span> <span> </span><span class="NLM_article-title">Phase I/Ib Study of the SERD LSZ102 Alone or in Combination With Ribociclib in ER+ Breast Cancer: Preliminary Single-agent Results</span>.  <i>Abstracts from the 40th Annual SABCS</i>, San Antonio, TX, December 4–9, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=D.+Juric&author=G.+Curigliano&author=S.+Cresta&author=Y.%0AS.+Yap&author=C.+Terret&author=F.+P.+Duhoux&author=S.+Takahashi&author=N.+Kundamal&author=S.+Bhansali&author=S.+Liao&author=A.+Crystal&author=K.+Jhaveri&title=Phase+I%2FIb+Study+of+the+SERD+LSZ102+Alone+or+in+Combination+With+Ribociclib+in+ER%2B+Breast+Cancer%3A+Preliminary+Single-agent+Results"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26atitle%3DPhase%2520I%252FIb%2520Study%2520of%2520the%2520SERD%2520LSZ102%2520Alone%2520or%2520in%2520Combination%2520With%2520Ribociclib%2520in%2520ER%252B%2520Breast%2520Cancer%253A%2520Preliminary%2520Single-agent%2520Results%26jtitle%3DAbstracts%2520from%2520the%252040th%2520Annual%2520SABCS%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F','PDB','6B0F'); return false;">PDB: 6B0F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERR','PDB','1ERR'); return false;">PDB: 1ERR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1ERE','PDB','1ERE'); return false;">PDB: 1ERE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K','PDB','1R5K'); return false;">PDB: 1R5K</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-9"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i115"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01682">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_51117"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01682">10.1021/acs.jmedchem.7b01682</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Crystallographic methods and parameters, as well as pharmacokinetic studies (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings as well as IC<sub>50</sub> and percent ERα remaining data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_001.pdf">jm7b01682_si_001.pdf (1.03 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01682/suppl_file/jm7b01682_si_002.csv">jm7b01682_si_002.csv (3.37 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for compound <b>10</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6B0F">6B0F</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01682&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-7%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01682%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01682" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799cb2649403cfa","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
